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ABSTRACT 
l. This study investigates the biochemical genetics of two plasma 
proteins, fibronectin and blood coagulation factor XIII, which inter-
act in the biological processes of blood coagulation and wound 
healing. 
2. An electrophoretic technique for the rapi d screening of blood 
samples for plasma fibronectin is described. This technique has 
been used to screen nearly 3,000 human plasma and serum samples 
as well as plasma samples from dogs, cats, pigs, goats, mice, 
donkeys, sheep, horses, camels, cattle and Highland ponies for 
genetic variants of plasma fibronectin. Only one possible 
variant from an Indonesian population was detected. 
3. The electrophoretic technique described here should, 1n combin-
ation with somatic cell hybrids, be useful in determining the 
chromosomal location of the fibronectin structural gene(s). 
In addition it could prove useful as a diagnostic aid in 
disorders which may be a result of functionally abnormal fibro-
nectin molecules. 
4. The distribution of the three previously reported alleles, with 
normal products, at the FXIII-A structural locus, FXIIIA*l ~ 
FXIIIA*2 and FXIIIA*4 has been extended by the study of popula-
tions from the region extending from the Indonesian archipelago 
through Papua New Guinea, Australia and New Zealand to the Paci-
fic Island regions of Micronesia, Melanesia and Polynesia. In 
addition a population from the Caspian Littoral of Iran and a 
population of S. American Indians were studied. The FXIIIA*l and 
FXIIIA*2 alleles were polymorphic in all populations studied. 
The distribution of the FXIIIA*4 allele suggests that it may be a 
a Melanesian marker. 
5. A new allele, FXIIIA*3 , was found in a sample from New Zealand. 
The A subunits coded for by this allele are apparently unstable. 
The potential importance of this allele in congenital factor 
XIII deficiency is discussed. The Type 3 A subunits were 
partially biochemically characterised. 
6. The Type 1 and Type 2 A subunits were purified and their sub-
strate specificities, heat stability, pH range and optima were 
compared. There does not appear to be any physiologically 
important differences between them. 
7. The literature concerning fibronectin and blood coagulation 
factor XIII is reviewed. 
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EXPERIMENTAL AIMS 
The basic objectives of thi:s project can be summarised into three 
main points: a) attempt to elucidate the genetic relationship of 
plasma and cellular fibronectin; b) to further the knowledge of the 
biochemical genetics of coagulation factor XIII A subunit~ and c) to 
study the interaction between plasma fibronectin and the products of 
the two common alleles at the FXIII-A structural locus, FXIIIA*1 and 
FXIIIA *2. 
Fibronectin, a high molecular weight glycoprotein, is widely 
distributed in the body of most multicellular animals. The biological 
functions of fibronectin have not yet been clearly defined, but it 
has been proposed that fibronectin plays an integral role in the 
mediation of cell-cell and cell-substratum interaction, the mainten-
ance of normal cell morphology and cell movement and tissue formation 
during embryogenesis as well as being involved in the wound healing 
process and the normal functioning of the mononuclear phagoc~tic 
system (see Chapter 1). 
Although studies have attempted to determine the structure of 
the fibronectin molecule from different sources within the body and 
look at the relationship of these different forms of fibronectin, no 
studies have attempted to determine the genetic control of fibronectin. 
Therefore, because of the lack of knowledge concerning the genetics 
of fibronectin and the known interaction between factor XIII and fibro-
nectin during the blood coagulation and wound healing processes, it 
was considered important to develop an electrophoretic system which 
would allow the biochemical genetic investigation of fibronectin 
( see Chapter 2). 
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Electrophoresis in a number of different media is a standard tool 
for the investigation of the genetic control of proteins. By utilising 
a suitable electrophoresis system to screen plasma fibronectin samp les 
from a number of different human populations from several areas of the 
world it was hoped to determine the gene frequencies of any poly-
morphic or rare alleles at the structural locus for plasma fibronectin. 
In addition, it was hoped that the electrophoretic bandi~g patterns 
produced by these alleles would allow a genetic model for plasma fibro-
nectin to be determined together with the exact genetic relationship of 
plasma and cellular fibronectin. With the finding that plasma fibronectin 
fro m man was electrophoretically invariable, plasma samples from a 
number of domestic animals were also investigated in a further attempt 
to produce an explanation of the genetic control of fibronectin (see 
Chapter 2). 
If plasma fibronectin was ~olymorphic, it was intended to look 
at the interaction of the purified products of the different alleles 
with the products of the polymorphic alleles, FXIIIA*l and FXIIIA*2 
at the factor XIII A subunit structural loci to determine if there 
were any differences which could be physiologically important. 
However, as plasma fibronectin proved to be electrophoretically 
invariable, this part of the study had to be restricted to the normal 
form of plasma fibronectin with the Type l and Type 2 A subunits of 
factor XIII ( see Chapter 5). 
The A subunits of coagulation factor XIII are polymorphic for 
two common alleles in all populations studied. In addition, a third 
allele, FXIIIA*4 , has been reported in Melanesians fro m Fiji. Because 
of the potential imp ortance of factor XIII A subunits as a genetic 
marker in population genetic studies, it was i mportant to define the 
distribution of the alleles at the A subunit structural locus more 
- 3 -
closely. Therefore, a number of populations in the region from the 
Indonesian archipelago, through Papua New Guinea and Australia to the 
Pacific Island regions of Melanesia, Micronesia and Polynesia as well 
as a population from the Caspian Littoral of Iran and of Pima Indians 
from South America, were investigated (see Chapter 4). 
During the course of the population survey for factor XIII a 
new allele was found which codes for unstable A subunits. Because 
of the probable importance of this allele in the aetiology of congen-
ital factor XIII deficiency it was considered that families with 
factor XIII deficiency should be investigated in order to determine 
the frequency of the occurrence of this allele in individuals with 
this disorder (see Chapter 4). In addition, the biochemical charac-
teristics of these functionally abnormal A subunits were investigated 
to a limited extent (see Chapter 5). 
) 
The biochemical characteristics of the two common alleles of the 
factor XIII A subunit locus are largely unknown. Therefore, the Type 
land Type 2 A subunits were purified and investigated in an attempt 
to determine if any physiologically important biochemical differences 
exist between them. 
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Chapter 1 
I. HISTORICAL EVENTS (1948-76) 
A. Nomenclature 
The name Fibronectin 1s used to describe a family of structurally 
and immunologically related high molecular weight glycoproteins that are 
widely distributed in animal tissues and body fluids. The term fibro-
nectin was suggested by Kuusela et al . (1976) to emphasise the tendancy 
of the protein to bind to fibrous proteins (fibra~ fiber and nectere ~ 
to bind). Prior to the use of the term fibronectin the glycoprotein 
had been known by an abundance of names (Table 1.1). 
B. History 
In 1948, Morrison et al. reported the presence of cold insoluble 
globulin (Cig) in plasma cryoprecipitates. Unlike fibrinogen (another 
component of the cryoprecipitate) Cig was not thrombin coagulable. 
The report of Edsall et al. (1955) led to the suggestion that Cig was 
a modified dimer of fibrinogen. In 1957, Smith and Von Korff described 
a protein with similar properties to Cig in heparin-induced cold 
precipitates. 
Mosesson e t al. (1968) demonstrated that Cig was immunochemically 
identical with a serum protein unrelated to fibrinogen during the 
investigation of a patient with a chronic intravascular coagulation 
syndrome. This led to the purification of Cig with the concomitant 
production of evidence that Cig was a unique and major plasma protein 
(Mosesson and Umfleet, 1970). 
By the 1970 1 s, a number of studies were focussed on the effect of 
transformation by oncogenic viruses on the cell surface proteins of 
fibroblasts. In 1975, Ruoslahti and Vaheri reported that Cig was 
- 5 -
TABLE l . l . 
PREVIOUS NAMES OF FIBRONECTIN 
Name 
Cold-Insoluble Globulin 
Large, External, Trans-
formation Sensitive Protein 
Surface Fibroblast Antigen 
Cell Surface Protein 
Galactoprotein A 
Anti-Gelatin Factor 
Cell Attachment Protein 
Opsonic Protein 
Cell Adhesion Factor 
Zeta-Protein 
Cell Spreading Factor 
Band l, LI Band, Band I 
Major Fibroblast Glycoprotein 
Micro-Fibrillar Protein 
Abbreviation Reference 
Cig Morrison et al . 1948 
LETS Hynes and Bye, 1974 
SFA Ruosl ahti et al. 1973 
CSP Yamada and Weston, 1974 
Gap A Gahmberg and Hakomuri, 
AGF Maurer, 1954 
c-CAP Klebe, 1974 
Saba, 1970 
1973 
CAF 
z 
Pearlstein, 1976 
Blumberg and Robbins, 
1975 
CSF Grinnell, 1976 
Hogg, 1974 
Sear et al . 1976 
Ross and Bornstein, 1969 
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antigenically identical to a large transformation-sensitive glyco-
protein (LETS) released from the fibroblast cell surface. Thus, the 
uniqueness of fibronectin as a cell surface/matrix protein and as a 
blood protein was demonstrated. Subsequently, numerous studies of the 
various forms of fibronectin have been undertaken. 
- 7 -
II. DISTRIBUTION 
A. Cellular 
Fibronectin 1s a maJor component of the connective tissue matrix. 
It is particularly abundant in basement and limiting membranes (Linder 
et al. 1975), however, Heathcote and Grant (1981) have suggested that 
fibronectin 1s a component of the cell surface-basement membrane inter-
face rather than a subunit of the basement membrane matrix. Fibronectin 
has been located 1n the embryonic skin, trophoblast and alveolar base-
ment membranes, the sinusoidal walls of the liver, the stroma of lymph-
atic tissue, exocrine glands, mucous membranes, sweat, sebaceous, 
mammary and parotid glands, the spleen and intestine (Mosesson and 
Amrani, 1980 and Pearlstein et al. 1980). Sanes and Cheney (1982) 
have shown that fibronectin is present synaptically and extrasynapti-
cally in the basal membrane of muscle fibres as well as being present 
on the overlying reticular lamina, the surface of blood vessels, 
muscle spindle capsules, myelinated axons and the perineurium and 
diffusely throughout the endoperi- and epimysial connective tissue. 
The absence of fibronectin from glomerular basement membranes indicates 
that it is not invariably associated with basement membrane structures 
(Ruoslahti et al . 1981) . 
In culture fibronectin has been found to be synthesised by, or 
to be associated with, a variety of cells: fibroblasts, amniotic fluid 
cells, vascular and corneal endothelial cells, smooth muscle cells, 
astroglial cells,. secondary Schwann cells, glomerular cells, intesti nal, 
kidney and liver epithelial cells, hepatocytes, chondrocytes, myoblasts, 
some macrophages and early mesenchyrnill cells (Yamada and Olden, 1978; 
Mosesson and Amrani, 1980 and Pearlstein et al . 1980). Fibronectin has 
also been shown to be associated with cervical uterine epithelial cells 
(Alitalo et al . 1982), alveolar macrophages (Czop et al . 1982b), pri mor-
- 8 -
dial germ cells (Heasman e t al. 1981) and platelets and megakaryocytes, 
where it is mainly found in the a-granules (Mosesson and Amrani, 1980 
and Taketomi and Bevel, 1982), but it appears to be absent from liver 
parench_yi :,al cells (Kojima et al. 1981) and neutrophils, eosinophils, 
lymphocytes, monocytes and red blood cells (Grinnell and Feld, 1981). 
The fibronectin on the cell surface and in the extracellular 
matrix is usually located in fibrillar arrays, although on some cells 
the distribution may be punctate in appearance (Yamada and Olden, 1978; 
Mosesson and Amrani, 1980 and Pearlstein et al . 1980). Lyubimov and 
Vasiliev (1982) found that, on mouse fibroblasts, large fibronectin 
fibrils are preferentially located on the surface of the endoplasm, 
while smaller structures are only found on the lammeloplasm. It is 
proposed that the centripetal movement of receptor-attached fibro-
nectin, a characteristic of other receptor-attached proteins (Vasiliev 
and Gelfand, 1981), on the cell surface promotes this distribution 
pattern. Intracellular fibronectin has been located on the cisternae 
of rough endoplasmic reticulum and in the large vacuoles of the Golgi 
area in a granular perinuclear distribution (Yamada, 1978 and Vaheri 
et al. 1980) . The distribution of fibronectin is usually determined 
by immunolocalisation studies with anti-fibronectin antibodies. 
B. Body fluids 
Fibronectin 1s also found 1n plasma and serum (Morrison et al . 
1948), amniotic fluid (Chen et al. 1978), synovial fluid (Vartio et al . 
1981), the cerebrospinal fluid (Kuusela et al . 1978, the bronchial 
fluid (Rennard and Crystal, 1982) and human milk (Zardi et al . 1982). 
The source of fibronectin in body fluids is uncertain. The results 
of Sodium ·oodecyl Sulphate gel electrophoresis (Birdwell et al . 1980) 
suggest that plasma fibronectin does not originate in vascular endo-
thelial cells as has been proposed (Mosesson and Amrani, 1980). At 
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least in plasma, where fibronectin is one of the maJor proteins (325+76 
µg/ml, Stathakis et a l. 1981) it is likely that fibronectinis secreted 
by a variety of cells. Oh et al . (1981) suggested that plasma fibronectin 
1s in equilibrium with tissue fibronectin and that they act as pools for 
each other. The concentration of plasma fibronectin increases exponen-
tially with age (Labat-Robert e t al . l98lb). It is thought that this 
may be related to the fact that fibronectin from senescent fibroblasts 
does not bind to the cell surface in the normal manner (Vogel et al. 
1981 ) . 
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III. FUNCTIONS 
A. The cellular matrix 
Fibronectin has been shown to interact with two components of the 
extracellular matrix, collagen and glycosaminoglycans. These inter-
actions have been discussed in detail elsewhere (Mosesson and Amrani, 
1980; Pearlstein et al. 1980; Ruoslahti et al . 1980a and 1980b; 
Yamada et al. 1980; Mosher and Furcht, 1981 and Vuento et al . 1982). 
The type of matrix formed by a cell appears to differ in a manner 
which is dependent on the type of adhesion exhibited by the cell, for 
example, the typical fibrillar matrix is only shown by non-motile cells 
(Coushman et al. 1982). The extracellular matrix structure is also 
one of the components that determines the growth potential of a cell 
(Couchman et al. 1982). 
Fibronectin binds to all the genetic types of collagen. The 
interstitial collagens (Type I, II and III) interact more readily 
than the basement membrane collagens (Type IV and V) (Engvall et al . 
1978). This is probably due to the conformation of the collagen 
molecules. Silver et al. (1981) have suggested that cells use fibro-
nectin to bind collagen in the matrix but, as will be discussed below, 
the glycosaminoglycan composition of the matrix is important in the 
fibronectin-collagen interaction. Mosher et al . (1980) demonstrated 
that fibronectin could be cross-linked to collagen by the plasma 
transglutaminase, factor XIIIa. The in vivo significance of this 
reaction is uncertain, but it could lead to the stabilisation of the 
matrix. The collagen binding site is distinct from the site which is 
susceptible to factor XIII catalysed cross-linking. 
The use of double staining fluorescent antibody techniques has 
shown that both in connective tissues and the extracellular matrix 
fibronectin and collagen are distributed together (Linder et al. 1975 
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and Bornstein and Ash, 1977). However, some cells form a matrix wit hou t 
any collagen (Culp and Bensusan, 1978) so the interaction cannot be a 
necessity in all cell matrices. 
Fibronectin binds to the following glycosaminoglycans: the more 
heavily sulphated forms of heparan sulphate, hyaluronic acid and chondro-
itin sulphate - containing proteoglycans. Perkins et al . (1979) showed 
that fibronectin near the cell surface is closely associated with proteo-
glycans and suggested that the association may be important in cell-
extracellular matrix interactions. The role of glycosaminoglycans in 
determining the organisation of cell surface fibronectin and the compo-
sition and quantity of the extra-cellular matrix deposited by a cell 
has recently been more closely defined (Laterra and Culp, 1982 and 
Oldberg and Ruoslahti, 1982). Cell surface fibronectin is insolubilised 
by the presence of both collagen and proteoglycans (Oldberg and 
Ruoslahti, 1982). Only endogenous fibronectin binds to hyaluronate 
and then only if it is in multimer aggregates (Laterra and Culp, 1982 
and Rosso et al. 1982). As hyaluronate inhibits the formation of 
f i bron ect in-coll a gen complexes ( Rosso et al. l 982) this may represent 
an important difference between endogenous and exogenous fibronectins. 
The binding of fibronectin to heparin is of three types: a) 2+ Ca only 
sensitive; b) non-specific divalent cation sensitive; and c) diva-
lent cation insensitive . Each type of binding occurs at a unique site 
on the fibronectin molecule (see Chapter I.V.C) (Hayashi and Yamada, 
1982). 
The &n V&Vo formation of cross-linked multi mers of fibronectin by 
factor XIIIa has been demonstrated (Mosher, 1975 and Keski-Oja 
1976). Similar cross-linked multi mers have been located in vivo 
(Mosher and McKeown-Longo, 1982) and may, therefore, be important 
in the irreversible incorporation of fibronectin into the matri x. 
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However, the reduction of disulphide bonds 1n th e fibronectin molecul e 
may be a prerequisite for cross-linking to occur (Williams et al . 1982). 
It is probable that the formation and structure of the extra-
cellular matrix is dependent on the complex interactions between the 
cell, fibronectin, collagen, glycosaminoglycans and a transglutaminase, 
with fibronectin possibly acting as a central organiser. 
B. The cellular cytoskeleton 
Immunofluorescence studies have shown that extracellular fibro-
nectin fibrils run parallel to the long axis of the cell in a similar 
manner to intracellular microfilament bundles (Wartiovaara et al . 1974 
and Hynes and Destree, 1978) although they do not always coincide 
Yamada and Olden, 1978). As fibronectin has been shown to bind to 
actin i n vi t r o (Pearlstein et al. 1980) a transmembrane link has been 
postulated between the two proteins in areas where their distribution 
coincides. Singer (1979) used electron microscopy to show that, in 
the area of cell-substratum interaction actin cables and fibronectin 
fibres are co-linear with a maximum separation of 8-22 nm. 
Fibronectin is particularly abundant in the area of cell-substratum 
contact (Culp, 1976). Transformed fibroblasts have no detectable 
fibronectin and an abnormal morphology. If exogenous fibronectin 1s 
added, the fibroblasts return to a normal morphology and form normal 
actin containing microfilaments (Yamada et al . 1976a and 1976b). 
This 1s possibly due to the area in contact with the substratum being 
used to anchor the microfilaments. 
It is uncertain whether fibronectin controls the distribution of 
microfilaments or if microfilaments control the distribution of cell 
associated fibronectin (Pearlstein et al . 1980). Ho wever, Virtanen 
et al . (1982) have shown that in vitro fibroblasts which lac k fibro-
nectin do not form the characteristic bundles of microfilaments and 
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plaques of vinculin at adhesion sites. 
C. Cell adhesion and spreading 
From the interactions discussed in the previous t wo sections and 
the interaction of fibronectin with fibrin (Ruoslahti and Vaheri, 1975) 
it is likely that one of the main functions of fibronectin i n vivo is 
to mediate cell-cell and cell-substratum interactions. Although the 
demonstration that cellular fibronectin agglutinates formalinised sheep 
red blood cells (Yamada e t al. 1975) indicated that fibronectin played 
a role in cell-cell interactions, most studies have concentrated on 
cell-substratum interactions in in vitro models. 
The normal cell is anchorage dependent for growth in culture. 
It is possible that this is caused by the presence of fibronectin, as 
cells with intercellular and surface fibrillar fibronectin do not 
grow under anchorage-independent conditions (Rajaraman and Lonergan, 
1982). The attachment of cells to the substratum requires divalent 
cations and the expenditure of cellular metabolic energy (Klebe, 1974; 
Grinnell, 1976 and Pearlstein, 1976). The presence of fibronectin 
appears to be essential for most cell types to adhere to a substratum 
in culture (Pearlstein, 1976; Pearlstein and Gold, 1978; Grinnell 
and Hays, 1978 and Couchman et al. 1982). However, some cell types can 
adhere in the absence of fibronectin (Federgreen and Stenn, 1980). 
Virtanen et al. (1982) have demonstrated that cultured human fibro-
blasts do not require fibronectin for adhesion and spreading, although 
focal adhesion sites are not formed in the absence of fibronectin. 
It is suggested that there are cell-dependent and cell-independent 
phases in cell-substratum adhesion and that the deposition of endogenous 
pericellular fibronectin is only required in the former phase. 
Investigators in the early 1970 1 s described the presence of cellu-
lar attachment plaques, areas of the cell in contact with the sub-
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stratum and other cells. Fibronectin 1s found in high concentrations 
in attachment plaques (Abercrombie et al . 1971; Harris, 1973 and 
Shields and Pollock, 1974) and in several cell types it is concen-
trated in the area where the cell is in contact with the basement 
membrane (Pearlstein et al. 1980). In addition to fibronectin, a 
140,000 molecular weight protein is also abundant in cell attachment 
plaques and is thought to act in a cooperative manner with fibronectin 
1n cell attachment (Carter, 1982 and Rieber and Rieber, 1982). 
All these observations suggest that fibronectin forms a bridge 
between cell surfaces and between the cell surface and the substratum. 
The proof that the cell binding site is in a ~eparate domain of the 
fibronectin molecule to the collagen binding site is important in this 
regard (McDonald e t al. 1981). If this model is correct then there 
must be receptors for fibronectin on the cell surface. Yamada et al . 
(1981) have shown that these receptors consist of or contain ganglio-
sides or other negatively charged lipids. Glycoprotein receptors which 
contain N-acetyl-glycosamine residues have been isolated from platelet 
membranes (Hansen and Clemmensen 1981 and 1982). As some cells only 
adhere to fibronectin complexed with collagen (Pearlstein, 1978) the 
receptors of these appear to only recognise the complex. The stability 
of the cell-cell and cell-substratum links is probably enhanced by the 
interaction of fibronectin which heparan sulphate and the fact that 
fibronectin molecules can be cross-linked by intermolecular disulphide 
bonds and by a transglutaminase. The binding polysaccharide for fibro-
nectin on neural tumo~rcells is a heavily N-sulphated heparan sulphate 
(Culp and Darnen, 1982). Grinnell and Feld (1982) proposed that in vi-vo 
heparan sulphate is as important as fibronectin in cell spreading. 
The behaviour of fibronectin in the cell cycle is consistent with 
a role in the maintenance of cell morphology and cellular attachment 
(Hynes and Bye, 1974). 
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Culp et al . (1979) suggested that hyaluronic acid and chondroitin 
may interact with fibronectin to loosen the adhesion for cell movement 
to occur as these two molecules are deposited in "footprints" left 
behind by cells when they move over a substrate. Fibronectin has also 
been shown to stimulate the directed migration or chemotaxis of cells 
(Vaheri et al. 1980 and Baron-Van Evercooren et al. 1982). 
D. Embryogenesis 
If fibronectin mediates cell adhesion and spreading through a 
variety of molecular interactions as suggested above, it is probable 
that the levels of fibronectin 1n embryonic tissues will play a role 
in development. Linder et al. (1975) showed that the amount of fibro-
nectin in embryonic tissues is developmentally regulated with the 
report that the differentiation of myoblasts to form muscles is 
accompanied by a loss of fibronectin. Hassel et al . (1979) suggested 
that the loss is due to the cells no longer being able to bind fibro-
nectn rather than through a reduction of fibronectin synthesis. 
Support for this hypothesis comes from the results of Chiquet et al . 
(1981). 
Studies of embryogenesis in several diverse organisms, sea 
urchins (Spiegal et a l. 1980), Xenopus l aevis (Heasman e t al . 1981 ), 
avian species (Hanke and Sawyer, 1982; Mitrani and Faberov, 1982 and 
Tomasek et al. 1982) and mice (Brownell e t al. 1981 and Silver et al . 
1981) indicate that the deposition of fibronectin on the cell surface 
1s important as early as the blastula and gastrula stages as well as 
1n tissue and organ morphogenesis. It is probable that fibronectin 
1s essential for directed cell migration and the maintenance of the 
cohesion and orientation of cells during the cleavage stages of embryo-
genesis (Spiegal et al . 1980 and Mitrani and Faberov, 1982). 
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E. Blood coagulation and wound healing 
Fibronectin has been shown to interact with fibrinogen and fibrin 
during clot formation (Ruoslahti and Vaheri, 1975). The concentration 
of fibronectin in human serum is between 20-50% lower than in plasma 
and· a normal clot contains 94-95% fibrin, 3-5% fibronectin and 0-1 % 
a2-plasmin inhibitor (Chen et al . 1977 and Mosher and Furcht, 1981). 
In vi tro fibronectin can bind covalently or non-covalently with fibrin. 
The covalent association results from y-glutamyl- s-lysyl cross-linkages 
catalysed by plasma factor XIIIa (Mosher, 1975). In patients with 
factor XIIIa deficiency the fibronectin concentration is the same in 
the serum after clot formation as that in the plasma (Mosher, 1976a). 
It is therefore probable that in vivo fibronectin is cross-linked to 
the clot. McDonagh (1981) has suggested that a direct interaction 
between factor XIII and fibronectin could be part of a control mechanism 
that ensures that a sufficiently high level of enzyme concentration 
exists for normal clot formation to occur. 
Fibronectin is also associated with platelets (Mosesson and 
Umfleet, 1970). Most of the fibronectin is found in the intracellular 
a-granules. After the platelet release reaction induced by thrombin 
about 50% is released into the medium, the rest is bound to the platelet 
plasma membrane (Zucker et a l. 1979 and Ginsberg and Plow, 1981). Plow 
and Ginsberg (1981) have shown that thrombin-stimulated platelets 
specifically bind plasma fibronectin. Both these reactions will result 
in fibronectin concentrations being high at the site of clot formation. 
The presence of fibronectin on the platelet surface should enable the 
platelets to be cross-linked into the clot. 
The presence of fibronectin in the clot only subtly alters the 
properties of the clot. In fine clots the elastic modulus is reduced 
by half while, in coarse clots, t he elastic modulus is do ub led (Mosher, 
1975). 
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At the site of the wound fibronectin forms a coat on the fibrin 
clot (Grinnell and Feld, 1981) which may play a dual role. If the 
fibronectin is cross-linked to the surrounding collagen substratum, 
the clot would be anchored and stabilised. It could also act as a 
matrix for collagen deposition (Mosher and Furcht, 1981). 
Grinnell et al . (1980) have shown that fibronectin is required 
for fibro~asts to interact with fibrin in vitro . The implication that 
the presence of fibronectin in the clot is required for normal healing 
is supported by studies on factor XIII deficient patients (Duckert 
et al. 1960 and Beck et al. 1961 ), where the abnormal processes of 
wound healing are probably associated with the failure of fibronectin 
to be covalently incorporated into the clot and that the migration of 
fibroblasts into the clot is dependent on the chemotactic activity of 
fibronectin (Seppa et al. 1981). The observation that exogenous 
fibronectin can promote the premature entry into the growth phase 
by motile fibroblasts may also be important in the wound healing 
process (Couchman et al. 1982). Fibronectin may also play a role 1n 
clot lysis as the presence of fibronectin enhances the initial rate 
of activation of plasminogen by urokinase (Iwanaga et al . 1978). 
The occurrence of fibronectin in the necrotic area of fibrotic 
human livers (Hahn et al . 1980 and Kojina et al . 1981) and 1n 
arthritic joints (Scott et al . 1982) suggests that the presence of 
fibronectin is important in the early stages of fibrosis. At least 
in the liver, it appears that the deposition of fibronectin precedes _ 
that of collagen at the locus of tissue repair (Kojima et al . 1981). 
F. The mononuclear phagocytic system (The reticuloendothelial system) 
The mononuclear phagocytic cells (macrophages) are distributed 
throughout the body, although they are mainly associated with the spl een, 
liver and bone marrow. Macropha ges function by recognising and removin g 
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(via phagocytosis) a var ietyof particulate matter from the vascular 
system, including bacteria, immune complexes, injured platelets, 
fibrin aggregates and tumour cells (Saba, 1970; Mosesson and Amrani, 
1980 and Pearlstein et al . 1980). The uptake of particulate matter is, 
at least partly, controlled by the presence of opsonic signals on the 
surface of the targets. The best studied opsonins are immunoglobulin G 
(IgG) and C3b, a component of the complement pathway. 0psonisation 
means the promotion of particle ingestion by phagocytic cells. Generally 
opsonins mediate particle recognition and initiate the mechanisms 
necessary for ingestion. 
The exact role that fibronectin has in phagocytosis is uncertain. 
In vitro studies have shown that fibronectin mediates the attachment of 
certain particulate matter to macrophages and monocytes (Molnar 
1979a; Mosesson and Amrani, 1980 and Marquette et al . 1981). The 
ability to maintain normal phagocytic activity i n vi vo has been 
correlated with the level of plasma fibronectin (Saba, 1970 and Blumen-
stock et al. 1978). However, no causal relationship has been proven 
for the two factors (Lundsgaard-Hansen, 1982 and Rubli et al . 1982). 
The opsonin-independent phagocytosis of particles that activate the 
alternative complement pathway by alveolar macrophages is enhanced by 
fi:bronectin (Czap et al . 1982b). Also an 160,000 M.W. protein thought 
to be derived from fibronectin promotes the phagocytosis of the above 
particulate activators by peripheral blood monocytes (Czop et al . 1982a). 
This observation is important as other studies have shown that the 
complete fibronectin molecule does not promote pha gocytosis by the 
mononuclear phagocytic system (Molnar et al . 1979a; Mosesson and Amrani, 
1980 and Marquette et al . 1981). 
Fibronectin binds and can be cross-lin ked to Staphylococcus aureus 
but not to Escherichia coli or Mycobacterium butyricum (Mosher and 
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Procter, 1980 and Mosher and Furcht, 1981) . Verbrugh et al . ( 1981) 
have shown that fibronectin binds to a staphylococcal surface protein 
shared by strains of S. aureus and Staphylococcus epidermidis~ but that 
compared to IgG and C3b fibronectin has a relatively minor role as an 
opsonin for staphylococci. Fibronectin also mediates the attachment of 
S. aureus to neutrophils (Procter et a l. 1982), Streptococcus pyogenes 
to neutrophils (Simpson et al. 1981) and Pseudomonas aeniginosa to buccal 
epithelial cells (Woods e t al . 1979). Although S . aureus is not ingested, 
the number of colony forming units is reduced, therefore this attachment 
may play an important role in limiting acute infe(tion prior to the 
development of specific immunity (Procter e t al . 1982). Fibronectin 
also specifically promotes fibrin attachment to monocytes (Jilek and 
Hormann, 1978), stimulates the alternative complement pathway (Czap 
e t al. 1981), binds to Clq, a component of the complement pathway 
(Menzel et al. 1981 and Bing et a l. 1982) and binds deoxyribonucleic 
acid (DNA) (Mosher and Furcht, 1981). 
It is therefore apparent that fibronectin 1s involved 1n the mono-
nuclear phagocytic system, but whether it acts as an opson1n,as a 
stimulator of the alternate complement pathway, as a molecule that 
permits macrophages to attach to their targets or all three in vivo 1s 
unclear at the present. 
G. Summary 
Fibronectin, through its primary interactions with collagen, fibrin 
(ogen), glycosaminoglycans and cells, has been shown to have a range of 
bi o l o g i cal act iv i ti es (Tab l e 1 . 2 ) . As a res u l t of these act i vi ties , 
fibronectin has been postulated to play an important role in the main-
tenance of cellular morpholo gy, tissue morphogenesis, wound healing, 
blood coagulation and the mononuclear pha gocytic system. 
Fibronectins from the cell surface and plasma do not exhibit 
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identical biological activities (Yamada and Kennedy, 1979). The bio-
logical activities in the mediation of cell attachment to collagen and 
in cell spreading in serum-free medium are the same, but they differ 
markedly (plasma fibronectin shows very little activity) in the capacity 
to haemaglutinate or to restore a normal morphology and social behaviour 
to transformed fibroblasts. These results suggest that plasma fibro-
nectin is more important for platelet attachment or cell spreading, 
while the cellular form has a more general role. 
TABLE l .2. 
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THE PROPOSED BIOLOGICAL ACTIVITIES 
OF FIBRONECTIN 
The deposition of the extracellular matrix 
The mediation of cell-cell aggregation 
The mediation of cell-substrate interaction 
The control of cell spreading 
The Mediation of fibrin(ogen) attachment to macrophages 
The control of clot lysis 
The mediation of fibrin clot retraction by fibroblasts 
The control of platelet binding to clots 
A chemotactic activity 
A regulatory role in the cell cycle 
A role in cell differentiation and morphogenesis 
·-
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IV. FIBRONECTIN IN DISEASE 
A. Fibronectin and malignant transformation 
Hynes and Bye (1974) reported the presence of a large, external 
transformation sensitive protein (fibronectin) on cell surfaces. The 
changes in the distribution of cell surface fibronectin on transformed 
cells and the possible importance of these changes have been the subject 
of a large number of studies since that report. Several comprehensive 
reviews of the role of fibronectin in malignant transformation have been 
published (Vaheri and Mosher, 1978; Yamada and Olden, 1978; Chen et al. 
1979; Hynes et al. 1979; Pearlstein et al . 1980; Ruoslahti et al . 
1980a and Yamada, 1980) therefore only the current views are summarised 
here. 
The amount of cell surface fibronectin is usually decreased after 
cell lines have been transformed by oncogenic viruses (Vaheri and Mosher, 
1978). The correlation between fibronectin loss and transformation 1s 
best illustrated by temperature sensitive oncogenic virus mutants. At 
the permissive temperature fibronectin is lost, but if the temperature 
is reduced to a non-permissive level fibronectin is bound to the cell 
surface (Yamada and Olden, 1978). The level of surface fibronectin is 
also reduced in some chemically and spontaneously transformed cell lines 
and some cultured tumour cells. However, there are exceptions where 
the surface bound fibronectin 1s unaltered, especially among spontan-
eously transformed cell lines (Ruoslahti et al . 1980a). Stanbridge 
et al . (1982) have utilised human cell hybrids between fibroblasts 
and Hela cells to show that both nontumouri genic and tumour i genic 
hybrids express reduced levels of fibronectin relative to the fibro-
blast parent cell. However, the distribution of fibronectin on the 
cell surface differs. The nontumourigenic hybrids exhibit an incom-
plete branched fibrillar network over areas of cell contact, while 
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tumourigenic hybrids show a short stitchlike pattern exclusively at 
cell-cell junctions. 
Reports which correlated the loss of cell surface fibronectin 
with tumourigenicity or the propensity of tumours to metastasise have 
been questioned because of the methodology used (Vaheri and Mosher, 1978) 
and the results of in vivo studies of human rectal carcinomas (Niemczuk 
et al . 1982). However, Rajaraman and Loriergan (1982) have demonstrated 
a correlation between the loss of cell surface fibrillar fibronectin 
and the ability of cells to grow in anchorage independent conditions 
(a property usually considered to be the best in vitro correlate of 
in vivo tumourigenicity). The proteolysis of fibronectin may be 
involved in cell transformation as De Petro et al, (1981) have shown 
that the transformation of fibroblasts infected with temperature 
sensitive mutants of Rous sarcoma virus is enhanced by defined proteo-
lytic fragments of plasma fibronectin. 
The addition of fibronectin to the culture medium of transformed 
cells can partly restore the normal morphology of the cells (Yamada and 
Olden, 1978). The changes seen can all be accounted for by the restora-
tion of normal cell-substratum adhesi·dn . (Vaheri and Mosher, 1978) and 
intracellular microfilament structure (Rieber and Rieber, 1982); both 
of which involve fibronectin (Chapter l .III.Band C). 
The cellular matrix of transformed cells show a loss of collagen 
and an alteration in quantitative proportions of glycosaminoglycans as 
well as the loss of fibronectin (Hayman et al . 1982). This indicates 
that there is a general disorganisation of the cell matrix around trans-
formed cells which removes controls on cell multiplication and loco-
motion (Vaheri and Mosher, 1978). The fact that this can occur with-
out fibronectin loss suggests that it is the alteration of a number 
of the cell matrix components rather than just one that 1s important. 
- 24 -
It 1s unlikely that these changes are the mechanis ms which cause cells 
to metastasise or be tumourigenic, but rather that they are one of the 
changes that allow these two processes to occur when the cell responds 
to some, as yet unknown, signal (Vaheri and Mosher, 1978 and Pearlstein 
et al. l 980). 
The mechanisms which cause the loss of fibrillar fibronectin fro m 
the cell surface are uncertain (Vaheri and Mosher, 1978). Some cells 
show a decreased synthesis of fibronectin but in hepatocytes synthesis 
i s i n c re a s e d by transform at i on ( Ha h n et a Z. l 9 8 2 ) . I ha r a et al . ( l 9 8 2 ) 
have demonstrated that the human cytomegalovirus,a suspected oncogen, 
can specifically suppress fibronectin synthesis in some cell types. 
Transformed cells exhibit an altered microfilament structure but, as 
discussed above (Chapter l .III.B), fibronectin is only one factor 
involved in the formation of actin bundles. If the model of Lyubi mov 
and Vasiliev (1982) for the cell surface distribution of fibronectin 1s 
correct (Chapter l .II.A), then the loss of fibrillar fibronectin may 
involve an intracellular change which effects the movement of cell 
surface receptors for fibronectin. The possibility that the increased 
proteolytic activity associated with transformed cells results in the 
proteolytic cleavage of fibronectin is doubtful as the fibronectin 
released 1n culture has the same molecular weight as the intact 
molecule (Vaheri and Mosher, 1978). However, a fragment of fibronectin 
(MAD-2) which binds DNA, has an elevated concentration 1n the serum of 
patients with malignant disease (Parsons e t al . 1979). A major alter-
action in the structure of fibronectin does not occur after transform-
ation (Vaheri and Mosher, 1978 ), althou gh fib ronectin fro m malignan t 
cells migrates at a slower rate on sodium dodecyl sulphate gels. 
Embryonic fibronectin mi grates at the same rate as fibronectin fro m 
ma l i g n a n t c el l s ( Va h er i et a l . l 9 8 0 ) . 
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It has recently become apparent that abnormal prot~in phosphory-
lation has an important role in some virally mediated cancers (Cohen, 
1982). Therefore, the finding of an increased phosphorylation of fibro-
nectin from transformed cells (Ali and Hunter, 1981) may be of special 
significance. 
The level of plasma fibronectin in most car.cer patients does not 
differ from that of controls, 348 µg/ml compared to 350 µg/ml (Statha-
kis et al. 1981; Kl ingemann et al. l 982 and Suzuki and· Abe!I 1982). 
However, in extensive liver metastases the level is lowered to 
. 
259.8 µg/ml (Stathakis et al. 1981) which suggests that the liver 
either synthesises some of the plasma fibronectin or that its catabol-
ism is increased. The levels of plasma fibronectin have also been 
reported to drop to 50% of normal in acute leukaemia patients in poor 
clinical condition (Brodin et al. 1982), while in chronic lymphatic 
leukaemia a reduction in serum opsonic activity, which is not corre-
lated with IgG, IgA, IgM, C3 or C4 ( Kansu et al . 1982), may be corre-
lated with fibronectin levels. Two complications of cancer also alter 
the plasma levels: in obstructive jaundice, due to carcinoma of the 
pancreas, the level 1s raised to 444.6 µg/ml while, if cryofibrino-
genaem,a 1s a complication, the level drops to 282.2 µg/ml (Stathakis 
et al. 1981 ) . Kl in gemann et al. ( 1 982) have reported the presence of 
a slower fibronectin component (FN:C) in the plasma of acute myelocytic 
and acute lymphocytic leukaemia patients after two-dimensional immuno-
electrophoresis. The levels of FN:C are correlated with the clinical 
state of the patients with the lowest levels occurring during rem1ss1on 
(Klingemann et al. 1982). Suzuki and Abe (1982) have found a similar 
component in the plasma of patients with gastric carcinomas. 
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B. Other diseases 
l. Liver and kidney disease 
The liver is thought to act in the turnover of plasma fibronectin 
1n at least two ways: a) fibronectin synthesis by hepatocytes and 
b) consumption by Kupffer cells (Hofelar et al . 1982). In severe liver 
disease, either due to neoplastic infiltration (Stathakis et al . 1981 
and Matsuda et al. 1982) or due to cirrhotic lesions (Hofelar et al . 
1982), the plasma concentration 1s reduced to as low as· 50% of normal. 
The degree of reduction is dependent on the severity of the lesion 
(Hofelar et al. 1982) . The reduction of plasma fibronectin levels 
could be due either to an increase in catabolism mediated by a raised 
fibrinolytic activity (Matsuda et al. 1982) or to. a reduced hepatic 
synthesis (Hofelar et a l. 1982). In some less severe liver and kidney 
disorders the plasma level of fibronectin 1s raised (Stathakis et al . 
1981 and Matsuda e t a l . 1982); possibly due to an increased synthesis 
of fibronectin for tissue repair . 
Hofelar et al. (1982) have found a second slower migrating 
fraction of fibronectin after two-dimensional electrophoresis in plasma 
from cirrhotic patients, similar to that found in some cancer patients 
(Klingemann et al . 1982 and Suzuki and Abe, 1982) (Chapter 1 .IV.A) , 
which increases with the severity of the disease. It is possible that 
it is fibronectin bound to phagocytable biological substances, which 
are not eliminated from the circulation because of the impaired clear-
ance function of the liver mononuclear phagocytic system (Hofelar et al . 
1982). It is probable that a similar model could exp lain the FN:C 
band 1n some cancer patients . 
2. Interstitial lun g diseases 
The interstitial lung diseases are a het ero ge nous group character-
ised by the abnormal accummulation of inflammatory cells and connective 
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tissue elements in the pulmonary interstitium together with changes ,n 
parenchymal cell populations and organisation. They often lead to 
fibrosis with derangements of interstitial collagen (Rennard and 
Crystal, 1982). 
Fibronectin may play a role in the mononuclear phagocytic system 
(Chapter l .III.F). Therefore the knowledge that alveolar macrophages 
are activated in interstitial lung diseases and that there are 
increased levels of fibronectin 1n the lower respiratory tract of 
patients with interstitial lung diseases (Rennard and Crystal, 1981) 
suggests that the two may be involved in the alteration of alveolar 
structures associated with these diseases. 
Rennard et al. (l98la) have shown that alveqlar macrophages are 
probably the only inflamnatory and immune effector cells in the human 
lower respiratory tract that produce significant quantities of fibro-
nectin and that in patients with interstitial lung disease alveolar 
macrophages produce an increased level of fibronectin (Table l .3). 
The increased synthesis of fibronectin by alveolar macrophages is 
probably responsible for the reported increased fibronectin levels 
in the bronchial lavage fluid (Rennard and Crystal, 1982) (Table 1.3). 
The fibronectin produced is chemotactic for fibroblasts. Rennard 
et al. (l98la) suggest that alveolar macrophages play a role in the 
reorganisation of alveolar structures in interstitial lung diseases 
through the increased secretion of fibronectin, which may function 
in a number of ways, which include fibroblast recruitmentj the 
induction of fibroblast division and collagen opsonisation, all of 
which lead to the development of fibrosis. 
3. Scleroderma and systemic lupus erythematosus 
In normal skin fibronectin is found in the papillary layer and 
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TABLE l .3. 
FIBRONECTIN PRODUCTION IN INTERSTITIAL LUNG DISEASES 
(from Rennard et al . 1981a; Rennard and Crystal, 1982) 
Fibronectin Concentration 
Fibronectin of the Bronchial Patients Production Lavage Fluid 
mg/10 6 cells/hr µg/mg albumin 
Normal 0.49+0.23 1 . 6+0. 4 
* Idiopathic Pulmonary 10. 5+ 1 . 7 4.3+0.9 
Fibrosis 
* Sarcoidosis 5.4+2.4 5.4+0.l 
Others 3.5+1 .3 4.3+0.8 
* Significant P~0.02 
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within collagen bundles in the reticular dermis. Subcutaneous tissue 
1s negative for its presence as judged by i mmunofluorescence. 
Scleroderma (progressive systemic sclerosis) is a generalised 
connective tissue disorder characterised by the deposition of collagen 
in the skin and internal organs. In this disorder there is an increa-
sed deposition of fibronectin in the involved deep dermis which paral-
lels the accummulation of collagen in the involved reticular dermis. 
Fibronectin is also found in the subcutaneous tissue, but there 1s 
only slight change in the subepidermal papillary region (Cooper et al. 
1979 and Fleischmajer et al . 1980). Fibronectin . binds to collagen 
in the region of the collagenase cleavage site. It is, therefore, 
possible that collagenase may be inhibited by steric hindrance. A 
decrease in collagenase activity has been demonstrated in scleroderma 
and is thought to be responsible for collagen accummulation (Brady, 
1975). 
Changes 1n the skin distribution of fibronectin have also been 
reported in patients with systemic lupus erythematosus (Fyrand, 1980 ). 
There are fibronectin negative gaps and slit formation in the dermal/ 
epidermal junction combined with the presence of fibronectin positive 
globular bodies and the transport of fibronectin into the epidermis. 
Also fibronectin is found in cryoprecipitates of the synovial fluid 
of systemic lupus erythematosus patients (Beaulieu et al . 1981). 
4. Inflammatory bowel disease (Scott et al . 1981) 
In the normal rectal mucosa fibronectin is found in epithelial 
cells, on basement membranes and as a loose cribriform network in 
the extracellular matrix of the lamina propria,which codistributed 
with reticulin (a matrix bound to i mmatu re collagen). Immunoelectron-
microscope studies show fibronectin on collagen fibres, on smooth 
muscle cells and within and between columnar epithelial cells. 
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Patients with active ulcerative colitis, or active Crohn 1 s colitis, 
with marked inflammatory changes show a different distribution. Fibro-
nectin is thickened and more prominent on the basal membranes and is 
seen as sparse strands between inflammatory cells that have infiltrated 
the lamina propria. In patients with longstanding ulcerative colitis, 
which 1s no longer active, there 1s a diffuse increase in fibronectin 
which 1s densely and uniformly present throughout the la~ina propria. 
The fibronectin distribution of the lamina propria appears to go 
through a sequence of changes ininflammatory bowel disease. At first 
the cribriform distribution is unaltered, but a soarse reticular 
pattern develops which leads to an eventual diffuse distribution. 
As fibrosis is not typical of these diseases the deposition of 
fibronectin is apparently involved 1n a different function. It is 
thought that the changes in fibronectin distribution may be a useful 
means of indirectly assessing the disease process in rectal biopsies. 
5. Rheumatoid arthritis 
The synovial cavity of joints 1s an extension of the interstitial 
space and lacks a basement membrane. The composition of the synovial 
fluid is dependent on the permeability of the adjacent blood vessels 
and on the local synthesis of proteins by cells of the synovial mem-
brane. Under normal conditions the amount of synovial fluid is too 
small to permit samples to be taken. However, in the inflammed joint, 
characteristic of rheumatoid arthritis, the joint volume and protein 
content increase to levels that allow the aspiration of samples. 
Vartio et al . (1981) reported that the average synovial fluid 
fibronectin level in arthritis pati ents was 445+103 µg/ml while t he 
plasma levels were in the normal range, a result confirmed by 
Clemmensen and Anderson (1982 ) and Scott et al . (1982) . Ther e was 
also a prominent increase of fibronectin 1n the proli feratin g con-
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nective tissue in rheumatoid arthritis as compared to the normal mem-
brane. These results suggest that the level of fibronectin is due to 
an increased local synthesis in the synovial cavity (Vartio et aZ. 
1981 and Scott et aZ. 1982). Cryoprecipitates are found in the syno-
vial fluid and the plasma of rheumatoid arthritis patients (also in 
ankylosing spondylitis and mixed essential cryoglobinaemia patients). 
-Fibronectin is present in and facilitates the formation of all mixed 
cryoglobulins~ but is absent from polyclonal cryoglobulins (Levo, 
1980). It is therefore not responsible for the formation of the 
cryoprecipitate antigen-antibody complexes (Bea~lieu et aZ. 1981). 
Tissue breakdown and repair is a continuous process in most 
inflammatory diseases and it is possible that th~ increased local 
production of fibronectin 1s a general marker for the formation of 
new connective tissue rather than a specific marker for disease. 
The fact that fibronectin is generally at a higher level in differ-
entiating tissues lends support to this possibility. However, Scott 
et aZ. (1982) suggest that fibronectin levels in the synovial fluid 
could serve as an indicator of tissue response to rheumatoid arthritis. 
Clemmensen (1981) has suggested that the proteolytic products 
of fibronectin may play a role in the inflammatory process. However, 
the evidence for. fibronectin proteolysis in the synovial fluid 1s 
contradictory (Vartio et aZ. 1981 and Clemmensen and Anderson, 1982). 
6. Shock, trauma and septicaemia 
A reduction in the level of plasma fibronectin is a common 
feature of patients with sepsis after surgery, in trauma (burn and 
haemorrhage) patients and patients with intravascular coagulation 
syndromes (Mosesson et a Z. 1975; Mosher and Williams, 1978; Saba 
et a Z. 1978 and Pott et aZ . 1982). Part of the reason for this is 
the formation of fibrinogen-fibrin complexes in which fibronectin 
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appears to act as the nuclear molecule (Mosher and Furcht, 1981 and 
Clemmensen, 1982). The other major reason for the reduction in fibro-
nectin levels is thought to be the increased utilisation of fibro-
nectin in the opsonisation of autologous tissue and colloidal matter 
1n the circulatory system (Saba et al. 1978 and Clemmensen, 1982). 
The reduction in fibronectin levels appears to be important in the 
depression of the mononuclear phagocytic system 1n the above patients 
(Dillon and Saba, 1982 and Dillon et al . 1982). The injection of 
cryoprecipitate or purified fibronectin intravenously has been shown 
to restore the level of plasma fibronectin and improve septicaemia, 
pulmonary insufficiency and the duration of recovery (Saba et al . 
1978). The mononuclear phagocytic systems acti~ity is also raised 
(Saba et al . 1978). The depression of the mononuclear phagocytic 
system in disseminated intravascular coagulation is partially 
mediated by plasmin breakdown products of plasma fibronectin (Ehrlich 
et al . 1981). Despite this the infusion of cryoprecipitate in septic 
injured patients offers a simple method for the prevention of multiple 
organ failure (Saba et al. 1978). 
The concentration of plasma fibronectin required for normal 
function of the mononuclear phagocytic system is not known, but patients 
with less than 50% of the normal concentration (less than 150 µg /ml) 
have a higher mortality rate (Mosher and Furcht, 1981). Despite this 
uncertainty, Saba et al . (1978) have suggested that the measurement of 
plasma fibronectin levels during severe sepsis which follows trauma 
may be an accurate non-intrusive measure of the activity of the mono -
nuclear phagocytic system. It is also possible that low plasma fibro-
nectin concentrations may define a group of patients at high risk 
for developing disseminated intravascular coa gula tion (Clemmensen, 
1982). 
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Fibronectin levels are also reduced in somE infectious diseases, 
for example, Rocky Mountain Spotted Fever (Mosher, 1976). In septi-
caemia the fibronectin pattern on isoelectric focussing gels is 
altered; possibly due to the action of proteases and glycosidases 
which show increased levels in patients (Pott, 1982). 
7. Ehlers-Danlos syndrome 
The Ehlers-Danlos syndromes (EDS) are a heterogenous group of 
heritable disorders of the connective tissue characterised by skin 
and joint hyperextensibility. Bleeding manifestations are common 
and, occasionally, a defect in platelet aggregation or an abnormality 
in blood coagulation have been reported. In some kindreds a bio-
chemical defect in collagen synthesis has been sbown (Hollister, 1978) 
but 1n the rest the underlying defect has not been determined. 
A new form of EDS, designated EDSIX, characterised by hypermobile 
joints, defective wound healing, hyperdistensible skin and defective 
platelet aggregation has been recently reported (Furcht et al . 1979 
and Arneson et al. 1980). It is a mild recessively inherited variant 
of EDS in which all the abnormalities cosegregate. The defective 
platelet function was shown to result from a consistent resistance to 
collagen induced aggregation. This defect could be partially corr-
ected in vitro by the addition of cryoprecipitate or purified fibro-
nectin, from normal individuals, to the patients platelet rich plasma. 
The fact that only incomplete correction of platelet aggregation was 
achieved, is possibly explained by the fibronectin of the platelet 
a-granule having a role in aggregation. 
As fibronectin plays an adhesive role ,n platelet aggregation 
(Furcht et al . 1979) and binds to collagen and other components of the 
extracellular matrix in connective tissue, it is possible that EDSIX 
results from an alteration of the collagen binding site of fibronectin, 
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presumably caused by a point mutation . 
8. Glanzmann's thrombasthenia 
Glanzmann's thrombasthenias are probably a heterogeneous group of 
rare inherited disorders. The normal mode of inheritance is recessive, 
but a dominant form has been reported (McKusick, 1978). Glanzmann's 
thrombasthenia is characterised by a bleeding diathesis, deficient 
clot retraction and abnormal platelet morhpology in vivo and reduced 
platelet aggregation and adhesivenss in vitro . A patient with the 
typical laboratory characteristics, but with an additional wound 
healing abnormality has been reported (Donati et al . 1977 and 
Remuzzi et al. 1977). Additionally fibroblasts from the skin of this 
patient are unable to induce fibrin-clot retraction. The presence of 
fibronectin has been shown to be essential for fibrin-clot retraction 
(Grinnell et al. 1980). 
As the levels of plasma fibronectin are normal in thrombasthenic 
patients (Pearlstein et al. 1981) it has been claimed that the fibrin 
binding site of fibronectin 1s deficient (Clemmenson, 1981). However, 
there is no direct evidence to support this claim. An abnormal 
platelet membrane glycoprotein (152,000 M.W.) and the loss of a 
platelet membrane glycoprotein (M.W. 120,000-132,000) have been rep-
orted in some thrombasthenic patients (Nurden and Caen, 1974 and Degas 
et al. 1975) which is compatible with the recent observation that there 
1s either a deficient membrane binding site for ca2+ or a deficient 
membrane glycoprotein which anchors the major platelet antigen to the 
membrane in Glanzmann's thrombasthenia (Howard et al . 1982) . This, 
combined with the fact that platelets from thrombasthenic patients do 
not bind fibronectin (Ginsberg et al . 1981), suggests that the plate-
let membrane receptors for fibronectin, rather than the fibronectin 
molecule, are abnormal in some cases of Glanzmann's thromba sthenia. 
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However, as the disease appears to be heterogeneous (M~ser et al. 1968 
and Hathaway, 1972), a fibronectin with an abnormal fibrin-binding 
site could be the cause of some cases. 
C. Summary 
Although changes 1n fibronectin distribution and concentration 
are associated with a variety of disease states in man, · no disease 
has been proven to result from an alteration of the structure or 
function of the fibronectin molecule. While it seems certain that the 
loss of cell surface fibronectin is important i~ the oncogenic process, 
it is doubtful that it is a causal mechanism. The increased levels of 
fibronectin in diseases that are associated with fibrosis or tissue 
repair (Chapter l .IV.B l-5) probably reflects the role of fibronectin 
in these processes (Cooper et a l. 1979; Fleischmajer et al. 1980 
and Kojima et al. 1981). The exact relationship between plasma fibro-
nectin depletion and the reduced function of the mononuclear phagocytic 
system in several groups of patients is uncertain, but is the subject 
of continued study. 
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V. THE MOLECULAR STRUCTURE OF FIBRONECTIN 
Fibronectin from several species of mammals has been examined in 
an attempt to determine the molecular structure of fibronectin with 
nearly identical results. Therefore, results from these studies, which 
include bovine, equine, porcine, hamster and human fibronectin, will be 
combined to give a current model for the structure of {i6ronectin. 
A. Primary structure 
l. Sodium dodecyl sulphate gel electrophoresis. 
Sodium dodecyl sulphate (SOS) polyacrylamide electrophoresis has 
been used to examine plasma, amniotic fluid and cellular fibronectin. 
While the results for amniotic fluid and cellular fibronectin are 
similar, the results for plasma fibronectin suggest that it might be 
structurally different. 
Non-reduced amniotic fluid and cellular fibronectins migrate as a 
single diffuse band which corresponds to a Molecular Weight of 450,000 
(Mosesson et al. 1975) to 480,000 (Pande et al . 1981). Some high 
molecular weight material from cellular fibronectin did not enter the 
gel and was found to correspond to multimers of the above molecule 
(Hynes and Destree, 1977; Keski-Oja et al . 1977 and Yamada et al . 
1977). Examination of the multimers showed a high degree of inter-
chain disulphide bonds which are thought to account for the insolubil-
ity of these multimers (Ruoslahti and Vaheri, 1974 and Yamada et al . 
1977), however, the 450,000 M.W. molecule is also less soluble than 
the amniotic fluid derived mo lecule (Mosesson and Amrani, 1980) . 
md berg and Ruoslahti (1982) have recently shown that the inter-
reaction of fibronectin with collagen and proteoglycans in the extra-
cellular matrix are the cause of the insolubility of fibronectin from 
this source. Reduced cellular fibronectin migrates as a single broad 
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band which corresponds to a Molecular Weight of 210,000-250,000 (Hogg, 
1974; Yamada and Weston, 1974 and Mosesson et al. 1975), while the 
molecular weight of amniotic fluid fibronectin is 235,000 (Balian et al. 
1979a) to 240,000 (Pande et al. 1981). SOS gel electrophoresis, there-
fore, suggests that cellular and amniotic fluid fibronectin is a dimer 
of two identical polypeptide chains. 
Non-reduced plasma fibronectin also migrates as a stngle band of 
about 450,000 M.W. (Mosesson et al. 1975 and Sekiguchi ?t al. 1981 ). 
Reduced plasma fibronectin, however, migrates as a closely spaced 
doublet (Mosesson et al. 1975 and Mosher, 1975). Jhe exact molecular 
weights of the two bands is uncertain but estimates of the difference 
vary from 5,000 (Kurkinen et al. 1980) to 20,000 (Sekiguchi et al. 
1981). Both molecularweights are in the same range as that given for 
reduced cellular fibronectin above. However, Yamada et al. (1980) have 
estimated that the molecular weight of plasma fibronectin is 5,000-10,000 
lower than cellular fibronectin. 
It, therefore, appears that plasma fibronectin is a dimer of non-
identical polypeptide subunits which are possibly both different to the 
polypeptide subunit of cellular and amniotic fluid fibronectin (Table 1 .4). 
The plasma fibronectin dimer is probably composed of non-identical sub-
units as SOS gel electrophoresis only resolves a single band (Yamada et al. 
1980), but as the band is diffuse it may comprise two bands, each a 
dimer of identical subunits (Sekiguchi et al. 1981) or three bands formed 
by two homodimers and a heterodimer. 
Isoelectric focussing of SOS treated plasma and amniotic fluid 
fibronectin revealed similar banding patterns with an apparent iso-
electric point of 5.0 (Pande et al . 1981). 
SOS gels have also been used in the mapping of the functional 
domains of fibronectin (Chapter l.V.C). 
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TABLE 1.4 . 
THE APPARENT MOLECULAR WEIGHTS OF PLASMA, 
CELLULAR AND AMNIOTIC FLUID FIBRONECTINS 
(for references see text) 
Plasma 
Dimer 450,000 
Monomer 210,000 - 215,000 
230,000 - 230,000 
Source of Fibronectin 
Cellular Amniotic Fluid 
480,000 
240,000 
480,000 
240,000 
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2. The amino acid composition of fibronectin 
The amino acid composition of fibronectin from plasma, amniotic 
fluid and the cell surface, are very similar (Table l .5 and Vuento et al . 
1977 and Pande et al . 1981). Fibronectin has an unusually high threo-
nine content (Balian et al . 1979~ and is relatively rich in praline and 
poor in cystine residues (Mosesson et al . 1975 and Mosher, 1975). The 
amino-terminus is blocked by pyroglutamate in all the forms studied 
except for chick cell-associated fibronectin (Yamada et al . 1977). 
Pearlstein et al. (1980) have calculated that a maximum of 22 disul-
phide bonds may be present in the dimer. However, there are probably 
less as, at least, three free sulphydryl groups are thought to be 
required for cell binding (Fukuda and Hakomori, 1979). Petersen et al . 
(1981) have reported the presence of 10 intrachain disulphide bridges in 
the first 259 residues from the amino terminus and 2 in the first 52 
residues from the carboxyl terminus. An interchain disulphide bridge is 
located close to the carboxyl terminus (Chen et al . 1977). Vibe-Pedersen 
et al. (1982) were only able to locate l free thiol group (per subunit) 
close to a carbohydrate residue in a 27 amino acid sequence from the 
central 170,000 M.W. region of the molecule. Smith et al . (1982) have 
narrowed the location of this thiol group to a 80,000 M.W. region in 
the carboxyl half of the molecule. 
The complete amino acid sequence of fibronectin has still to be 
elucidated, although 1050 of the proposed 1880 amino acids of a sub-
unit of bovine plasma fibronectin have been sequenced (Skorstengaard 
et al . 1982). The sequencing studies have revealed 3 different domains 
of internal homology (Vibe-Pedersen et al . 1982) one of which has 5 
copies in the amino terminal 259 residues (Petersen et al . 1981). Amino 
terminal sequencing has been used to study the structure of the 
functional domains of fibronectin (Pande and Shively, 1982) (Chapter l .V. C). 
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TABLE l .5. 
THE AMINO ACID COMPOSITION OF FIBRONECTIN 
Residues/l ,000 residues 
Plasma Amniotic Fluid Cellular Amino Acid 
a b p . C d Human Hamster Human Human orc,ne 
Aspartate 94 94 91 95 93 
Threonine l 03. 7 104 l 04 l 01 l 03 
Serine 74.7 73 80 78 76 
Glutamate 117 120 114 122 118 
Praline 83.7 85 87 92 74 
Glycine 84.3 86 84 88 98 
Alanine 42.3 44 44 43 47.5 
Half-Cystine 25 29 16 25 20.5 
Valine 76.3 72 84 73 71 . 5 
Methionine 9.7 10 l l l l 12.5 
Isoleucine 43.7 47 46 42 41 . 5 
Leucine 54 56 56 56 58 
Tyrosine 42.3 41 40 36 38.5 
Phenylalanine 24.7 24 22 25 23 
Histidine 21 . 7 19 21 20 l 9. 5 
Lysine 36 36 38 32 35.5 
Arginine 52.3 53 51 50 52.5 
Tryptophan 21 . 5 21 l l 36 
a from Mosesson et al . (1975), Mosher (l975)and Balian et al . (1979b); 
b Seki guchi et al . ( 1981); 
c Isemura etal . (1981); 
d Balian et al. (1979b); 
e from Ya ma da et al . (1977) and Balian et al . (1979b). 
e 
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The amino-terminal 13 residues of fibronectin from plasma, amniotic 
fluid and the cell are identical (Pande et al . 1981). The tryptic pep-
tides of fibronectin from various sources show extensive correspondence 
(Balian et al. 1979b), but each type does have unique bands on SOS 
electrophoresis (Pande e t al. 1981). However, 2-dimensional peptide 
maps of cellular and plasma fibronectin, as wel1 as the two subunits 
-
of plasma fibronectin appear identical (Birdwell et al . 1980). 
3. The carbohydrate content of fibronectin. 
The amount and type of sugar residues attached to fibronectin is 
dependent upon both its origin 1n the body and the species from which 
the sample is taken. There is generally 4-6 oligosaccharide units on 
each fibronectin monomer, which account for 4-7% of the weight of the , 
fibronectin molecule. Because of the differences in the carbohydrate 
composition of plasma, amniotic fluid and cellular fibronectin (Table 
1 . 6 ) , i t 1 s ea s i est to cons i de r · th em separately. 
a) Plasma fibronectin - the oligosaccharide units are biantenn-
ary asparagine-linked carbohydrate chains with branching predominantly 
at 3,6-linked mannose and with an equal distribution of 4- and 6-linked 
intrachain galactose. Sialic acid is the predomin ant terminal sugar. 
N-acetylglucosamines are also present and traces of fucose and N-
acetylgalactosamine have been reported. In man there are 4-6 sites 
of attachment and the carbohydrate accounts for 4.8% of the weight of 
the fibronectin monomer (Mosesson et al . 1975; Vuento et al . 1977; 
Yamada et al . 1977; Carter et al. 1978; Balian et al. 1979b; 
Fu k u d a and Ha k omo r i , 1 9 7 9 ; Ta k a s a k i et al . 1 9 8 0 and Pan de et al . 
1981). The predominant carbohydrate structure in hamsters 1s almost 
identical (Fukuda etaZ. 1982). 
b) Amniotic fluid fibronectin - the oligosaccharide units are 
more complex than those of the plasma form, with 3,6- and 2,4-lin ked 
- 42 -
TABLE l .6. 
THE CARBOHYDRATE COMPOSITION OF FIBRONECTIN FROM MAN 
% Dry Weight 
Residue Plasma a Amniotic Fluidb Celle 
Fucose Trace 0.4 
Mannose l . l l . l l . 3 5 
Gal actose 0.95 l . 7 l . 00 
Xylose 
- 0.03 
N-acetylglucosamine l . 65 2.5 l . 50 
N-acetylgalactosamine 0. l 0.7 
Sialic acid 0.75 0.6 0.60 
4.55 7.0 4.48 
a from Vuento et a l. (1977) and Balian et al . (1979b); 
b Balian et al. (1979b); 
C 
from Vuento et al . (1977) and Yamada et al . (1977). 
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mannose and 3- and 4-linked, but no 6-linked, galactose. The terminal 
sugars are fucose, mannose, galactose, N-acetylglucosamine and sialic 
acid. N-acetylgalactosamine is also present. The carbohydrate content 
1s 6.8% by weight (Balian et al. 1979b and Pande et al . 1981). 
c) Cellular fibronectin - there is a core region of N-acetyl-
glucosamine and mannose attached to asparagine residues which has 
-terminal galactose, fucose and sialic acid residues. Xylose has been 
reported to be present. The carbohydrate content 1s similar to that 
of plasma (Mosesson et al. 1975 and Yamada et al. 1977). The cell-
associated fibronectin has differnt carbohydrate ·groups in different 
species. Chick embryo fibronectin has twice as much sialic acid, 
glucose and xylose (Yamada et al. 1977) and hamst~r embryo fibro-
nectin has 3 terminal galactose and 2 terminal sialic acid residues 
(Fukuda and Ha~omori, 1979); the sialic acid is linked c3 to galac-
tose while human is linked c4 or c6 (Pearlstein et al. 1980). 
Olden et al. (1978) have shown that fibronectin without carbo-
hydrate moieties has a normal rate of synthesis and secretion and 
unchanged biological activities, but it is 2-3 times more sensitive 
to proteolysis. It therefore appears that the role of the carbo-
hydrate moieties is to protect the fibronectin molecule from proteo-
lytic cleavage. Bernard et al. (1982) have confirmed this observa-
tion and shown the collagen-binding region of fibronectin (Chapter l .V. 
C), which normally contains 3-4 carbohydrate structures, is completely 
digested by proteases if the structures are removed. 
It is possible that the difference in carbohydrate composition of 
plasma and amniotic fluid fibronectin accounts for their different 
behaviour on SOS gel electrophoresis (Balian et al . 1979b and Pande 
et al. 1981), but there may be other causes ( see Chapter l V C). 
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4. Phosphorylation of fibronectin 
Covalently bound phosphorylation of fibronectin occurs intra-
cellularly and is the same on fibroblast surface, plasma and fibro-
blast secreted fibronectin (Ledger and Tanzer 1982). Phosphate groups 
are only present as phosphoserine(Ali and Hunter, 1981 and Ledger and 
Tanzer, 1982) which are restricted in a 20,000-50,000 M.W. region near 
one of the ends of the molecule (Ledger and Tanzer, 1982). 
B. Immunological studies 
The various forms of fibronectin show complete immunological 
identity (Mosesson et al. 1975 and Mosher, 1975). The antigenic 
activity of fibronectin closely reflects the structural intactness of 
the monomer (Vuento et al. 1980 and Koteliansky e~ al. 1982a). The 
reduction of disulphide bonds in the presence of BM urea followed by 
alkylation decreased the antigenic activity by 90%. Vuento et al . (1980) 
reported a rapid loss of antigenic activity at 60°c, but their results 
have been criticised because the assay used was sensitive to protein 
solubility (Wallace et al. 1981 ). 
Several groups of workers have raised monoclonal antibodies to a 
variety of antigenic determinants on the fibronectin molecule (Ather-
ton and Hynes, 1981; Atherton et al. 1981; Kotel i an sky et al. 1982a; 
Sekiguchi et al. 1982; Smith and Furcht, 1982 and Smith et al. 1982). 
The monoclonal antibodies have been used as an aid to map the function-
al domains of fibronectin (Chapter l.V.C) and to locate a species-
specific determinant (Chapter 1 . VI . B), as well as to define two areas 
of difference between cellular and plasma fibronectin (Chapter l .V.C). 
C. The location of functional domains 
If a protein consists of several functional doma ins, a si mple 
method of generating specific fragments, which are structurally and 
functionally intact, is limited proteolysis. This is because an 
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extended polypeptide chain is accessible to proteases and is readily 
hydrolysed, whereas any cleavage sites located within a folded domain 
tend to be buried orinaccessible because of steric hindrance (Yamada 
et al. 1980). Studies which have utilised enzyme degradation have 
suggested that fibronectin contains domains connected by such an 
extended polypeptide chain (Balian et al. 1979a), and have located a 
sequence of four amino acids, Pro- Gln- Pro- His which is repeated 1n 
these chains (Pande and Shively, 1982). Therefore, a riumber of pro-
teases have been used in conjunction with SOS electrophoresis (for 
molecular weight determinations)and affinity chromatography (for 
functional determinations) to map the different protease resistant 
functional domains of fibronectin. Recent studies have also used 
monoclonal antibodies as an additional aid. The general procedures 
for these studies have been discussed clearly elsewhere (Yamada e t al. 
1980; Sekiguchi et al. 1981; Hayashi and Yamada, 1981 and Vartio, 
l 982) . 
A composite arrangement of the plasma fibronectin molecule is 
shown in Figure l.l. The data for the map is drawn from the following 
references: Chen et al. (1977); Jilek and Hormann (1977); Iwanaga 
et al. (1978); Balian et al. (1979a) and (1979b); Gold e t al . (1979); 
Furie et al. (1980); McDonald and Kelly (1980); Mosher and Procter 
(1980); Mosher et al. (1980); Sekiguchi and Hakomori (1980); Yamada 
et al. (1980); Akiyama et al. (1981); Hayashi and Yamada (1981); 
Isemura e t al. (1981); McDonald e t al . (1981); Petersen et al. (1981); 
Pierschbacher et al. (1981); Sekiguchi et al . (1981); Ehrisman et al . 
(l 982); Hayashi and Yamada ( 1982); Hormann et al . ( 1982); Isemura 
et a l. (1982); Pande and Shively (1982); Sekiguchi et al . (1982); 
Smith and Furcht (1982); Smith et al . (1982) and Vartio (1982). 
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A MODEL FOR THE STRUCTURE OF PLASMA FIBRONECTIN 
A. Proposed binding sites (not in linear order within 
domains) - A: actin; F: fibrin; S: Staphylococcus 
aureus ; T: Transglutaminase cross link sites; 
H: heparin; C: collagen; P: polyamine; 0: QNA; 
X: cell attachment site; FN: fibronectin self-
association sites. 
In addition, another polyamine site is present 1n 
domains 5-7 and a fibronectin self-association site 
1s present in domains l-4. 
B: known differences with cellular fi_bronectin, 
approximate locations. 
B. Sulphydryl Groups 
Domains l and 2 have 10 intrachain disulphide 
bonds; domain 9 has 2 intrachain disulphide 
bonds; domain 6 contains a free sulphydryl 
group; S-S: interchain disulphide bond 
Carbohydrate Residues 
Domains 3 and 4 contain 4 groups; domain 6 
contains a single group. 
The domain sizes shown do not represent their sizes 1n 
the fibronectin molecule. 
A F S T H C P HADS F X H S F FN H D T 
NH2 I · ·2H3· · 5 8 COOH 
s15 
NH2 I · ·3H4· · 5 7 ·- ? • COOH 
fi 
+ 1 ·J kd 
fl 
- 10 kd 
~ 
+ I kd 
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l. Regions of uncertainty in the doma in map 
The major area of uncertainty surrounds the exact difference between 
the two subunits of plasma fibronectin. A region of between 20,000-
25,000 M.W. next to the carboxyl terminal fragment which contains a fibrin 
binding site (Sekiguchi et al. 1981), a fibronectin self-association site 
(Ehrisman et al. 1982) and possibly a factor XIII susceptible site 
(Hormann et al. 1982) appears to be either partially or totally absent 
in the smaller subunit (Fig. l .l ). While the results of Isemura 
(1981), Sekiguchi et a l. (1981) and Ehrisman et al. (1982) suggest that the 
deletion is extensive, Smith and Furcht (1982) and Smith et al. (1982) 
suggest that, if there is a deletion, it is of no more than 5000 M.W. 
There are, however, other differences between the subunits; · proteolytic 
digestion with thermolysin shows at least three differences (Akiyama 
l 981 ) . 
The exact order of functional sites within some domains is un-
certain (Fig. 1.1) as is the number of binding sites for certain macro-
molecules. The number of heparin binding sites has been reported as 
between 2 (Sekiguchi et al. 
(Hayashi and Yamada, 1 981 ) . 
dependent on divalent cation 
(Hayashi and Yamada, 1982) . 
(Hayashi and Yamada, 1982) . 
1981 and Smith and Furcht, 1982) and 5 
However, the report that heparin binding 1s 
concentration may explain these differences 
There appear to be a minimum of three sites 
The relationship between these sites and 
those for hyaluronate is uncertain. Isemura et al. (1982) suggest that 
there are multiple sites for hyaluronate distinct from those for heparin, 
while Yamada et al. (1980) suggest that at least one site is shared. In 
contrast Laterra and Culp ( 1982) and Rosso et al . ( 1982) found that 
plasma fibronectin did not bind to hyaluronate. The number of sites for 
attachement to fibrin (Ehrisman et al . 1982). S . aureus (Kur kinen et al . 
1980 and Vartio 1982), polyamines (Vartio, 1982) and DNA (Mc Master and 
Zardi, 1982) are also uncertain. In add ition Koteliansky et al . (1982 b) 
have shown that fibronectin has an affinity 
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for four actin-binding proteins, vinculin, a-actinin, tropomyosin and 
myos1n, but it is uncertain if binding sites for these proteins are 
present on the fibronectin molecule. It appears that the larger subunit 
of plasma fibronectin contains at least 22 functional sites and the 
smaller subunit at least 20. 
2. Differences between cellular and plasma fibronectin 
SOS gel electrophoresis after protease cleavage suggested that 
differences in the polypeptide sequence and the molecular weight of 
cellular and plasma fibronectin exist (Yamada and Kennedy, 1979 and 
Chapter ·1. V.A). At present three definite differences have been found 
by digestion with thermolysin. However, others may be present as of 
twentynine fragments generated fifteen show a different migration on 
SOS gels (Hayashi and Yamada, 1981). There is no · evidence for two 
different subunits 1n cellular fibronectin, but the relationship of 
the single subunit to the proposed two subunits of plasma fibronectin 
1s not known (Chapter l.VI.A.l). Two of the identified differences are 
an extra 1,300 M.W. segment near the collagen binding site and an extra 
1,000 M.W. segment near the carboxyl terminal in plasma fibronectin 
(Hayashi and Yamada, 1982). These two segments probably correspond to 
differences located by monoclonal antibodies close to the collagen 
binding site (Atherton and Hynes, 1981) and close to the carboxyl 
terminal (Atherton et al . 1981). The third polypeptide difference 
involves an extra 10,000 M.W. segment in cellular fibronectin in a 
region containing a heparin binding site (Hayashi and Yamada, 1982 
and Fig~ 1 . 1 ) . 
D. Secondary and tertiary structure 
Electron microscopy has shown the fibronectin molecule to be 
approximately 160 nm long (but ranges from 120 nm) and 2 nm 1n diameter 
(Erikson et al . 1981). There are no visible globular units and the 
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two subunits are joined · at the carboxyl termini (Engel et al. 1981 
and Erikson et al. 1981). It is uncertain whether the subunits are 
joined end to end (Erikson et al. 1981) or whether they enclose an 
angle of 70° with each arm measuring about 60nm in length (Engel et al . 
1981). The subunit arms show a limited flexibility with three distinct 
regions at which preferential flexion occurs (Engel et al . 1981 ). It 
is probable that these three regions are proteolytic susceptible areas 
between the functional domains. 
The sedimentation coefficients reported for fibronectin range from 
7.2-7.6 (Pearlstein et al. 1980) to 12-14 (Vaher ·i and Mosher, 1978). 
The former suggests an assymetric non-globular protein, while the latter 
suggests a spherical, globular protein. Yamada and Olden (1978) also 
suggested that the molecule is assymetric. None of these results agree 
entirely with those from electron microscopy. 
The results from circular dichroism are also contradictory. In 
some reports no secondary structure is revealed (Yamada and Olden, 
1978 and Koteliansky et al. l98la) while in others considerable 
S- st ru ct u re i s pre d i ct e d ( Moses son et al. l 9 7 5 ) . Fi bro n e ct i n does 
appear to contain some s-structure as infrared spectroscopy indicates 
that an anti-parallel s-structure accounts for 35% of the molecule 
(Koteliansky et al. l98la). Neither of these techniques reveal any 
evidence for fibronectin being a globular protein. 
Thermal stability, differential scanning colorimetry and intrin-
sic fluorescence studies suggest that fibronectin contains at least 
three domains connected by flexible segments which allow the domains 
independent movement in solution (Alexander et al. 1979; Kotel iansky 
et al . l 9 81 b and Wa l l ace et al . l 9 81 ) . Moses son and Amr an i ( l 9 8 0 ) 
have suggested that the conformational features can be accounted for 
by interactions between aromatic side chain groups within the peptide 
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backbone and the presence of a B-pleated sheet a~d S-turns. However, 
further studies are required before the secondary and tertiary struct-
ures of fibronectin are fully elucidated. 
E. Summary 
A structural model for plasma fibronectin based on the results 
given above is shown in Figure 1 .1. The essential features of the 
structure of fibronectin that have been revealed are: 
a) All forms of fibronectin consist of two polypeptide subunits. 
In the plasma form of the molecule they are apparently non-
identical, while in the cellular form they appear to be 
identical; 
b) Fibronectin molecules from all sources are immunologically 
identical and have very similar amino acid compositions; 
c) The carbohydrate residues attached to fibronectin differ on 
fibronectin from different sources. These residues protect 
the molecule from proteolysis; 
d) Fibronectin consists of at least three functional domains 
connected by flexible polypeptide chains; 
e) Three differences between cellular and plasma fibronectin have 
been localised by the use of proteolytic cleavage and mono-
clonal antibodies; 
f) At least two differences exist between the subunits of plasma 
fibronectin; one is within the cell spreading domain, the 
other is an extra fibrin-binding domain in the larger subunit; 
g) All the differences found are located in the internal part of 
the mo lecule, and are therefore not the result of simple proteo-
lytic cleava ge . 
These results indicate that the adhesive and binding interactions 
between cells, extracellular macromolecules and fibronectin can be ex-
plained by a combination of the appropriate active sites. A prediction 
- 51 -
of this model 1s that cell substratum interaction· only requires the 
monomer while cell-cell adhesion requires at least the dimer (Yamada 
et al. 1980) . 
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VI. THE EVOLUTION AND GENETICS OF FIBRONECTIN 
A. Genetics 
l. How many structural loci? 
There have been few genetically oriented studies of fibronectin 
Consequently, it is not known whether or not the different forms are 
-
under the control of a single structural locus. Some of the results 
obtained from studies of the function (Section III) and· the structure 
(Section V) of fibronectin are pertinent to this problem. 
a) The functional properties of plasma and ·cellular fibronectin 
are different. Cellular fibronectin is a more affective haema-
glutinin and ,sable to restore nonnal morphology and social 
behaviour to transformed fibroblasts (Yamada and Kennedy, 1979). 
b) SOS polyacrylamide gel ·electrophoresis suggests that cellular 
and amniotic fluid fibronectins are heavier than plasma fibro-
nectin and that while cellular and amniotic fluid fibronectins 
consist of identical subunits, the subunits of plasma fibro-
nectin have different molecular weights (Mosesson et al . 1975; 
Mosher, 1975 and Balian et al. 1979b). 
c) Proteolytic cleavage indicates that there are a number of 
internal differences in amino acid sequence in fibronectins. 
The collagen-binding domain is longer in plasma fibronectin and 
the larger subunit of plasma fibronectin has an extra fibrin-
binding domain and a longer cell spreading domain than the 
smal 1 er subunit ( Yamada et al . 1980; Isemura et al . 1981 and 
Sekiguchi et al . 1981). 
There are a number of possible explanations for the above results, 
some of which involve the presence of more than one structural locus 
for fibronectin (Yamada et al . 1980; Ehrisman et al . 1982 and Late r ra 
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and Culp, 1982). At present it is impossible to be certain how many 
loci exist, but a copy of a fibronectin gene has been isolated and 
clo~ed (Fagan et al. 1981). Therefore, with available recombinant DNA 
technology, an answer should be available in the near future. 
2. The chromosomal location of the fibronectin structural loci 
0werbach e t al. (1978) suggested that a gene required for the 
expression of fibronectin was located on human chromosome number 8 
as in the human/mouse cell hybrids which they studied fibronectin 
production was concordant with the presence of chromosome 8 and an 
enzyme marker for chromosome 8, glutathione reductase (GSR). However, 
the fibronectin assay used was not species specific and when one of 
their positive cell lines was re-examined with specific anti-human 
and anti-mouse antisera the fibronectin was found to be mur1ne 
(Klinger and Ruoslahti, 1980). Studies utilising a non-species 
specific antisera suggested that a structural locus for fibronectin 
was on chromosome 11 (Eun and Klinger, 1979 and 1980). Smith et al . 
(1979) also suggested that a structural locus was present on chromo-
some 11 but, in addition, a regulatory locus was present on chromo-
some 3. 
Klinger and Ruoslahti (1980) apparently confirmed the presence of 
a structural locus on chromosome 11 by the use of human specific anti-
sera to fibronectin. Fibronectin fibril formation was syntenic with 
chromosome 11 and an enzyme marker for chromosome 11, lactate dehydro-
genase A. However, they reported the presence of one cell line with a 
chromosome 11 which did not produce fibronectin fibrils. A possible 
criticism of their assay is that it measures the formation of fibro-
nectin fibrils rather than the production of fibronectin. It 1s, 
therefore, possible that the locus on chromosome 11 controls the 
formation of fibrils ( Chapter 1 .II. A). 
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Rennard et al . (l98lb) and Church (19 81) have used a species 
specific enzyme immunoassay and have shown a 100% concordance between 
the production of fibronectin and chromosome 8 and GSR, thereby 
indicating that a structural locus for fibronectin is present on 
chromosome 8. 
A possible explanation of the contradictory results of the above 
studies is that more than one structural locus for fibronectin is 
present in the human genome. One locus may be present· on chromosome 
8 and another on chromosome ll. In the cell hybrids examined it is 
possible that the locus being expressed is different. Until further 
studies are carried out the location of the structural gene(s) 
remains uncertain, but is likely to involve chromosome 8. 
B. Conservation of the fibronectin molecule during evolution 
The role of fibronectin in cell-cell adhesion, cell-substratum 
interactions and the mononuclear phagocytic system suggests that the 
fibronectin molecule could show a considerable degree of conservation 
during evolution. Studies on mammals and birds with an antisera 
raised against human fibronectin in rabbits, indicate that this may 
be the case. All species studied to date have shown immunogenic 
cross reactivity, for example, chicken (Blumberg and Robbins, 1975; 
Linder et al. 1975; Yamada et al . 1975 and Kotelians ky et al . 1982a), 
mouse (Yamada et al . 1976a), rhesus monkeys (Mosher, 1976b and 
Koteliansky et al . 1982a), bovines (Iwanaga et al . 1978 and Birdwell 
et al . 1980), rat (Molnar et al . 1979b), hamster (Fu kuda and Ha komori, 
1979) and porcines (Isemura et al . 1981). The structure and functions 
of fibronectin from these species is also similar. 
Fibronectin has also been detected in the elasmobranch, Torpedo 
californica (Engvall et al . 1978) , the sea urchin, Sphaerechinus granu-
laris (Spiegal et al . 1980) , th e horse shoe cra b, Limulus (Ak iyama et al . 
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1981), the marine spon ges, Microconia porifera (Akiyama et al . 1981) 
and Tethya (Labat-Robert et al . 1981a) and the freshwater sponge , 
Ephydatia mulleri (Labat-Robert et al . 1981a), but not the earthworm 
(Akiyama et al . 1981) with anti-human fibronectin antisera . As the 
sponges (Porifera) represent the earliest forms of multicellular life, 
these results suggest that the fibronectin molecule has been highly 
conserved durin g phylogenesis. As some of the antigenic sites of fibro-
nectin appear to be conformationally determined (Vuento ·etal . 1980 and 
Wallace et al. 1981),the above results would suggest that some of the 
functional domains present in mammalian fibronectin existed in some of 
the earliest multicellular organisms to evolve. 
It is possible to raise monoclonal antibodies with species-speci-
ficities, one such antibody to a site in the central region of the 
plasma fibronectin molecule will cross react to human and rhesus 
macaque plasma fibronectin, but not to rat, calf, pig and chick plasma 
fibronectin (Koteliansky et a l. 1982a). 
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Chapter 2 
I. INTRODUCTION 
In view of the biological processes 1n which fibronectin is 
involved and its apparent role as a substrate for factor ~III in blood 
coagulation and wound healing (see Chapter l .III) in addition to the 
absence of any definite information on the genetic control of the vari-
ous forms of fibronectin (see Chapter l .VI.A), it was decided to deve-
lop a procedure by which structurally abnormal, as well as normal, 
variants of fibronectin could be rapidly identif~ed. 
Fibronectin does not have a biological activity that could 
readily be used to develop a chromatogenic or fluorescent stain to 
detect its presence. However, the relatively high plasma concentration 
of fibronectin, 325+76 µg/ml (Stathakis et al. 1981), permits the 
localisation of the molecule by immunological techniques. Because 
crossed-immunoelectrophoresis does not permit the screening of large 
numbers of samples and is difficult to interpret from a genetic view, 
it was decided to locate plasma fibronectin by immunofixation after 
electrophoresis (Alper and Johnson, 1969). A procedure for the electro-
phoresis of fibronectin on thin layer agarose gels which would allow 
good resolution of the fibronectin molecule was therefore developed. 
The existence of genetic variants of plasma fibronectin, which are 
detectable by electrophoresis, would give some clues to the genetic 
control of the plasma form. In addition the examination of cellular 
fibronectin from individuals with variants of the plasma form should 
enable a better understanding of the genetic relationship of the two 
forms to be reached. 
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Studies of the structure of pl asma and cellular fibronectin have 
suggested that the plasma form of the protein is a dimer of non-
identical subunits, while the cellular (and amniotic fluid) form con-
sists of two identical subunits (see Chapter 1 .V). The relationship 
of the cellular fibronectin subunit to the two subunits of plasma 
fibronectin is uncertain (Yamada et al. 1980; Ehrisman et al . 1982 
and Laterra and Culp, 1982). 
As fibronectin is known to be a dimer (Mosesson et al . 1975; 
Mosher, 1975 and Balian et al. 1979b), the electrophoretic pattern 
of genetic variants in a heterozygote can be predicted. If a protein 
1s a dimer of identical subunits, as appears to be the case for 
cellular fibronectin, the heterozygous presence of a variant with a 
different electrophoretic mobility would result in a three banded 
pattern being observed after electrophoresis. The random assembly of 
the two types of subunit into dimers would result in the production 
of homodimers identical to those found in homozygotes for each form 
and a heterodimer with an electrophoretic mobility midway between the 
two homodimers. Whereas, if a protein is a dimer of non-identical, 
non-allelic subunits, the presence of a variant of one of the subunits 
would result 1n a two-banded pattern. The constant subunit would form 
a dimer with each of the variant and the usual form of the other sub-
unit. If the non-identical subunits are, ,n fact, allelic . then a 
three-banded pattern would be expected after electrophoresis. The 
three bands would represent dimers between the product of each allele 
with a modified product of the same allele (the fast and slow bands) 
and the product of each allele with a modified product of the other 
allele (the middle band). However, if the mutation in the variant 
allele altered the modification process, the exact banding pattern 
would be difficult to oredict. The modification could arise because I 
of differential gene processing or post-translational processes. 
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Five possible genetic explanations of the observed structures of 
plasma and cellular fibronectin, as well as the expected electrophoreto-
grams of plasma and cellular fibronectin ' when a variant is present 1n 
the heterozygous state, are discussed below and are illustrated in 
Figure 2. l : 
Model l: 
There 1s a single structural gene for both cellular and plasma 
fibronectin. The smaller plasma subunit is formed as a result of 
post-translational modifications of 50% of the subunits in plasma. 
This model would predict a three-banded pattern dfter electrophoresis, 
for both plasma and cellular fibronectin (Figure 2.1 .a). 
Post-translational modifications are, however, an unlikely explan-
ation for the two plasma subunits. Plasma and cellular fibronectins are 
known to have slightly different functional properties (Yamada and 
Kennedy, 1979), but the removal of carbohydrate groups and the alteration 
of sulphydryl and amino groups do not affect the functions of fibronectin 
(Olden et al. 1978 and Pearlstein e t al. 1980). In addition, the 
structural differences, both between cellular and plasma fibronectin 
and between the subunits of plasma fibronectin, are located internally 
rather than at the terminal ends of the molecule (Yamada et al . 1980; 
Atherton and Hynes, 1981; Atherton et al . 1981; Hayashi and Yamada, 
1981 and 1982 and Sekiguchi et al . 1981). Therefore, a proteolytic 
modification is unlikely. Finally, it is difficult to propose a post-
translational process which affects exactly 50% of the subunits. 
Model 2: 
There is a single structural gene for both plasma and cellular 
fibronectin. The smaller plasma subunit is the result of differential 
processing of the transcript of this gene. This model would also 
predict a three-banded pattern after electrophoresis, for both cellular 
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FIGURE 2.1: THE EXPECTED ELECTROPHORETOGRAMS OF PLASMA AND CELLULAR 
FIBRONECTIN, IF GENETIC VARIANTS ARE PRESENT IN THE 
HETEROZYGOUS STATE, FROM FIVE DIFFERENT GENETIC MODELS 
(see text). 
a) Models l and 2 
c) Model 4 
e) Model 5 
b) Model 3 
d) Model 5 
f) Model 5 
P = plasma fibronectin; C = cellular fibrone~tin 
The five models and the electrophoretograms are explained 
in the text. 
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and plasma fibronectin (Figure 2.1.a). 
If the fibronectin gene consists of a number of exons (possibly 
representing each functional domain) separated by intrans, as appears 
to be the case for the majority of eukaryotic genes (Gilbert, 1978; 
Blake, 1979; Lewin, 1979 and Kolata, 1980), differential splicing of 
the exons could account for the apparent difference in domain number 
between the two plasma subunits (Sekiguchi et al. 1981 and Ehrisman 
et al. 1982). 
Model 3: 
There are separate structural genes for plasma and cellular 
fibronectin. The two plasma subunits occur as a result of differential 
gene processing or post-translational modifications. This model would 
predict a three-banded pattern, after electrophoresis, for plasma fibro-
nectin. Cellular fibronectin would show either a one-banded pattern or 
a different three-banded pattern (Figure 2.1.b). The former would occur 
if no variant was present at the structural locus of cellular fibronectin 
and the latter if a variant was present. It is highly unlikely that the 
variants at the two loci would give identical electrophoretic results. 
The arguments against post-translational modifications are similar 
to those for Model l. 
Model 4: 
There are distinct structural genes for cellular fibronectin and 
the two subunits of plasma fibronectin. The predictions of this model 
for the electrophoretograms if genetic variation occurs are more complex. 
If variation occurs at only one of the plasma fibronectin loci, a two-
banded pattern would be expected, as only one of the subunits would be 
present in the variant form. But, if variation occurs at both plasma 
fibronectin loci a three- or four-banded pattern would be expected 
depending on the charge differences of the variants. The predicted 
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banding pattern for cellular fibron ectin would be independent of that 
of plasma fibronectin and would be the same as for Model 3 (Figure 2.1 .c ). 
The occurrence of gene families, which have apparently arisen by 
gene duplication, appears to be fairly common ,n the eukaryotic genome 
(Efstradi adis et al. 1980). 
Model 5: 
There 1s a common structural gene for the subunit of cellular and 
the large subunit of plasma fibronectin and a distinct structural gene 
for the small plasma fibronectin subunit. This model predicts three 
possible electrophoretic patterns. Firstly, if the variant occurred at 
the locus for the small plasma fibronectin subunit, then plasma fibro-
nectin would show a two-banded pattern and cellular fibronectin a one-
banded pattern (Figure 2.1 .d) . Secondly, if the variant occurred at 
the other structural locus, plasma fibronectin would again show a two-
banded pattern, but cellular fibronectin would show a three-banded 
pattern (Figure 2.1.e). Finally, the presence of variants at both loci 
would produce a three- or four-banded pattern in plasma fibronectin and 
a three-banded pattern ,n cellular fibronectin (Figure 2.1 .f) . It ls 
unlikely that the three-banded patterns would show identical mobility. 
I 
This model could be correct if the two extra segments of 1300 M.W. 
near the collagen binding site, and 1000 M.W., near the carboxyl 
terminal, and the deficient 10000 M.W. segment of plasma fibronectin, 
compared to cellular fibronectin (Hayashi and Yamada, 1982), are all in 
the smaller plasma subunit. 
The models described above are not exclusive and it 1s possible that 
a more complex model will explain the genetic control of fibronectin. 
The relationship of fibronectin from amniotic fluid, cerebrospinal 
fluid and milk to the plasma and cellular for ms, could be examined in a 
similar way. 
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The electrophoretic technique developed 1n this study was used to 
screen plasma samples from a number of human populations, from different 
racial groups and different areas of the world, for genetic variants of 
plasma fibronectin in an attempt to test the five models given above. 
In addition, since post-translational modifications can alter the mobil-
ity of proteins, the effect of desialysation and treatment with S-mercap-
toethanol on the electrophoretic mobility of plasma fibronectin was 
examined. Because of the extreme conservation of human plasma fibronectin 
found by these studies, plasma samples from a variety of domestic animals 
were also screened for genetic variants. 
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II. MATERIALS AND METHODS 
A. Purification of fibronectin 
Citrated plasma fro m normal blood donors was obtained from out-dated 
whole blood collected by the Canberra Red Cross Blood Transfusion Service, 
by centrifugation at 4000g for 10 minutes. Fibronectin was purified on 
a gelatin-Sepharose affinity column by a modification of the method des-
cribed by Engvall and Ruoslahti (1977). 
1. Preparation of the gelatin-Sepharose 
The cynaogen bromide (CNBr) activated Sepharose 4B required for the 
,> 
affinity chromatography column was prepared as described by Axen et al . 
(1967). Gelatin was coupled to the activated Sepharose 4B by the proced-
ure outlined below: 
a. 100g of CNBr activated Sepharose was washed on a glass filter 
with l mM HCl for 15 minutes. 
b. lg of gelatin was boiled in 100ml of O.lM NaHC0 3 containing 
0.5M NaCl. 
c. The Sepharose was added to the gelatin mixture and shaken for 
2 hours at room temperature. 
d. The Sepharose was washed with 0.lM NaHco 3 containing 0.5M NaCl. 
e. The Sepharose was added to 500 ml of lM ethanol amine, pH 8, and 
shaken for 2 hours at room temperature. 
f. The gelatin-Sepharose was washed with O.lM acetate buffer, pH 4, 
containing lM NaCl and O.lM borate buffer, pH 8, containing 
lM NaCl, alternately for three cycles. 
2. Column chromatography 
A volume of approximately 200ml of the gelatin-Sepharose was poured 
into a column and washed with buffer 1, containing 50mM Tris, 20mM sodium 
citrate and 5mM E-amino caproic acid at pH 7.5. Plasma (800ml) was appl-
ied to the column at a flow rate of 30ml/hr. The column was then washed 
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with buffer 1 until the 0.0280 of the eluate was zero. After washing 
the column with 600ml of buffer 1 containing lM NuCl, fibronectin was 
eluted by the application of buffer 1 containing 5M urea. Fractions 
were tested at 0.0280 for protein content. 
The eluted fibronectin was dialysed against three changes of 100 
volumes of buffer 1 for 24 hours to remove urea . The homogeneity of the 
final fibronectin preparation was checked by agarose gel electrophoresis. 
B. Production of anti-fibronectin IgG 
Antiserum was produced in rabbits to purified fibronectin by sub-
cutaneous injections, in multiple sites on the rabbits back, of an 
emulsion of aqueous protein and Complete Freunds adjuvant. Approximately 
20µg of protein was injected at intervals of one week for four weeks. 
Antiserum was harvested after the fourth injection. Antiserum was stored 
in 2ml aliquots at -20°C until use. The specificity of the antisera was 
checked on Ouchterlony diffusion plates. 
C. Agarose electrophoresis 
As a result of experimentation with purified fibronectin, a barbital 
buffer, rJ1 8.6, was found to give the best resolution. The electrode 
buffer contained barbituric acid 20mM, sodium barbitone, 70mM and calcium 
lactate 2mM. The gel buffer was a 2 in 3 dilution of the electrode buffer. 
The barbituric acid was dissolved 1n boiling water prior to being added 
to the rest of the buffer. 
Thin layer gels were prepa red on 15 x 17cm glass plates . The plates 
were warmed to 60°C and 30ml of 1% (w/v) agarose (Sigma Type 1) in the 
gel buffer was spread over each plate and allowed to solidify at room 
temperature for 20 minutes. Sample slots (14/gel) were cut by pressing 
a plastic slot former into the gel 3cm from the cathodal end of the 
plate. Samples of 4µ1 of thawed plasma were then applied to the gel. 
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Electrophoresis was carried out horizontally with the gel plate placed 
on a cooling block between the electrode tanks. The gel was connected 
to the electrode tanks by a double layer of Whatman 3MM chromatography 
paper. Electrophoresis was carried out at l3V/cm until a haemoglobin 
marker had migrated 2.5cm towards the anodal end of the gel. 
D. Immunofixation 
After electrophoresis fibronectin was specifically localised by 
overlaying the gel withal in 4 dilution (in physiological saline) of 
the antiserum. The antiserum was spread over the gel with a sealed 
and bent pasteur pipette tip, taking care not to touch the gel surface. 
The gel was incubated at room temperature, in a moist environment, for 
l-2 hours. Care must be taken, at this stage, to keep the gel level 
to prevent the antisera from flowing to one side. After immunofixation, 
the gel was rinsed briefly under running tap water, covered with a wet 
filter paper and compressed for 10-30 minutes under approximately 5mm 
of absorbent paper covered by a perspex plate and a 2kg weight. After 
compression, the gel was soaked overnight at 4°C ,n at least ll of l50mM 
NaCl to remove non-immunoprecipitated protein. 
The successful application of the immunofixation technique depends 
on achieving the optimum balance between the amount of antigen in the. 
gel and the titre of the antibody applied to the gel surface. The 
correct dilution of the antisera is therefore dependent on the initial 
titre of the antibody and must be determined empirically by testing 
different dilutions of each batch of antiserum. 
After soaking overnight in l50mM NaCl, the gels were washed under 
running tap water for 10 minutes and again compressed as described above. 
The gels were then dried before being placed in a 0.2% (w/v) Coomassie 
blue R solution (45% (v/v) methanol: 10% (v/v) acetic acid: 45 % (v/v) 
water) for 5 minutes. The • els w~re then washed in a destain solution 
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(2.5 % (v/v) acetic acid; 2.5% (v/v) Teepol t 95 % (v/v) water) and 
rinsed under running tap water. Zones of protein fixed by the anti-
fibronectin antisera react with the Coomassie blue to form blue bands. 
E. Origin of samples 
1. Human samples 
Plasma or serum samples from 2,981 individuals from 17 different 
populations were screened for genetic variants. Plasma or serum 
samples from these individuals had previously been collected and stored 
1n liquid nitrogen, or at -20°C for periods ranging from a few months 
to 10 years in the Department of Human Biology, John Curtin School of 
Medical Research. The plasma samples were collected on a variety of 
anticoagulants. 
2. Animal samples 
Plasma samples from a variety of animals, including goats, dogs, cats, 
sheep, highland ponies, horses, donkeys, mice, cattle, camels and pigs 
were collect ed on citrate, as an anticoagulant and stored at -20°C for 
l-6 months before use. 
F. Treatment of samples 
Several human samples and one of each of the animal samples were 
treated with 7mU of neuraminidase/µl of sample and dialysed overnight 
as described by Awdeh (1976). In addition, some samples were incubated 
at room temperature with ¼ volume of 0.5% B-mercaptoethanol (v/v) for 
30 minutes before electrophoresis. 
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III. RESULTS 
A. Purification of fibronectin 
The application of 5M urea to the affinity column produced a single 
peak of protein (Figure 2.2). Each 9ml fraction was tested for protein 
content by agarose gel electrophoresis in the buffer system described 
above and gel staining with Coomassie blue after having first fixed the 
proteins with picric acid. All the fractions containing detectable 
protein levels showed a single band (Figure 2.3), indicating that if 
any contaminants were present in the purified fibronectin they were very 
minor. 
The antisera raised against purified fibronectin showed two lines 
of cross-reactivity against plasma on Ouchterlony gels. When the anti-
sera was used for immunofixation after agarose electrophoresis a fa int 
band was present at a position which corresponds to the electrophoretic 
mobility of albumin 1n the buffer system used. It was, therefore, 
concluded that albumin was a minor contaminant in the purified fibro-
nectin . 
B. Human samples 
The single band of fibronectin obtained after electrophoresis of 
citrated plasma is shown in Figure 2.4. The use of heparin as an anti-
coagulant was found to result in significant losses of fibronectin to 
concentrations which were below the level of detection. Serum samples 
contained sufficient fibronectin levels for detection. Table 2.1 shows 
the results of a survey of 2,981 individuals from a wide ran ge of 
racial groups. 
A single sample from Ternate, a remote Indonesian island, pr esented 
an abnormal phenotype. The relative electro phoretic mobility of this 
variant form is shown in Figure 2.5a) and a sc hematic re presentation 
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THE ELUTION PROFILE OF PLASMA FIBRONECTIN FROM THE 
AFFINITY COLUMN WITH 5M UREA 
Urea was applied at fraction l and each fraction 
contained 9ml of eluate. 
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FIGURE 2.3: AGAROSE ELECTROPHORESIS OF PURIFIED PLASMA FIBRONECTIN 
F = Purified fibronectin 
FIGURE 2.4: AGAROSE GEL ELECTROPHORESIS OF PLASMA FIBRONECTION: 
THE COMMON PHENOTYPE 
C = Common phenotype of plasma fibronectin 
+ 
F F F 
+ 
C C C C C 
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TABLE 2.1. 
ELECTROPHORETIC SCREENING OF HUMAN PLASMA AND 
SERUM FIBRONECTIN 
Population Number Number Tested Ascertained 
AUSTRALIA 
Caucasian 235 234 
Aboriginal 198 52 
PAPUA NEW GUINEA 
Tep Tep (Morobe District) 326 313 
Simbai (Schrader Mt.) 128 88 
Buka Is. 76 76 
INDONESIA 
Ternates (Moluccas) 213 210 
Galelarese (Halmahera) 100 l 00 
Bimanese (Sumbawa) 100 100 
THAILAND 93 93 
JAPAN 149 78 
CHINA 118 83 
INDIA 70 42 
FIJI 
Melanesian 277 277 
CAROLINE IS. 224 224 
AMAZON INDIANS 135 125 
PIMA INDIAN 201 201 
SOUTH AFRICA 
Negroid 223 203 
CASPIAN SEA l l 5 114 
Variants 
l 
FIGURE 2.5: 
L 
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THE ELECTROPHORETIC PHENOTYPE OF THE INDONESIAN VARIANT 
OF PLASMA FIBRONECTIN 
a) Electrophoresis of the Indonesian variant 
b) A schematic representation of the Indonesian variant 
C = Common fibronectin phenotype; I= Indonesian variant 
a 
+ 
C I C I C 
b 
+ 
-
-
-
-
, C I C 
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of the variant is illustrated in Figure 2.5.b). Treatment of this 
sample or the normal form with B-mercaptoethanol did not alter the 
electrophoretic pattern (Figure 2.6). The effect of neuraminidase 
treatment on the normal phenotype and the variant form are illustrated 
in Figure 2.7. The latter is only shown schematically as the photo-
graphic reproduction of the gel was very poor. 
C. Animal samples 
The common phenotype exhibited by dogs, cats, sheep, goats, horses, 
highland ponies, donkeys, mice, cattle, camels and pigs and their 
mobility relative to human fibronectin, are shown in Figure 2.8 and 
Table 2.2. The results of a survey of 14 dogs, 47 cats, 62 sheep, 
38 goats, 151 horses, 6 highland ponies, 33 donkeys, 3 mice, 55 cattle, 
2 camels and 62 pigs are given in Table 2.3. The phenotype expressed 
by horses, donkeys, highland ponies, goats and sheep varied 1n some 
individuals as illustrated for horses in Figure 2.9. While treatment 
with S-mercaptoethanol had no effect on any of the phenotypes, neuram-
inidase treatment did alter the mobility of the most anodal band in all 
species studied and in all phenotypes expressed (Figure 2.10). 
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THE EFFECT OF B-MERCAPTOETHANOL TREATMENT ON THE ELECTRO -
PHORETC MOBILIT Y OF PLASMA FIBRONECTIN 
The Indonesian variant showed a loss of resolution 
similar to that seen here in the common phenotype. 
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THE EFFECT OF NEURAMINIDASE TREATMENT ON THE ELECTRO-
PHORETIC MOBILITY OF PLASMA FIBRONECTIN 
a) Neuraminidase treatment of the common form of fibro-
nectin 
b) A schematic representation of the effects of neuram-
inidase treatment of the common form and the Indo-
nesian variant of plasma fibronectin. 
C = common phenotype; I= Indonesian variant; 
N = Neuraminidase treated 
a 
+ 
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THE MOBILITY OF PLASMA FIBRONECTIN FROM ll ANIMALS 
RELATIVE TO THAT OF HUMAN PLASMA FIBRONECTIN 
Animal Relative Mobility 
Horse l . 00 
Donkey l . 00 
Highland Pony l. 00 
Goat l . 23 
Dog 0.92 
Cat 0.85 
Sheep l . 35 
Mouse 0.96 
Cattle l . 08 
Camel 0.89 
Pig 0.98 
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THE ELECTROPHORETIC PHENOTYPES OF PLASMA FIBRONECTIN FROM 
ANIMALS AND MAN 
M = mouse; C =camel; Ca= cat; 
H = human; S = sheep; G = goat; 
Do= donkey and HP= Highland pony 
D = dog; P = pig; 
Ct= cattle; Ho= horse; 
THE PHENOTYPIC VARIANTS OF PLASMA FIBRONECTIN SHOWN BY THE 
HORSE (see text for explanation) 
l = l band; 2 = 2 bands; 3 = 3 bands 
+ 
M C Ca D P H 5 G Ct Ho Do HP 
+ 
I 3 32 3 3 3 3 2 3 
- 77 -
TABLE 2.3. 
ELECTROPHORETIC SCREENING OF ANIMAL PLASMA FIBRONECTIN 
Number Number · Phenotype 
Tested Ascertained One Band Two Bands Three Bands 
Horse 151 1 51 39 9 103 
Donkey 33 33 11 22 
Highland Pony 6 6 6 
Goat 38 38 30 8 
Dog 14 14 14 
Cat 47 36 36 
Sheep 62 62 48 14 
Mouse 3 3 3 
Cattle 55 54 54 
Camel 2 2 2 
Pig 62 62 62 
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THE EFFECT OF NEURAMINIDASE TREATMENT ON THE ELECTRO-
PHORETIC MOBILITY OF FIBRONECTIN FROM ANIMAL PLASMA 
SAMPLES 
Upper gel: 
Lower gel: 
C = camel; Ho= horse; Ca= cat; 
Do= donkey; HP= Highland pony; 
M = mouse; N = neuraminidase treated 
Ct= cattle; S = sheep; p = pig; 
D = dog; G = goat; N = neuraminidase 
treated 
+ 
C N Ho N Ca N Do N HP N M N 
+ 
0 N S N P N D N G N 
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IV. DISCUSSION 
A. Human plasma fibronectin 
The single band of fibronectin obtained after electrophoresis 
(Figure 2.4) was the same from serum and plasma and was not altered 
by the type of anticoagulant used. Although in some populations, 
where samples were collected in heparin, ascertainment of the pheno-
type of every sample was not obtained. This was due to an apparent 
drop 1n the concentration of soluble plasma fibronectin. Fibronectin 
has been shown to become insoluble in the presence of heparin (Mosesson 
and Amrani, 1980). 
During the formation of a blood clot between 20% and 50% of the 
plasma fibronectin is incorporated into the clot (Chen et al . 1977). 
The fact that the fibronectin bands from plasma and serum samples are 
identical indicates that the fibronectin remaining in serum fibronectin 
which has not been incorporated into the clot and is not the result 
of some proteolytic event which might release part of the fibronectin 
molecule from the clot. Additionally, the identity of plasma and 
serum fibronectin suggest that fibronectin 1s not a substrate for the 
proteases released during blood coagulation. 
l. The Indonesian variant 
Of the 2,623 samples which gave positive results, only one sample 
from Ternate (The Moluccas Islands) in Indonesia presented an abnormal 
phenotype. The phenotype is difficult to photograph (Figure 2.5.a) 
and is therefore shownschema tically (Figure 2.5.b). The plasma sam-
ple was normal for 4 other protein systems and red cells from that 
individual collected at the same time were normal for 20 enzyme and 
protein systems. 
Treatment of the samp le with S-mercaptoethanol, prior to electro-
phoresis, did not affect the four-banded phenotype. However, neuram1n-
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idase treatment, to remove sialic acid groups, while not affecting the 
number or relative distribution of the bands in the variant phenotype 
did alter the overall mobility of the four bands. The change in mobility 
for each band was identical to the mobility change shown by the normal 
fibronectin band after neuramin'idase treatment (Figure 2. 7). This 
suggests that each of the four bands has the same sialic acid content 
as the normal fibronectin molecule. Therefore, if the three extra bands 
result from proteolytic cleavage of fibronectin the segment not contain-
ing sialic acid residues either does not cross-react with the antisera 
or has an electrophoretic mobility such that it is not detected in the 
buffer system used. 
Unfortunately, it has not been possible to test a fresh sample from 
that individual or to study other family members. Until such investiga-
tions can be completed it is not possible to make a definite conclusion 
about the origin of the abnormal phenotype. 
2. Genetic control of plasma fibronectin 
As only one sample with a variant phenotype was found in the screen-
ing programme carried out, it has not been possible to test the validity 
of the five models discussed above. The abnormal four-banded phenotype 
does fit the predictions of models 4 and 5. However, the four bands are 
not equally spaced as these models predict. Additionally, these models 
would only produce four bands if variants are present at two loci. The 
lack of detectable variation in any other samples means that it is 
extremely unlikely that this individual would have two detectable variants. 
Therefore, it would appear that either the variant phenotype is not 
genetic in or1g1n, or none of the models are correct. 
However, until the origin of the Indonesian variant 1s proven one 
way or the other, no conclusions can be drawn concerning the genetic 
control of fibronectin. The absence of electrophoretically detectable 
variation of plasma fibronectin from both man and ani mals indicates 
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that a different experimental approach is needed to find an answer to 
the problem of the genetic control of fibronectin. Fagan et al. (1981) 
have reported the cloning of a fibronectin gene. It therefore seems 
probable that studies such as this, which utilise the available recom-
binant DNA technology, will provide the solution to the problem. 
3. Genetic conservation of the fibronectin molecule 
Since antibodies raised against human fibronectin cross-react with 
fibronectin from many other species (Chapter l .VI.B) including Porifera 
(Akiyama et al. 1981 and Labat-Robert e t al. 1981a), which represent the 
earliest forms of multicellular life, it is apparent that the fibronectin 
molecule has been highly conserved during phylogenesis. 
The finding of only one possible genetic, electrophoretically 
detectable variant in the 2,623 samples that gave positive results suggests 
that this evolutionary conservation is present within species as well as 
between species. It is probable that the major reason for the extreme 
evolutionary conservation shown by the fibronectin molecule is the large 
number of molecular interactions that the molecule is involved 1n 
(Chapter 1 .III). The large numbers of functional sites on the fibronectin 
molecule suggests that an alteration in amino acid sequence is more likely 
to affect its function. Mcconkey (1982) has demonstrated that some 
proteins known to be involved in the complexities of intracellular 
organisation show very little genetic variation after examination by 
high-resolution two-dimensional polyacrylamide gel electrophoresis. 
B. Animal studies 
The antibodies raised against human plasma fibronectin crossreacted 
with plasma fibronectin from dogs, cats, sheep, goats, horses, highland 
ponies, donkeys, mice, cattle, camels and pigs. Therefore a number of 
plasma samples from each of these animals were examined to see if a 
genetic answer could be obtained from ani mals. However, most of the 
animals exhibited a single electrophoretic phenotype (Figure 2.8) 
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again demonstrating the lack of detectable genetic variation of plasma 
fibronectin. 
l. Variant samples 
Three species of animals exhibited variant phenotypes, while ,n 
goats and sheep two phenotypes were present, horses ;showed three 
phenotypes (Figure 2.9). The one-banded phenotype is similar to that 
-
expressed ,n other species. The two- and three-banded phenotypes 
appear to be derived from the one-banded form. In the three-banded 
forms an extra two relatively more cathodal bands are present. The 
relative intensity of these two bands to the more anodal band, varied 
between samples . As the intensity of the two bands increased the 
intensity of the anodal band diminished. In those samples where the 
cathodal bands were most intense the anodal band was absent resulting 
,n the two-banded phenotype. 
It therefore appears that the variant phenotypes are not genetic 
,n or1g1n. It is possible that they are the result of degradation 
of the fibronectin molecule or that they represent fibronectin bound 
to other plasma components . The recent reports of slower moving 
components after crossed-immunoelectrophoresis of human plasma fibro-
nectin from some individuals (Hofelar et al . 1982; Klingemann et al . 
1982 and Suzuki and Abe, 1982) which are thought to result from fibro-
nectin bound to another plasma component, give support to the latter 
suggestion. 
2. Relative mobility of the animal samples 
The electrophoretic mobility of plasma fibronectin from the animals 
tested and man is shown in Figure 2 .8 . As can be seen from Figure 2.10 
although treatment with neuraminidase alters the mobility,differences 
still exist between the animals and man. Therefore, the mobility differ-
ences are due to changes in amino acid content and not to a variation of 
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the carbohydrate content of the fibronectin molecule between species. 
C. The chromosomal location of the fibronectin structural loci 
As discussed in Chapter l .VI.A.2 there is conflicting evidence as 
to the chromosomal location of the fibronectin structural gene(s) 
(Owerbach et al. 1978; Eun and Klinger, 1979 and 1980; Smith et al . 
1979; Klinger and Ruoslahti, 1980; Church, 1981 and Rennard et al. 
l98lb). Several recent studies have suggested that the structural 
gene(s) are on chromosome ll and that the locus on chromosome 8 controls 
the expression of fibronectin on the cell surface (Gerald and Miller, 
1982 and Robson and Khan, 1982). In addition, Zardi et al . (1982b) 
have used species-specific monoclonal antibodies to suggest that a 
fibronectin gene is located on chromosome 2. 
It is possible that the electrophoretic technique described here 
could be used to map the locus of the structural gene for cytoplasmic 
fibronectin by the use of mouse/human somatic cell hybrids without the 
need for species specific antisera as there is a clear mobility differ-
ence between human and mouse plasma fibronectin (Figure 2.11). The 
problems involved with the cell surface expression of fibronectin would 
also be eliminated by the use of this technique. 
D. Abnormal fibronectins 
The electrophoretic procedure described here could be used as a 
diagnostic tool in those individuals with suspected fibronectin 
abnormalities (Donati et al . 1977; Remuzzi et al . 1977; Furcht et al . 
1979 and Arneson et al . 1980) as well as patients with wound healing 
and bleeding disorders of unknown cause, as an abnormal fibronectin 
molecule may well exhibit a variant phenotype. As fibronectin appears 
to play an integral role in embryogenesis (Chapter l .III.D) the 
occurrence of a fibronectin molecule with an abnorma l function 1n the 
homozygous state may lead to spontaneous abortion. Therefore, the 
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THE DIFFERENCE IN ELECTROPHORETIC MOBILITY BETWEEN 
PLASMA FIBRONECTIN FROM MOUSE AND HUMAN SAMPLES 
M = mouse; H = human 
+ 
M H 
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study of families with a history of spontaneous abortion, where no 
other cause has been diagnosed, could reveal the presence of abnormal 
fibronectin molecules. 
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V. CONCLUSIONS 
An electrophoretic technique which permits the rapid screening of 
plasma samples for abnormal fibronectins, by the process of immuno-
fixation, has been described. This technique was used to study samples 
from 2,981 individuals and a number of animals in a search for genetic 
variants of plasma fibronectin. Only one possible genetic variant was 
found in an individual from Indonesia, thereby suggesting that the 
fibronectin molecule is a highly conserved molecule within species. 
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Chapter 3 
I. HISTORICAL ASPECTS 
A. Nomenclature 
Blood coagulation factor XIII is the zymogen of an enzyme gener-
ated in the final stages of the blood coagulation cascade pathway. A 
variety of names have been suggested for both the zymogen and the 
active enzyme (Table 3.1) most of which are related to the function 
or mode of action of the enzyme. The International Committee on 
Haemostasis and Thrombosis officially named the protein factor XIII 
in 1963 (Hunter et al . 1964). However, Lorand and Konishi (1964) 
suggested that factor XIII was found in plasma as an inactive zymogen 
which was activated in the presence of thrombin. Thus, the term 
factor XIII was used for the zymogen only and the term factor XIIIa 
was used for the active enzyme. Although some of the other suggested 
names are still used 1n the literature, the above two names will be 
used throughout this discussion. 
B. History 
Robbins (1944) used dilute acids and alkalis to differentiate 
between two forms of fibrin and concluded that a factor in serum, 
which required the presence of calcium ions, was responsible for the 
formation of the insoluble fibrin. Laki and Lorand (1948) came to 
similar conclusions with urea as the solvent. Ho~1ever, it was not 
until Duckert et al . (1960) described a haemorrhagic diathesis that 
was attributable to a congenital deficiency of this plasma factor, 
then termed fibrin stabili:ing factor, that the importance of plasma 
factor XIII in blood coagulation was proven. 
Lorand and Jacobsen (1962) suggested that factor X Ila cross-
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TABLE 3.1. 
ALTERNATIVE NOME NCLATURE FOR FACTOR XIII AND FACTOR XIIIa 
Name Abbreviation Form Reference 
Fibrin -stabilising factor FSF Zymogen Lorand- (1950) 
Lacki - Lorand factor L-L factor Zymogen Loewy and Edsall (1954) 
Fibrinase 
Plasma transamidase 
Polymerase 
Plasma transglutaminase 
Fibrinoligase 
Protransglutaminase 
Active Loewy et al . (1961) 
Active Chandrasekar et al . 
(1964) 
Active Lorand and Konishi 
(1964) 
Active Loewy (1968) 
Active Lorand (1972) 
Zymogen Folk and Finlayson 
(1977 ) 
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linked an amino group (donor) of one fibrin molecule with a carboxyl 
group (acceptor) of another fibrin molecule. Work in the late l960's 
and early l970's (Folk and Chung, 1973 and Folk and Finlayson, 1977) 
showed that factor XIIIawas a transglutaminase and elucidated the mode 
of action of the enzyme (Chapter 3.IV.A). Lorand and Konishi (1964) 
proposed that the circulating factor XIII in plasma was inactive and 
that thrombin and calcium ions were required for activation. This was 
confirmed by later work and the mechanism of activation- is now well 
documented (Alami et al . 1968 and Lorand et al . 1980). 
In the late l960's and early l970's factor ~III was found in 
platelets (Kiesselbach and Wagner, 1966), the placenta (Bohn and 
Schwick, 1971) and the uterus (Chung, 1972) as weJl as 1n plasma. 
This wider distribution of factor XIII, together with the observation 
of wound healing abnormalities in some factor XIII deficient patients 
(Duckert et al . 1960 and Beck et al. 1961) and the discovery that 
factor XIII cross-links several proteins other than fibrin (Chapter 
3.IV), has led to factor XIII being considered as an enzyme important 
in the wound healing process rather than a specific blood coagulation 
factor. 
- 90 -
II. THE STRUCTURE OF FACTOR XIII 
Factor XIII has been shown to be present in plasma, platelets, 
placenta, the uterus, the prostate gland, liver and the spleen 
(Chung, 1972 and Ikematsu, 1981 ). Other transglutaminases are present 
in some of these tissues as well as other body tissues. These trans-
glutaminases are distinct from factor XIII as judged by their physical, 
chemical, immunological and enzymatic properties (Chung., 1972). 
A. The origin of Factor XIII 
The tissue forms of factor XIII appear to be synthesised in the 
tissues where they are found (Ikematsu, 1981). However, the origin 
of the platelet and plasma forms was for some years a subject of 
debate. In the early 1970 1 s a number of studies (Kiesselbach and 
Wagner, 1972; Loewy, 1972 and McDonagh and Wagner, 1972) sho\A1ed that 
platelet factor XIII is synthesised in the megakaryocytes of the bone 
marrow. These studies also suggested that the platelet was not a 
major source of the plasma form as had previously been thought 
( Hampton et al . 1972). 
Although a high correlation between platelet count and plasma 
factor XIII activity has been reported in animal models (Rider et al . 
1978) other studies have demonstrated that liver hepatocytes synthe-
sise both subunits of the plasma zymogen (see below) and that they are 
apparently the sole source of the B subunit of plasma factor XIII 
(Lee and Chung, 1976; Ikematsu, 1981 and Rasche, 19 82), as had been 
suggested previously (Bohn , 1972 ) . 
It therefore appears that the B subun its of plasma facto r XIII 
are produced in the liver, while the A subunits may be synthesised by 
a number of sources (Ikematsu, 1981 ) . 
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B. The structure of plasma Factor XIII 
In 1961, Loewy et al . reported that plasma factor XIII was a 
trimer of 300,000-350,000 M.W. with each subunit being 110,000 M.W. 
Further studies in the 1960 1 s and early 1970 1 s gave conflicting results, 
for example, Lorand et al. (1968) reported a total molecular weight of 
160,000 and Bannerjee et al . (1972) reported subunit weights of 
70,000 M.W. and 35,000 M.W. At this time Schwartz et ·ai . (1971a and 
1973) utilised SOS polyacrylamide gel electrophoresis and sedimentation 
equilibrium in the ultracentrifuge to produce a model for the structure 
of plasma factor XIII which is generally accepted as being correct. 
Plasma factor XIII consists of two different subunits, designated 
A and B (Schwartz et al . 1971a) of 75,000 and 88~000 M.W. respectively. 
These subunits form a tetramer of A2B2 of 320,000+20,000 M.W. which is 
joined by noncovalent bonds. Schwartz et al . (1971a and 1973) also 
clearly demonstrated that the enzymatic activity of plasma factor XIII 
was found only in the A subunits. Although this model has gained 
general acceptance Lorand et al . (19 80) proposed that the most common 
circulating form in plasma is a heterodi mer, AB, of 160,000 M.W. The 
results of other workers (Folk and Finlayson, 1977) and genetic 
analysis of the two subunits (Board, 1979 and 1980) do not agree with 
this proposal and confirm that plasma factor XIII consists of a di mer of 
two A subunits joined to t wo B· su bunits. 
Bohn et al . (l 973) reported that there was an excess of B sub-
units over A subunits in plasma, thus su gg esting that some B subunits 
are not combined with A su bunits. The findin g that B su bunits are 
synthesised at a greater rate than A subunits (Lee and Chung, 1976) 
gave a possible explan ation to this observat ion. In contrast, studies 
by McDonagh (19 82) have su ggested that no excess of B subunits are 
present in plasma. 
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C. The structure of other Factor XIII's 
Before the existence of two different subunits ,n plasma factor 
XIII was shown, the relationship of factor XIII from other sources to 
the plasma form, was uncertain (Bohn, 1970; Bohn and Schwick, 1971; 
Folk and Chung, 1973 and Folk and Finlayson, 1977). However, with the 
reports of A and B subunits in plasma factor XIII it soon became app-
arent that factor XIII from platelets, placenta, uterus, ·prostate 
gland and spleen consisted of a dimer of two A subunits- of 146,000+ 
10,000 M.W. (Schwartz et al. 1971a and 1973; Chung, 1972 and Ikematsu, 
1981). The identity of the two subunits with the A subunit of plasma 
was confirmed by a variety of studies (Folk and Chung, 1973 and Folk 
and Finlayson, 1977). 
D. The primary structure of the A and B subunits 
The amino acid composition of the A subunit from plasma, platelet 
and placenta is identical, while the amino acid composition of the B 
subunit is different from that of the A subunits (Table 3.2 and 
Schwartz et al. 1971a and 1973 and Bohn, 1972). The complete amino 
acid sequence of both subunits is unknown, although the amino-terminal 
42 amino acids of the A subunit have been sequenced (Takagi and Doo-
little, 1974). Chung et al. (1974) have shown that while the A sub-
unit contains six sulphydryl groups and no intrachain disulphide bonds 
the B subunit contains no sulphydryl groups and sixteen or seventeen 
disulphide bonds. A free sulphydryl group next to a glutamine residue 
is essential for the enzymatic activity of the A subunit (Alami et al . 
1968; Holbrook et al . 1973 and Chung et al . 1974). This active site 
is located in a 56,000 M.W. thrombin fragment of the A subunit (Fol k 
and Finlayson, 1977). 
Schwartz et al . (1971 a) re ported that only the B subunit contained 
carbohydrate moieties. However, Bohn (1972) demonstrated that, alt hou gh 
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TABLE 3.2. 
THE AMINO ACID COMPOSITION OF FACTOR XIIX 
Plateleta,b,c Placenta b Plasma Factor XIIIa,c 
Amino Acid Factor XIII Factor XI I I A Subunit B Subunit 
Residues/100 Residues 
Lysine 5.6 5.2 5.8 7.4 
Histidine 1 . 9 1 . 9 2.0 2.6 
Arginine 6. 1 6.2 5.8 4.4 
Aspartic acid 12. 7 12.3 12.9 9.2 
Threonine 6.6 6.3 6.3 7.2 
Serine 7.0 6.3 7.5 7.6 
Glutamic acid 11 . 6 11 . 1 12.3 13. 8 
Praline 5.2 4.9 5.4 7.8 
Glycine 8. 1 7. 1 9.4 8.5 
Alanine 6. 1 5.3 6.3 3.6 
Valine 8.5 9.8 7.8 3.9 
Half-cysteine 0.9 N.D. 0.8 5.0 
Methionine 2.6 2.6 1 . 9 1 . 3 
Isoleucine 4.3 5. l 3.7 3.7 
Leucine 7.0 6.8 7.2 8.4 
Tyrosine 3.9 4.4 3.7 6.5 
Phenylalanine 4.3 4.7 4.2 3.5 
Tryptophan N.D. N.D. N.D. N.D. 
N.D. - Not determined 
a Schwartz et al. 1971 a 
b Bohn, 1972 
C Schwartz et al . 1973 
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the B subunit contains more carbohydrate groups, _some are present on 
the A subunit (Table 3.3). The carbohydrate groups are not essential 
for enzymatic activity (Bohn, 1972). 
Microheterogeneity of both A and B subunits has been reported 
(Bohn, 1970; Schwartz et al. 1973; Barbui e t al. 1974; Curtis 
1974; Credo et al. 1977 and Lorand e t al. 1980). The role of genetic 
variation in the causation of this heterogeneity is discussed in 
Chapter 4. 
E. The interaction of A and B subunits 
The exact control mechanism of the levels of subunits in plasma 
has been of interest since the observation that the level of B subunit 
is reduced in patients who are deficient in or have reduced levels of 
the enzymatically active A subunit (Barbui e t al. 1978). An explan-
ation of the concomitant reduction of B subunit levels has resulted 
from the study of the effect on B subunit levels of the administration 
of A subunits to patients deficient in A subunits, and the levels of B 
subunits after an operation (Ikematsu, 1981; Rodeghiero e t al. 1981a 
and McDonagh, 1982). It appears that the level of A subunits exerts a 
positive feedback on the level of B subunits, so that as the concen-
tration of A subunits rises the liver is stimulated to either release 
stored B subunits or increase the rate of synthesis of B subunits. 
F. The role of B subunits 
The enzymatic activity of factor XIII is present in the A subunit, 
therefore the presence of the B subunits in the plasma molecule has led 
to speculation about the role that the B subunit has in v~vo . It has 
been suggested that it promotes the secretion of factor XIII from the 
liver (Schwartz et al . 1971a), but no supportative evidence exists. Several 
workers have demonstrated that the B subunit must disassociate from 
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TABLE 3.3. 
THE CARBOHYDRATE CONTENT OF FACTOR XIII (Bohn, 1972) 
Carbohydrate 
Group 
Hexose 
Fucose 
Acetylhexosamine 
Sialic acid 
Total 
a A and B subunits 
b A subunits only 
Plasma a 
Factor XIII 
.% 
l . 9 
0.2 
l . 6 
l . 2 
4.9 
Platelet6 Placenta b 
Factor XIII Factor XIII 
% . % 
l . 2 0.98 
0.0 0.0 
0. 16 0.28 
0. l 5 0. 21 
l . 5 l . 47 
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the A subunit for the active site to be exposed .(Chung et al . 1974; 
Cooke, 1974; Lorand et al . 1974 and Seelig and Folk, 1980). There-
fore, the B subunits could control the rate of ·activation of the zymo-
gen by thrombin (Folk and Finlayson, 1977) or protect the active site. 
The B subunit stabilises the A subunits in plasma by extending their 
halflife (Lee and Chung, 1976), possibly by dec r easing the rate of 
proteolytic degradation (Seelig and Folk, 1980), although it does not 
decrease plasmin digestion of the A subunit (Rider and .McDonagh, 1981). 
It is also possible that the B subunits act as transport proteins 
(Losowsky and Miloszews ki, 1977). 
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III. ACTIVATION OF THE FACTOR XIII ZYMOGEN 
The scheme for the activation mechanism of the factor XIII 
zymogen is outlined in Figure 3.1. The mechanism is different for the 
plasma zymogen compared to the other zymogens because of the presence 
of B subunits (Fig. 3.la), but in all cases it is basically a two step 
process. The first step is a proteolytic cleavage event · and the second 
is a conformational alteration. 
A. The thrombin catalysed proteolytic cleavage of the A subunit 
Studies in the l960's indicated that factor XIII could be activated 
by thrombin, as well as several other proteases, in the presence of 
calcium ions (Ca2+) (Folk and Chung, 1973). However, Tyler (1970) 
demonstrated that the thrombin catalysed proteolysis of factor XIII 
did not require ca2+, although ca 2+were required for factor XIIIa 
catalytic activity. Schwartz e t al. (1971a) utilised SOS polyacryla-
mide gel electrophoresis to clearly show that thrombin removed a 
4000 M.W. peptide from the A subunit. Takagi and Doolittle (1974) 
sequenced this 36 amino acid peptide and showed that it was the amino-
terminal 36 amino acids of the A chain. Factor XIII is cleaved by 
thrombin at an arginyl-glycine bond after the sequence Val-Pro-Arg 
(Takagi and Doolittle, 1974). Several studies have confirmed the 
report of Schwartz et al . (1971a) that no change occurs in the B sub-
unit (Folk and Finlayson, 1977). 
Several other proteases have been shown to catalyse the cleava ge 
I 
of A subunits to A subunits; trypsin and crude papain and reptilase 
(Schwartz et al . 1973), venom from Agkistrod.on rhodostoma~ Bitis 
gabonica~ Bothrops ja:rm:)aea and Bothrops atrox (Schwartz et al . 197 3 
and Folk and Finlayson, 1977). Plasmin (Fol k and Finlayson, 1977) 
and Factor Xa (McDonagh and McDona gh, 1975) have also been re ported 
- 98 -
FIGURE 3.1. 
THE ACTIVATION OF THE FACTOR XIII ZYMOGEN 
a) The plasma zymogen; b) the platelet zymogen 
A' - thrombin cleaved A subunit; * A - enzymatically active A subunit 
a) 
I 
~AzBz 
Ca2+ 
Fibrinogen 
4000 M.W. 
Peptide 
b) 
Thrombin 
\ I 
A2----~~---A2 Fibrinogen 
Ca2+ 
4000 M.W. 
Peptide 
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to activate factor XIII, but these results have not been confirmed by 
others (Schwartz et al. 1973; Folk and Finlayson, 1977 and Rider and 
McDonagh, 1981). 
The A' subunits show no enzymatic activity in the absence of ca2+ 
(Lorand et al . 1980) and remain associated with the B subunits 1n 
plasma (Schwartz et al . 1973), but the proteolytic cleavage is an 
essential first step in the activation process (Chung et al . 1974) 
B. Calcium 10n activation of the A' subunits 
In the presence of Ca 2+ the A' subunits are converted to th~ir 
* 2+ catalytically active form, A. In plasma Ca acts in a dual role 
(Fig. 3.la), while in platelets only a single conformational change 
occurs ( Fi g . 3 . l b and Lor and et al . l 98 0 ) . 
A series of studies in the early l970's (Chung and Folk, 1972; 
Chung et al. 1974; Cooke, 1974; Cooke and Holbrook, 1974; Curtis 
et al . 1974; Lorand et al . 1974 and Folk and Finlayson, 1977) 
examined the exact role of ca2+ in the conversion of A' subunits to 
* A subunits in the presence and absence of B subunits, as well as the 
kinetics of the reaction. In plasma ca2+ cause the B subunits to dis-
associate from the A1 subunits while a concomitant conformational 
change is induced in the A1 subunit which results in the exposure of 
the active site (Lorand et al . 1980). Platelet factor XIII also 
2+ requires the presence of Ca for the conformational change which 
results in the exposure of the active site and the forma tion of 
factor XIIIa. However, the appearance of enzymatic activity 1s more 
rapid in platelets, thus suggesting that, in plasma, the disassociation 
of the tetramer, A2B2, is the rate determining step (Lorand et al . 1980) . 
The published Ca 2+ concentrations required for activation in vitro 
2+ were generally higher than the plasma Ca levels (Chung and Folk, 1972; 
Lorand et al . 1974; Folk and Finlayson, 1977 and Lorand et al . 1980) 
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wh ich suggested that another factor could be involved in the activati on 
process in vivo . Credo et al . (1978) demonstrated that the presence 
of fibrinogen reduced the ca2+ requirement to physiological levels. 
Further studies showed that a specific domain on the a -chain of 
fibrinogen was responsible for the reduced ca 2+ requirement (Lorand 
et al . 1980). The probable in vivo importance of this interaction is 
supported by results that suggest that factor XIII circulates in plasma 
bound to fibrinogen by the A subunits (Greenberg and Shuman, 1981 and 
1982). However, previous studies have failed to detect any complex 
between fibrinogen and factor XIII (Folk and Chung, 1973). 
C. Summary_ 
Factor XIII is activated to factor XIIIa in · a precise sequential 
manner 1n the presence of thrombin, ca2+ and fibrinogen (Fig. 3.1 and 
Lorand et al . 1980). Nelson and Lerner (1978) have reported the 
presence of l-l . 5% factor XIIIa in plasma. The importance of this 
observation is uncertain. The report that in platelets factor XIIIa 
is the usual form (Tsukada, 1982) is in contradiction to previous 
results (Nelson and Lerner, 1978) and needs to be confirmed. 
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IV. BIOLOGICAL REACTIONS OF FACTOR XIII 
A. The chemical reaction 
2+ Factor XIIIa, as do all transglutaminases, catalyses a Ca -
dependent acyl-transfer reaction in which y-carboxamide groups of pep-
tide-bound glutamine residues are the acyl donors. Primary amino 
groups of lysyl residues of a variety of compounds function as acyl 
acceptors. The result is the formation of y-glutamyl-~-lysyl bonds 
between two proteins (Figure 3.2; Folk and Chung, 1973 and Folk and 
Finlayson, 1977). The studies which demonstrated that the formation 
of the y-glutamyl-s -lysyl bond is catalysed by transglutaminases and 
which analysed the properties of the bond, have ~een reviewed else-
where (Folk and Chung, 1973; Finlayson, 1974; Folk and Finlayson, 
1977 and Chapter 3. IV.C). 
B. The mechanism of reaction 
A scheme for the mechanism of the formation of y-glutamyl-s-lysyl 
bonds is illustrated in Figure 3.3. In this scheme initial velocity 
and product inhibition results define glutamine as, A (the first substrate 
to add to enzyme) and ammonia as, P (the first product released). The 
acyl-enzyme intermediate, F, may react with water to form glutamic acid, 
R, or with the primary amino group of lysine, B, to form the r-glutamyl-s -
lysyl crosslink, Q (Folk, 1969; Chung et al . 1970; Chung and Folk, 
1972; Folk and Chung, 1973 and Folk and Finlayson, 1977). Comp re-
hensive kinetic studies of factor XIIIa, which used the acetylated 
B chain of oxidised insulin and methylamine as substrates, conformed 
to the above mec hanism (Chung and Folk, 1972). 
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FIGURE 3.2. 
THE FORMATION OF THE y-GLUTAMYL-E-LYSYL BOND BY FACTOR XIIIa 
(adapted from Losowsky and Miloszewski, 1977) 
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FIGURE 3.3. 
THE MECHANISM OF THE FACTOR XIII~ CATALYSED REACTION 
(from Chung and Folk, 1972) 
For explanation see text (Section 3.IV.B). 
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C. Fibrin cross-linking 
In the course of blood coagulation in mammals fibrin, formed from 
fibrinogen by the catalytic action of thrombin ·(reviewed by Doolittle, 
1981), is converted to an insoluble polymeric lattice. By the late 
1960's the role of factor XIIIa in catalysing this polymerisation had 
been established (Duckert et al . 1960 and Alami et a1. 1968). However, 
the process by which fibrin cross-linking occurred rem~i~ed uncertain. 
Two basic techniques were used to determine the nature .of the cross-
linking reaction: a) the chromatographic isolation and subsequent 
analysis of polypeptide chains and, b) direct v~sualisation =of the 
subunit structure of cross-linked fibrin by SOS polyacrylamide elec-
trophoresis under reducing conditions (Folk and finlayson, 1977). The 
studies that led to the determination of the fibrin cross-linking 
process have been extensively reviewed elsewhere (Folk and Chung, 
1973; Finlayson, 1974 and Folk and Finlayson, 1977) and will only 
be summarised here. 
Mammalian fibrin 1s composed of two each of a-, S- and y-chains 
(Doolittle, 1981 ). It was generally presumed that factor XII Ia 
produced insoluble fibrin by cross-linking through the formation of 
y-glutamyl-E-lysyl bonds between these chains (Lorand et al. 1968; 
,# 
Matcic and Loewy, 1968 and Pisano et al. 1968). The first definitive 
evidence of cross-links between fibrin monomers came from the results 
of Chen and Doolittle (1969 and 1970) and Takagi and Iwanaga (1970), but 
w~ch chains were cross-linked was uncertain. McKee et al. (1970) 
utilised the SOS polyacrylamide gel system to show that Y--chain dimers 
were rapidly formed, followed by a slower cross-linkage of the 
a-chains. s-chains were not involved in fibrin cross-linking. Final 
proof of the occurrence of cross-links between y-chains to form 
dimers and a-chains to form insoluble polymers was provided by Chen 
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an d Do o l i t t l e ( l 9 71 ) and Mc Don a g h et al . ( l 9 71 b ) . 
Pisano et al . (1971 and 1972) demonstrated that the cross-links 
catalysed by factor XIIIa were y-glutamyl-s-lysyl bonds. In clots 
formed in normal plasma there are six cross-links per mole of fibrin, 
four are between a-chains and two are between y-chains, whereas 1n 
factor XIII deficient plasma little or no cross-links are found 1n 
clots. With the identification of the y-glutamyl-s-lysyl bonds the 
position of the cross-links ,n they-chains and the antiparallel 
arrangement of they-chains ,n the dimer was soon established (Chen 
' 
and Doolittle, 1971; McDonagh et al. 1972 and Sharp et al. 1972). 
The intermolecular nature of they-chain cross-links was confirmed 
by Moroi et al. ( 1975). 
Factor XIIIa, in vitro, catalyses the formation of y-glutamyl-s -
lysyl bonds between two y-chains and between the a-chains of fibrin 
and thus cross-links fibrin molecules to form an insoluble lattice. 
Factor XIIIa from a variety of sources forms identical patterns of 
cross-linkage (Schwartz et al. 1971a; Chung, 1972; Folk and Chung, 
1973 and Schwartz et al. 1973). The in vivo situation appears to 
reflect the in vitro results although the level of a -chain cross-
linking may be less (Pisano et al. 1972 and Folk and Finlayson, 1977). 
This could be because not all the sites are available due to the 
cross-linking of other proteins to fibrin (Chapter 3.IV.D) or 
because of the reported factor XIIIa inhibitory activity of plasma 
(de Cataldo and Baudo, 1972). 
Factor XIIIa also cross-links fibrinogen, but at a slower rate, 
apparently due to a shift from zero order to first order kinetics 
(Chung, 1972 and Kanaide and Shainoff, 1975). The in vivo signifi-
cance of this reaction is uncertain (Folk and Finlayson, 1977) as 
it is unlikely that FXIIIa would be generated without the concomitant 
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conversion of fibrinogen to fibrin. 
D. Interaction with other proteins 
Factor XIIIa has been shown to catalyse the formation of 
y-glutamyl-E-lysyl bonds between fibronectin ~olecules (Mosher, 1975 
and Keski-Oja et al. 1976), plasma fibronectin and a -chains of fibrin 
(Mosher, 1975; Mosher, 1976a and Tamaki and Aoki, 1981), collagen and 
Y-chains of fibrin (Nyman and Duckert, 1975), fibronectin and collagen 
(Mosher et al. 1979 and 1980), a-chains of fibrin and a 2 -plasmin 
inhibitor (Sakata and Aoki, 1980 and Tamaki and Aoki, 1981), between 
myos1n molecules (Cohen et al. 1979), between actin molecules (Cohen 
et al. 1980, but see Mui and Ganguly 1977), between dansylcadaverine 
and a2 -macroglobulin (Mosher, 1976a and Wierzbicki and Mosher, 1982), 
between fibronectin and Staphylococcus au:rieus (Mosher and Procter, 1980) 
and between monodansylcadaverine and a 110,000 M.W. protein (Mosher, 
1976a) which could be a subunit of factor VIII related antigen (Folk 
and Finlayson, 1977 and Hada et al. 1982). 
The biological importance of these interactions 1s discussed 
1n Chapter 3.V, as well as in Chapter l (for the fibronectin inter-
actions). 
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-V. BIOLOGICAL FUNCTIONS OF FACTOR XIII 
A. Haemostasis 
The ability of the circulation system to maintain blood fluid 
within the vessels and to prevent excessive blood loss upon 1nJury, 
is defined as haemostasis (Murano, 1980). The importance of factor 
XIII in the blood coagulation system was shown in l960 _by the effects 
of the absence of factor XIII (Duckert et a l. 1960 and Chapter 3.VI). 
Basically, the blood coagulation process is the formation of an 
insoluble fibrin clot at the site of injury. As described above 
(Chapter 3.IV.C), factor XIII is responsible for the final step ,n 
this process, the covalent cross-linking of fibrin molecules by the 
formation of inter-chain y-glutamyl-c-lysyl bonds. Although the 
presence of factor XIII in the circulation system is essential for 
normal haemostasis (Duckert et al. 1960 and Duckert, 1972), the 
formation of a cross-linked fibrin clot does not appear to account 
for the effects of its absence on the haemostatic process (Folk and 
Finlayson, 1977). 
Studies in the late 1970 1 s and 1980 1 s (Chapter 3.IV.D) have 
shown that factor XIII probably cross-links several other haemostati-
cally important proteins into the clot and is also probably involved 
1n clot retraction by platelets (see below). 
l. Clot stability 
a) mechanical: Duckert (1972) proposed that the cross-linking of 
fibrin could promote haemostasis by producing a mechanically stronger 
and more rigid clot. Cross-linked fibrin has a greater rigidity than 
non-cross-linked fibrin, although the differences are small (Moc kros 
et al . 1974 and Roberts et al . 1974). It has been su ggested that this 
is due to the prevention of slippage of fibrin monomers under stress 
(Gerth et al . 1974). Cross-lin ked fibrin also has an increased 
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elastic modulus; this increase is dependent on a -chain cross-linking 
(Shen et al . 1974 and 1975). These results are supported by the thrombo-
elastogram of factor XIII deficient patients being subnormal and 
decreasing at a greater rate than normal (Duckert, 1960 and Folk and 
Finlayson, 1977). It is, therefore, possible to imagine a weaker, 
non-cross-linked clot, buffeted by circulating forces, being distorted, 
dismembered or dislodged (Hartert, 1974 and Folk and Finiayson, 1977). 
Additional support for this hypothesis is provided by the fact 
that bleeding in factor XIII deficient patients normally occurs 24-36 
hours after injury (Duckert, 1972) and that a-Chtiin cross-linking which 
provides rigidity occurs at a later stage (Chapter 3.IV.C). However, 
only l-5% of normal plasma factor XIII levels proyide haemostatic pro-
tection (Folk and Finlayson, 1977) whereas considerably higher levels 
are required for a-chain cross-linking over a shorter period in vitro 
(Pisano et al. 1972). 
The observation that fibronectin is covalently crosslinked to fibrin 
by factor XIII at a similar rate to that at which fibrin a-chain cross-
linking occurs (Mosher, 1975; Tamaki and Aoki, 1981 and Chapter l.IIl.E) 
offers a further mechanism by which the clot can be anchored and stabil-
ised. The fibronectin could then bind to and be cross-linked to the 
surrounding collagen matrix (the molecular interactions of fibronectin 
are discussed in Chapter l .III). Factor XII Ia has been reported to 
mediate fibronectin-collagen cross-linking (Mosher et al . 1979 and 1980). 
Also the clot may be stabilised by the possible format ion of direct fibrin-
collagen cross-lin ks (Nyman and Duckert , 1975). 
b) solubility: The presence of factor XIII in plasma was originally 
determined by its ability to render fibrin clots insoluble in a variety 
of reagents (Alami etal. 1968 and Lorand, 1972). The insolubility of 
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cross-linked fibrin clots in 2% acetic acid is dependent on y-chain 
cross-links (Schwartz et al. 1971b and Moroi et al . 1975), while in 1% 
monochloroacetic acid a-chain cross-links are also required (Scully 
1976). The biological significance of these solubility tests 1s un-
certain apart from the indication that cross-linked clots are more 
stable. 
c) proteolysis: In vivo fibrinolysis of the clot 1s catalysed by 
plasmin. The two maJor natural inhibitors of plasmin area2 macroglobulin 
and a 
2
- pl a s mi n i n h i bi tor ( He d n er , l 9 7 3 and Ao k i , l 9 7 9 ) , but on 1 y 
a 2 -plasmin inhibitor (a 2 PI) prevents clot proteolysis (Aoki, 1979). 
Schwartz et al . (1973) and Gaffney and Brasher (1973) suggested that 
extensive fibrin a-chain cross-linking substantially increased clot 
lysis time. These reports, combined with the results of several other 
studies, led to the general assumption that a-chain cross-linking by 
factor XIIIa made fibrin less susceptible to fibrinolytic enzymes 
(Lorand and Jacobsen, 1962; Gormsen et al . 1967; Henderson and 
Nussbaum, 1969; McDonagh et al . 1971 a; Gormsen and Federsen, 1972 
and Gaffney and Whitaker, 1979). However, studies which utilised 
purified proteins rather than plasma, failed to show any difference 1n 
lysis rates between cross-linked and non-cross-linked fibrin clots 
(Haverkate, 1975 and Rampling, 1978). 
These anomalies are apparently explained by the observation that 
factor XIII catalyses the rapid covalent incorporation of a 2 PI into the 
fibrin clot (Sakata and Aoki, 1980 and Tamaki and Aoki, 1981) and the 
fact that a 2-PI levels are lower in serum than plasma (Sakata and Aoki, 
1980). Therefore, the reduced susceptibility to proteolysis of fibrin 
clots formed ,n the presence of factor XIIIa in vivo and in vitro is 
probably due to the covalent attachment ofa2 PI to the clot rather than 
the format ion of fibrin cross-links (Ichinose and Aoki , 1982 and Sakata 
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and Aoki, 1982). 
2. Clot retraction 
Kiesselbach and Wagner (1972) showed that ~latelet factor XIII, 
which comprises 30-50% of factor XIII in blood, is not needed for the 
formation of the fibrin clot. The physiological function of platelet 
factor XIII was, therefore, unknown. The interaction of fibrin, myosin 
and actin from platelets is an important process in clot retraction 
(Cohen and de Vries, 1973 and Cohen et al. 1975). As the association 
of these proteins occurs in the presence of platelet factor XIII (Lopaciuk 
et al. 1976), it is possible that the formation of cross-linkages between 
them may stabilise the interactions. Cohen et al. (1979 and 1980) have 
shown that in vitro factor XIIIa does catalyse the cross-linking of actin 
and of myosin (light and heavy chains). In addition calmodulin reduces 
the ca2+ requirement to levels obtainable in the platelet cytosol (Cohen 
and Kahn, 1981). 
It is, therefore, hypothesised that the factor XIIIa catalysed 
cross-linking of fibrin, actin and myosin plays an important role in 
stabilising the irreversibly contracted gel mass seen in platelets 
following the release reaction and during clot retraction. Adenosine 
triphosphate (ATP) may have a regulatory role in this process (Cohen 
et al. 1980). The observation that platelets in factor XIII deficient 
plasma fail to develop tension and long pseudopods supports this 
hypothesis (Gerrard et al. 1981 ). 
3. Others 
The above discussion involves the role of factor XIII in the later 
stages of haemostasis. A possible early role could be 1n the process 
of local clotting at the site of injury if the ability of factor XIIIa 
to irreversibly cross-link fibrin (Ly et al . 1974 and Kanaide and 
Shainoff, 1975) reduces the concentration of fibrin monomer necessary 
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for gel formation (Shen et al . 1975). 
The physiological importance of the factor XIIIa, cofactor enhan-
ced, incorporation of primary amines into the protease inhibdtor, 
a 2 -macroglobulin, is uncertain but it is possible that factor XIIIa 
could irreversibly bind proteases produced during blood coagulation to 
a 2 -macroglobulin and thus aid in their inactivation (Mosher 1976a and 
Wierzbicki and Mosher, 1982). 
B. Wound healing 
Approximately 20-25% of factor XIII deficient patients show ab-
normal wound healing processes (Duckert, 1972), which suggest that 
factor XIII is involved in these processes. However, why 75-80% of 
deficient patients have apparently normal wound healing 1s difficult 
to explain. Studies which have utilised animal models, as well as some 
in vitro studies support the idea that factor XIII is necessary for 
normal wound healing (Beck et al. 1961; Marktl and Rudas, 1974; Folk 
and Finlayson, 1977; Bruhn, 1981 and Chung et al. 1982). The observa-
tion that plasma factor XIII levels are reduced to 40% of normal at a 
time after major surgery when fibroblast activity would be expected also 
suggests that factor XIII is used in the wound healing process (Letheby 
et aZ. 1974). 
The likelyrole of factor XIII in wound healing became apparent from 
the ability of factor XIIIa to cross-link proteins other than fibrin. 
The importance of the factor XIIIa catalysed cross-linking of fibro-
nectin has been discussed elsewhere (Chapter l .III.E and see Bowness, 
1982). In addition the possibility that wound strength is increased 
by the factor XIIIa mediated polymerisation of collagen may be important 
(Nyman and Duckert, 1975 and Soria et al . 1975). Through its ability 
to cross-link a number of proteins that are vital to the wound healing 
process, factor XIII appears to play an important role in normal wound 
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healing. 
C. Pregnancy 
The level of factor XIII in plasma falls steadily throughout 
pregnancy to a level 50-60% of normal, possibly to counterbalance an 
increased rate of fibrin formation and thus protect against thrombo-
embolic complications (Coopland et al . 1969 and Ebert e t al. 1981, 
but see Padar 1972). However, it is possible that the reduced 
levels represent an increased consumption of factor XIII during preg-
nancy since factor XIII is known to bind to fibrin (Folk and Chung, 
1 97 5) . 
As pregnant women deficient in factor XIII abort spontaneously 
unless they receive adequate replacement therapy (Lorand et al. 1980), 
it is apparent that factor XIII activity is required for a normal 
pregnancy. Factor XIII is present in the plasma, placenta and uterus 
and is absent from all three sites 1n deficient patients, therefore 
it is uncertain in which site the deficiency is important. The fact that 
plasma therapy enables pregnancy to reach term does not mean that 
factor XIII in the placenta and uterus 1s not important in normal preg-
nancies (Folk and Finlayson, 1977). 
One role of factor XIII in pregnancy could be to cross-link fibro-
nectin from the amniotic fluid (Chen et al . 1978) or from the plasma 
with a large amount of fibrin from the maternal blood in the placental 
basement membrane so that a safe and effective anatomical barrier exi sts 
between the mother and foetus (Folk and Finlayson, 1977). A second 
role for factor XIII is suggested by the ability of factor XIIIa to 
cross-link actin and myosin in muscle (Cohen et al . 1979 and 1980). It 
is possible that, as hypothesised by Alving and Laki (1967), the uterine 
factor XIIIa serves as a catalyst for the connection of muscle protei ns 
into a contractile network necessary for delivery. 
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Recent investigations into the mechanisms by which the embryo is 
protected against rejection by the mother's immune system during its 
first days 1n the uterus have suggested a role for factor XIII 
(Mukherjee et al. 1981). It appears that factor XI I I cross-1 inks 
uteroglobulin, a protein synthesised by the uterus, to transplantation 
antigens on the embryonic surface, thereby hiding them from the 
mother's immune system. As mentioned previously the fact that women 
deficient in factor XIII are protected from spontaneous abortions by 
replacement therapy suggests that the presence of factor XIII in the 
blood system is sufficient for the process described above to occur. 
D. The mononuclear phagocytic system 
The interaction of factor XIII with St ap hylococcus aureus and 
fibronectin and its possible role in the mononuclear phagocytic system 
has been discussed in Chapter 1 .III.F. 
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VI. FACTOR XIII IN DISEASE 
A. Factor XIII deficiency 
Lorand et al. (1980) in an extensive review have classified 
factor XIII deficiency into three groups: I. Hereditary absence 
of factor XIII; II. Acquired inhibitors of factor XIII and III. 
Lowered levels of factor XIII in association with another disease 
state. In group I factor XIII is deficient in all body tissues and 
fluid, whereas, 1n II and III only the plasma levels are reduced. 
Each group will be considered separately here. 
1. Congenital factor XIII deficiency 
In 1960, Duckert et al. reported the first case of a bleeding 
disorder due to a congenital deficiency of factor XIII. Since that 
initial report approximately 100 further cases have been diagnosed 
(Lorand et al. 1980). The clinical manifestations have been compre-
hensively reviewed (Britten, 1967; Alami et al. 1968; Duckert, 1972; 
Losowsky and Miloszewski, 1977; Kitchens and Newcomb, 1979; Lorand 
et al. 1980 and Miloszewski and Losowsky, 1982). The characteristic 
clinical observation is haemorrhage from the umbilical cord within 
days or weeks of birth (Losowsky and Miloszewski, 1977). Other common 
clinical findings are li.sted in Table 3.4. 
Although the bleeding diathesis is mild 1n some reported cases, 
,n the majority it is serious. The life of the patient is marred and 
put at risk by the recurrent and severe bleeding which occurs 24-36 
hours after mild trauma. In early life intracranial haemorrhage is 
often a cause of death (Lorand et al. 1980). However, a long term 
prophylactic treatment which allows patients to live a normal life, 
1s possible. 
Since an initial report of successful treatment (Ottaviani and 
Mandelli, 1966) factor XIII from a variety of sources has been used 
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TABLE 3.4. THE COMMON CLINICAL MANIFESTATIONS OF FACTOR XIII DEFICIENCY 
Umbilical Haemorrhage 
Epistaxis 
Intracranial Bleeding 
Recurrent Abortion 
Haemarthrosis 
Intramuscular Bleeding 
Abnormal Wound Healing 
Superficial Bruising 
Subcutaneous Bleeding 
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,n treatme nt, including fresh frozen plasma and placental concentrates 
(Britten, 1967; Bohn, 1972 and Losowsky and Miloszewski, 1977). The 
danger of the development of antibodies has not been reported to be a 
problem (Losowsky and Miloszewski, 1977) with the possible exception of 
one patient (Lorand et al . 1969a). Because of the relatively long half-
life of factor XIII in vivo, 10-14 days (Miloszewski and Losowsky, 1970; 
Ikkala, 1972 and Lorand et al . 1980) and the fact that only l-5% of 
normal plasma levels achieve haemostasis (Britten, 1967 and Duckert, 
1972), replacement therapy is only required once in every 5-6 weeks 
(Losowsky and Miloszewski, 1977). The readily available prophylactic 
treatment negates the necessity for antenatal diagnosis and selective 
abortion in this disorder, as has been suggested (Fried et al . 1981). 
Congenital factor XIII deficiency ,snow generally accepted as 
being an autosomal recessive disease (see Chapter 3.VII. A), and ,s 
apparently present in most races (Lorand et al . 1980). In the majority 
of cases plasma factor XIIIa activity is either absent or below 1% of 
normal (McDonagh, 1982), although levels·of up to 1.7% of normal have 
been reported (Rodeghiero and Barbui, 1980). As detected by immuno -
precipitation, which will not detect levels below 5% of normal, A sub-
units are absent and B subunits are at concentrations of about 50% of 
normal (Bohn et al . 1973; Israels et al . 1973; Barbui et al . 1974; 
Rodeghiero and Barbui, 1980 and Ikematsu, 1981 ). However, the presence 
of inactive A subunits has been suggested 1n some cases (Ukita et al . 
1976 and Forman et al . 1977) as well as the total absence of A and B 
subunits in one case (Girolami et al . 1978). All this data suggests 
that there is probably genetic heterogeneity of factor XIII deficiency 
(see Chapter 3.VII.B). 
In mo st heterozygotes factor XIIIa activity and the plasma levels 
of A and B subunits are between t hose of deficient homozygotes and 
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normal controls (Board et al. 1980; Ikema tsu, 1981 and McDonagh, 1982). 
Various procedures have been used for the diagnosis of factor XIII 
deficiency: Thromboelastography (Duckert et al. 1960); clot histology 
(Alami et al . 1968); clot solubility (Loewy et al . 1961; Lorand and 
Konishi, 1964; Barry and Delage, 1965 and Kitchens and Newcomb, 1979); 
SOS polyacrylamide gel visualisation of fibrin cross-linking (Lorand 
et al . 1969b and Schwartz et al. 1971b); amine incorporation rate 
a s says for enzyme act i v i t y ( Lor and e t al . l 9 6 9 a ; D v i l ans ky et al . l 9 7 0 ; 
Lorand and Gotah, 1970; Lorand et a l. 1971; Lorand et al . 1972 and 
Curtis and Lorand, 1976); fluorescent polarization analysis (Yamada and 
Meguro, 1977); electrophoresis on N-dimethylcasein agarose (Lorand et al . 
1979) and the localisation of A subunits on agarose gels, by a fluores-
cent technique, after high voltage electrophoresis (Board, 1979; Sten-
berg and Stenflo, 1979; Board et a l. 1980 and Stenberg et al . 1980). 
While the enzyme assays offer the most accurate measure of enzyme 
activity (Lorand et al . 1980) they are rather complex for most diagnostic 
laboratories and it has, therefore, been argued that gel electrophoresis 
should be routinely used (Stenberg et al . 1980). In the case of hetero-
zygote detection, problems arise with the enzyme rate assays because of 
the wide range of activity in normal subjects (Lorand et al . 1980) and 
the possibility that an unstable A subunit with raised activity would 
not be detected in combination with a normal A subunit (Castle et al. 
1981). The preferred method of heterozygote detection would therefore 
be the electrophoretic system of Board (1979), which enables individuals 
to be genotyped (see Chapter 3.VII and Chapter 4). 
2. Acquired inhi bitors 
In 1972, Lewis su ggested that inhibitors of factor XIII could act in 
four ways; a) inactivation of the zymog en; b) blocka ge of activation; 
c) depression of enzyme activity and d) blockage of fibrin cross-li nkage 
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sites. Evidence exists for the presence of all four types of inhibitors 
in the few reported cases (Lewis, 1972 and Lorand et al . 1980). In most 
cases the inhibition is associated with drug therapy, in particular with 
the use of isoniazid in anti tuberculous therapy (Lewis, 1972). As isonia-
zid is a potent inhibitor of factor XIIIa this may not appear surprising, 
but inhibition persists after drug therapy has ceased (Lewis, 1972 and 
Lorand et al. 1980). It has been shown that inhibition is due to the 
presence of immunoglobin G (IgG) which cross reacts with factor XIII 
(Lorand et al. 1980 and Ikematsu, 1981) . The reason why IgG is produced 
against the factor XIII molecule is not known. Recently Galanikis et al . 
(1982) have demonstrated the presence of inhibitors specific for factor 
XIIIa in the gas-phase, water-soluble components of cigarette smoke. 
The possible importance of factor XIIIa inhibition in the pathophysiology 
of smoking is discussed by these workers. 
3. Factor XIII deficiency in other disease states 
Reduced levels of factor XIII have been reported in a wide range of 
conditions; malignant disorders (Lorand et al . 1980; Zuck et al . 1981; 
Gramse et al . 1982 and Matsuda, 1982); anaemias; haemorrhagic disease<;1nd 
renal disease (Lorand et al . 1980); uraemia (Nussbaum and Morse, 1964); 
iron intoxication (Henriksson et al . 1979); erosive gastritis (Nilsson et al . 
1975); cerebral infarction (Matsuda, 1982); arteriosclerosis (Alkjaersig 
et al . 1977); antibiotic-associated pseudomembranous colitis (Kuratsuji 
et al. 1982); disseminated intravascular coagulation (DIC) (Merskey et al. 
1967; Ikematsu, 1981; Rodeghiero et al. 1981b and Matsuda, 1982); 
Henoch-Schonlein's purpara (Henriksson et al . 1975); septicaemia (Holst 
et al . 1981; Egbrin g et al . 1982; Jochum et al . 1982 and Matsuda, 1982) ; 
liver disease (Lorand et al . 1980 and Matsuda, 1982) and after surgery 
(Letheby et al . 1974 and Ikematsu, 1981 ) . The mechanism of reducti on in 
several of the above conditions is no w reasonabl y cl ear. 
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-Liver disease: As discussed previously, plasma factor XIII is synthe-
sised largely in the liver (C hapter 3.II.A) and evidence from a variety 
of sources suggests that reduced hepatic synthesis is the cause of 
decreased levels of plasma factor XIII in some liver disorders (Yavu gil 
et a l. 1967; Mandel and Gerhold 1969; Walls and Losowsky, 1969; Cucuianu 
et al. 1973 and 1976; Biland et al. 1979; Lorand et al. 1980 and 
Matsuda, 1982). 
Leukaemia and Septicaemia: Approximately 30% of acute myeloid leukaemia 
patients (Gramse et al. 1982) and 33% of septicaemia patients (Egbring 
et al . 1982) have markedly reduced plasma factor XIII levels. In both 
cases the cause appears to be direct proteolysis of the molecule, 
probably by elastase (Holst et al. 1981; Gramse et al . 1982 and 
Jochum e t al. 1982). 
Surgery and DIC: The probable reason for the low factor XIII levels 
in these two conditions is the utilisation and consumption of the 
molecule in wound healing and the coagulation process respectively 
( I k e ma ts u , l 9 81 ) . 
B. Other diseases 
Factor XIII and tissue transglutaminases have been implicated in 
the development of neoplasms (Yancey and Laki, 1972; de Petro et al . 
1980 and Bruhn, 1981). While factor XIIIa has been shown to prevent 
focal appearance and cause the reversion to normal cell morphology of 
Rous-sarcoma virus-induced transformed cells in vitro (de Petro et al . 
1980), it 1s probable that, in vivo tissue transglut am inases are more 
important as transglutaminase activity is reduced in transformed cells 
(Birckbichler et al . 1977). While Yancey and Lak i (1972) suggested 
that metastasis is inhibited by trans glutaminases, Bruhn (1981) cl ai ms 
that tumour cells are stimul ated by factor XIII. Therefore, any role 
for factor XIII in neo pl astic develo pment remains unce r t ain. 
- 120 -
It has been suggested that the liberation of thrombin and the 
subsequent activation of plasma factor XIII ,n arteriosclerotic lesions 
could induce the proliferation of cell wall cells and cause intima 
fibrosis (Bruhn, 1981) rather than the platelet-induced smooth muscle 
proliferation hypothesis of Ross (1980). However, previous work has 
suggested that tissue transglutaminases are probably more important 
than factor XIII in arteriosclerosis (Laki et al. 1972). 
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VII. THE GENETICS OF FACTOR XIII 
A. The mode of inheritance of congenital factor XIII deficiency 
The initial reports of factor XIII deficiency indicated that the 
disorder had an autosomal recessive mode of inheritance (Duckert 
1960; Barry and Delage, 1965; Lorand, 1965 and Fisher et al. 1966), 
but because of reportedly lower factor XIIIa activity in males (as 
measured by clot solubility) and the apparent absence of male to male 
transmission in two families, Hampton et al . (1966) suggested an X-
linked recessive mode of inheritance. However, further studies demon- · 
strated that the defect in these families was due to the presence of 
an a bnorma 1 f i br i nogen, fi bri no gen Ok 1 ahoma (Hampton, 1968 and 1970 and f-amp:on 
and Morton, 1970). Although, in a review of the literature, Britten 
(1967) showed that the disorder fitted an autosomal recessive model 
by four recognised criteria, an X-linked model was again proposed 
because of an excess of affected males (Ratnoff and Steinberg, 1968 
and Steinberg and Ratnoff, 1969). By 1971, the male to female ratio 
in reported cases was closer to unity and further studies of the 
initial family reported by Duckert had supported the autosomal recessive 
model (Lorand et al. 1970; McDonagh et al. 1971c and Duckert 1972). 
However, those families with only males affected, had lower levels of 
consanguinity than families with both sexes affected thus suggesting 
two forms of the disorder with X-linked and autosomal modes of inheri-
tance respectively (Ratnoff and Steinberg, 1972). 
In the early 1970 1 s more specific and accurate assays became 
available for the mea surement of factor XIII activity (Chapter 3.VI.A.1 ). 
Studies which have utilised these assays have failed to reveal any 
cases that need to invoke the X-linked model , thus suggesting that 
congenital factor XIII deficiency is an autosomal recessive disorder 
(McDonagh et al . 1974; Barbui et al . 1978 and Kitchens and Newcomb, 
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1979). However, because or the difficulty in identifying heterozygotes 
caused by the wide range of activity of factor XIII in normal subjects 
(Walls and Losowsky, 1969 and Lorand et al . 1980) some authors felt 
that X-linked inheritance could not be ruled out in some cases (Losowsky 
and Miloszewski, 1977 and Lorand et al. 1980). 
Board (1979 and 1980) utilised an agarose gel electrophoresis 
system (see Chapter 4) to demonstrate that genes for both the A and B 
subunits of factor XIII are located on autosomes. The same technique 
has shown that a null allele, FXIIIA*QO and an allele with an unstable 
product, FXIIIA*3 at the A locus are inherited in an autosomal manner 
(Board et al. 1980 and Castle et al. 1981). It therefore appears that 
factor XIII deficiency is an autosomal recessive disorder and is not 
an X-linked condition (see also Chapter 4). 
B. Genetic heterogeneity of factor XIII deficiency 
The possibility of genetic heterogeneity of factor XIII deficiency 
was originally put forward because of the dispute over the mode of 
inheritance of the disorder (Hampton et al . 1972 and Ratnoff and Stein-
berg, 1972). Later work, which reported unusual immunological results 
,n some deficient cases again suggested the presence of more than one 
genetic type of the disorder (Ukita et al. 1976 and Forman et al . 1977). 
Recently, two different alleles capable of causing factor XIII 
deficiency have been reported (Board et al . 1980; Castle et al . 1981 
and see Chapter 4). 
C. Genetic polymorphism of the A subunit locus 
The development of a suitable thin layer agarose electrophoresis 
system and a specific fluorescent staining technique led to the discov-
ery of a genetically determined polymorphism of the A subunit in 
Caucasian Australians (Board, 1979). Studies of additional populations 
have shown the pol ymorph ism to be widely spread, with the frequency of 
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the different alleles varying between groups (Table 3.5). In addition 
to the three alleles which code for proteins with normal activity, a 
null allele and an allele which codes for an unstable protein are present 
at the A locus (Board e t al 1980; Castle et al . 1981 and Chapter 4). 
D. Genetic polymorphism of the B subunit locus 
The B subunit of plasma factor XIII has no known en?ymatic activity 
but can be localised after electrophoresis in agarose by immunofixation 
with specific antiserum (Board, 1980). The screening of several popu-
lations has revealed a large degree of genetic heterogeneity (Table 3.6). 
Recently the use of isoelectric focussing of plasma samples has 
been advocated to separate the products of the different alleles (Kera 
et al. 1981). This technique concentrates the protein into very fine 
zones which enhances their staining intensity and makes the phenotypic 
band patterns easier to observe. Unfortunately the use of isoelectric-
focussing, as described by Kera et al. 1981, does not clearly resolve the 
products of the FXIIIB*l and FXIIIB*2 alleles (Board and Castle, 1982). 
Despite this fact it is likely that the FXIIIB*2 allele ,s rare in the 
Japanese population studied by Kera et al. (1981) since no type 2 B 
subunits were detected by electrophoresis. However, the new rare variant 
reported in Japanese (Nakamura and Abe, 1982) is possibly the FXIIIB*2 
allele. The studies of Kreckl and KUhnl (1982) and KUhnl et al . (1982) 
have helped confirm the existence of the FXIIIB*2 allele. 
The phenotypes obtained by electrophoresis and isoelectricfocussing 
of the different combinations of the FXIIIB*l ~ FXIIIB*2~~ FXIIIB*3 and 
FXIIIB*4 alleles are shown in Figure 3.4. The FXIIIB*4 allele has only 
been observed in a single Australian blood donor (Board and Castle, 1982). 
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TABLE 3.5 
FREQUENCIES OF FACTOR XIIIA LOCUS ALLELES WITH FUNCTIONALLY 
NORMAL PRODUCTS IN VARIOUS POPULATIONS 
Population N FXIIIA*l FXIIIA *2 FXIIIA*4 Reference 
Australiant 383 .795 .205 Board (1979) 
Europeans# 239 . 797 .203 Kreckl e t a l . (1982) 
Japanese § 561 .887 . 11 3 Nishigaki et ai. 
( 1 981 ) 
Japanese§ 250 . 900 . l 00 Kera and Nishimukai 
( l 982) 
Fijians 
Melanesian§ 137 .783 .209 .008 Board and Coggan 
( 1981 ) 
Indian§ 137 .768 .232 -ditto-
Loyalty Is. 
Melanesian§ 133 .925 .075 -ditto-
Cook Is. 
Polynesian§ 100 .980 .020 -ditto-
t Plasma and platelets 
# Platelets 
§ Plasma 
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TABLE 3.6. 
FREQUENCIES OF FACTOR XIIIB LOCUS ALLELES IN VARIOUS POPULATIONS 
Population N FXIIIB*1 FXIIIB*2 FXIIIB*3 Reference 
Australian 245 .747 .084 . 16 9 Boa rd- ( 1980) 
European 236 .725 .095 . 180 Kreckl and Kuhnl ( l 982) 
and Kuhnl et al . ( l 982) 
Japanese 182 .336 .664 Kera et al . ( l 98 l ) 
Japanese 310 .252 . Ol3t .735 Nakamura and Abe ( l 982) 
Japanese 119 .303 .697 Nishigaki et al . ( 1982) 
Fijian 
Melanesian 127 . 61 .02 .37 Board and Castle (1982) 
Indian 128 .66 .08 .26 -ditto-
t not reported as FXIIIB*2 
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FIGURE 3.4. 
THE ELECTROPHORETIC PHENOTYPES SHOWN BY THE ALLELES AT THE 
FXIII-B LOCUS (from Board and Castle, 1982) 
a) Isoelectric focussing of the four alleles at the FXIII-B locus 
b) A comparison of the results of electrophoresis and isoelectric 
focussing of the Type 2 B subunits 
E = electrophoresis; I= isoelectric focussing 
a 
+ 
-
1 1-3 3 1-4 1-3 1 1 1-2 2 1 1-2 
b E I 
+ - + 
0 
-1 1-2 2 1 1-2 2 
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E. The chromosomal locations of the A and B subunit loci 
Neither loci has been assigned to a specific chromosome at the 
present time. However, there is no evidence of close linkage of the A 
subunit locus to the following markers; ACPl, 3cen, GC, MNSs, Akl, ABO, 
9cen, ESD, l3p, 14p, l5p, HP, PGP, ADA, 2lp, C6, TF, GPT, K, lGK and 
JK and the factor XIIIA locus is excluded from the vicinity of lp, the 
PEPC and Fy locus on chromosome l and from between the HLA and GLO loci 
on chromosome 6 the NP loci and 14p ter, the PI and GM loci on chromo-
some 14 and the centromere and GOT2 on chromosome 16 (King and Cook, 
1981). In addition, deletion mapping techniques have been used to 
exclude the A subunit locus from the following chromosome segments 
lq24, 4pl5.l • pl6.l, 4q23• q24, 4q27• q32, 6q22, 7q22, l3ql3, l3q23• q31, 
l8q2l • q23 and 2lq2l • qter and the B subunit locus from chromosome 
segments 4pl5.l • l6.l, 4q27-+q3l, 9p22• pter and 9pter• qll (Mulley et al. 
1980 and 1982; Cook et al. 1981 and King and Cook, 1981). 
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, Chapter 4 
I. INTRODUCTION 
A. Genetic polymorphism of the A subunit locus 
Bohn (1970) reported the occurrence of a charge heterogeneity of 
platelet factor XIII, thus suggesting that more than one -type of A 
subunit was present in platelets. In 1973, Schwartz et al . noted the 
occurrence of two species of factor XIII A subunits from plasma in 
polyacrylamide gels containing urea at pH 3.2. It therefore appeared 
that there was a microheterogeneity of A subunits in man. As discussed 
briefly in Chapter 3. VII. C,this microheterogeneity can be explained 
by a genetic polymorphism at the A subunit locus. 
Board (1979) developed a ·thin · layer agarose gel electrophoresis 
system (pH 8.6), which gave good resolution of factor XIII A subunits, 
along with a specific fluorescent staining technique based on the 
incorporation of monodansyl cadaverine into casein by factor XIIIa 
(Lorand and Campbell, 1971). These two techniques were combined to 
demonstrate a genetic polymorphism at the A subunit locus in Australian 
blood donors. Two common alleles, designated FXIIIA*l and FXIIIA*2 , 
were reported with frequencies of 0.79 and 0.21 respectively. Although 
this initial report indicated that the polymorphism was also present in 
New Guinea, Samoan, Chinese and Australian Aboriginal populations, no 
data was given. 
Subsequently, several studies have extended the occurrence of this 
genetically determined polymorphism to German Europeans (Kreckl et al . 
1982), Japanese populations (Nishigaki et al . 1981 and Kera and 
Nishimukai, 1982) and four Pacific Island populations, Loyalty Islanders 
(Melanesian), Cook Islanders (Polynesian) and Fijians (Melanesian and 
Indian) (Board and Coggan, 1981 ). These studies have shown that the 
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frequencies of the FXIIIA*l and FXII IA*2 alleles are different 1n the 
various population groups (Table 3.5). In addition, Board and Coggan 
(1981) have reported the occurrence of another allele, FXIIIA *4 in 
Melanesians from Fiji at a frequency just below that generally recog-
nised as being at a polymorphic level (Stern, 1973). 
In the normal population, this polymorphic variation 1s not 
associated with any clinical abnormality. The products of the FXI IIA* l 
and FXIIIA*2 alleles show similar enzyme activity, as measured by the 
rate of incorporation of 14c putrescine into casein by unpurified 
plasma samples (Board et al. 1980). 
The electrophoretic appearance of the various phenotypes observed 
for factor XIII A subunits are illustrated in Figure 4.1. Homozygotes 
present a single banded pattern, but heterozygotes present a more 
complex three banded phenotype. Since heterozygotes produce A subunits 
with different electrophoretic mobilities, their random assembly into 
dimers results in the production of homodimers identical to those found 
in homozygotes and heterodimers which have an electrophoretic mobility 
midway between the extremes of the fast and slow homodi rners. 
Since individual phenotypes for the FXIIIA locus can be readily 
determined from plasma samples by an inexpensive technique, the FXIIIA 
locus is potentially of considerable value as a genetic marker for 
population studies. Therefore it was decided to obtain gene frequency 
data for the FXIIIA locus from a number of populations. Particular 
emphasis, in these studies, was placed on population groups from Indo-
nesia, Papua New Guinea and the Western Pacific. However, data was 
also obtained for South American Indians and for a population from 
the Caspian Littoral in the Middle East. 
B. The genetics of factor XIII deficiency 
The mode of inheritance of con genital factor XI II deficiency has 
+ 
2 1-2 2-4 1-4 1 
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been discussed in Chapter 3.VII.A. As the published cases show several 
features characteristic of autosomal recessive inheritance: i) high 
incidence of consanguinity in the affected families; ii) absence of 
haemorrhagic symptoms in preceding generations although in several 
instances siblings have been affected with the disorder; iii) occur-
rence of the disorder in both sexes and iv) presence of subclinical 
laboratory defects 1n both parents of affected children (Britten, 1967) 
and both the A and B subunit loci of factor XIII are located on auto-
somal chromosomes (Board, 1979 and 1980), it is probable that congenital 
factor XIII deficiency is an autosomal recessive disorder. 
Board et al. (1980) used the electrophoretic technique described 
above,in combination with a quantitative assay for factor XIIIa to 
show that factor XIII deficiency in a family originally described by 
Hamer and Rae (1971) was due to the presence of a null allele, FXIIIA*QO 
at the FXIIIA locus. However, studies that utilised immunological 
techniques have suggested the presence of more than one genetic type 
of this disorder (Ukita et al. 1976 and Forman et al . 1977) therefore 
suggesting that other alleles with abnormal or deficient products may 
exist in some populations. 
In the course of the population screening programme mentioned above 
an apparently unstable A subunit protein was found in a normal New 
Zealand blood donor. Subsequent electrophoretic and quantitative 
studies in the family of the blood donor with this unstable protein 
revealed the same variation in his daughter, while his wife and son 
were both normal. As in the homozygous state, or 1n a heterozygous 
state with the previously reported null allele (Board et al . 1980), 
this variant protein would be expected to result in congenital factor 
XIII deficiency, it was considered to be of importance to investigate 
families which have reported cases of the disorder in an attempt to 
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determine the relative frequencies of the null and type 3 alleles ,n 
congenital factor XIII deficiency cases. Unfortunately, no cases of 
the disorder have been reported in Australia and it has only been 
possible to obtain samples from two additional families with confirmed 
cases and one family with a suspected case of congenital factor XIII 
deficiency for investigation. 
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II. MATERIALS AND METHODS 
A. Agarose gel electrophoresis 
The buffer system used was essentially the discontinuous system 
described by Ashton and Braden (1961). The electrode buffer contained 
29 mM lithium hydroxide and 191 mM boric acid. The gel buffer was 
prepared by combining 9 vol solution containing 7.62 mM citric acid 
and 52 mM Tris with 1 vol electrode buffer. The two components of 
the buffer system were always prepared within 24 hours of use. 
Thin layer agarose gels were prepared and set up for electro-
phoresis as described in Chapter 2. Electrophoresis was carried out 
at 18 V/cm until a haemoglobin marker migrated at least 6.5 cm to 
the anodal end of the gel. After electrophoresis of the samples for 
5 minutes, the sample slots were overlaid with 1% agarose (w/v) 
dissolved in the gel buffer. 
B. Localisation of factor XIIIa activity 
After electrophoresis factor XIII A subunits were localised on 
the gel by their thrombin activated transamidase activity, incorporating 
monodansylcadaverine into casein (Board, 1979). Lorand and Campbell 
(1971) demonstrated that monodansylcadaverine was an excellent fluor-
escent substrate for factor XIIIa in the presence of casein. In the 
procedure used here monodansylcadaverine is covalently linked to 
casein in areas of factor XIIIa activity. The subsequent treatment 
with trichloroacetic acid (TCA) precipitates the casein in the gel, 
thus fixing the fluorescent complex at the site of factor XIIIa 
activity. Elution of the unreacted fluorescent substrate under running 
water removes the background fluorescence and leaves clearly defined 
fluorescent zones. 
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To identify the zones of factor XIIIa activity, the gels were 
overlaid with a filter paper strip (Whatman No. l) soaked in a reaction 
mi x tu re con ta i n i n g , l M Tri s . H Cl ( pH 7 . 4 ) , l ml ; 0 . 2 M Ca Cl 2 , l ml ; 
10 mg/ml casein (Sigma purified powder) dissolved 1n lM Tris. HCl 
(pH 7.4), 3 ml; 0.025M monodansylcadaverine, l ml; 8-mercaptoethanol, 
20 µl and 2U thrombin (0rtho Diagnostics). The monodansylcadaverine 
was initially dissolved 1n a small amount of 0.5M HCl and then made up 
to volume with lM Tris. HCl (pH 7.4). The gel was then inc0bated at 
37°c, in a moist environment for 16 hours for plasma samples. Platelet 
extracts were only incubated for 4 hours. 
After incubation, the filter paper containing the staining reagents 
was removed and the gel fixed by the application of a filter paper over-
lay containing 5% (w/v) TCA for 5 minutes. After fixation, the gel is 
again overlaid for a further 5 minutes with another filter paper soaked 
in 0.3 M Na 2HP04. The unincorporated monodansylcadaverine is removed by 
washing the gel under running tap water for 1-4 hours. The areas of 
factor XIIIa activity were viewed under short wave (254 nM) UV light. 
For most samples the zones of factor XIIIa activity can be viewed before 
the fixation and elution procedure due to a change in the em1ss1on wave-
length of monodansylcadaverine bound to casein. However, the latter is 
necessary for good photographic reproduction of the gels. 
C. Immunofixation 
After electrophoresis, factor XIII A subunits were specifically 
localised by overlayin g the gel with a 30% solution (v/v) of rabbit 
anti-human factor XIII subunit A antiserum (Behringwerke). The 
diluted antiserum was applied to the gel and the gel was processed and 
stained as described in Chapter 2. 
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D. Factor XIII assay 
Thrombin activated plasma factor XIII activity was determined by 
the incorporation of 14c putrescine (New England Nuclear) into a-casein 
(Sigma). The method was a modification of the procedure described by 
Dvilansky et al. (1970). The final putrescine concentration was 
elevated to l mM in this system. The reaction mixture contained, 0.3 M 
Tris. HCl (pH 7.5), 25 µl; 0.1 M CaCl 2, 25 µl; l mM EDTA; 25 µl; 
0.5 M B-mercaptoethanol, 25 µl; 50 U/ml thrombin, 25 µl; 10 mM 14c 
putrescine, 25 µl; l0mg/ml a-casein, 75 µl and plasma sample, 25 µl. 
Plasma samples were heated at 56°c for 3 minutes and centrifuged at 
2000g for 5 minutes to remove fibrinogen prior to use in the assay. 
The reaction was carried out at 37°c and the rate was determined 
at intervals by transferring 25 µl aliquots of the reaction mixture 
onto 2 cm Whatman 3MM chromatography paper discs which were immediately 
quenched in 5% TCA and processed as previously described by Mans and 
Novelli (1961). Because of the lag phase during enzyme activation, 
the rate of 14c putrescine incorporation into casein did not reach 
its maximum until after 30 minutes. Aliquots were removed at 30 minute 
intervals up to 180 minutes and the reaction rates were calculated 
from least square regression of the incorporated radioactivity between 
30 and 180 minutes. 
E. Sample collection and preparation 
The plasma samples for population screening had been collected 
previously, on a variety of anticoagulants, and had been stored for up 
to 10 years on liquid nitrogen or at -20°c. Platelets for screening 
were obtained from expired packs of concentrated platelets prepared by 
the Canberra Red Cross Blood Transfusion Service and the Auckland Blood 
Transfusion Centre. Platelets were separated from plasma by differ-
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ential centrifugation and washed twice 1n ice cold 150 mM NaCl. Before 
electrophoresis platelets were treated with equal volumes of 1% Triton 
XlOO to release the A subunits. 
Blood from the families with suspected or confirmed factor XIII 
deficiency was collected onto citrate, as an anticoagulant, 1n other 
laboratories. Plasma was immediately prepared and shipped, by air, to 
the laboratory 1n Canberra where it was stored in liquid nitrogen for 
later evaluation. 
Blood from the family with the apparently unstable A subunits was 
collected onto citrate, as an anticoagulant, in Auckland, New Zealand. 
Platelet-rich plasma was immediately prepared and shipped, by air, to 
the laboratory 1n Canberra. Platelets were prepared as described above. 
Determinations of activated plasma factor XIII activity were carried 
out within 48 hours of blood collection. Control samples were collected 
from laboratory workers and were treated in a similar fashion. 
I. Populations studied 
Indonesia: Eight populations from the Indonesian archipelago were 
studied. The populations were from Java, Lombok, Sumbawa, Timor, 
Celebes, Ternate and Northern Halmahera. The samples, therefore, 
represented the more Mongoloid people of the West and the people with 
Melanesian characteristics in the Eastern Region of Indonesia. 
Papua New Guinea: Five populations from Papua New Guinea were studied. 
Three were from the mainland, the Western and Eastern Highlands and 
the Gulf District, the fourth was from Buka Island of the N.E. coast 
and the fifth was from Goodenough Island of the S.E. tip of Papua New 
Guinea. 
Australia and New Zealand: A collection of Australian Aboriginal plasma 
samples was examined in addition to platelets from Australian and New 
Zealand blood donors. 
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Western Pacific: Collections from New Caledonia (Melanesians) to the 
North East of Australia, Guam (Micronesians) to the North of Australia 
and the Samoan and Tokelau Islands (Polynesians) to the East of Aust-
ralia were examined. 
Others: Plasma samples from Pima Indians (South America) and a 
population from the Caspian Littoral of the Middle East were also 
examined. 
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III. RESULTS 
A. Population studies 
Zones of factor XIIIa activity appeared as fluorescent bands 4-7 cm 
from the or1g1n. As expected from previous studies, heterozygotes 
showed a symmetrical triplet pattern with three equidistant bands whose 
ratio was approximately l :2:l. Homozygotes had a single -band , although 
in some of the older collections of plasma samples a fainter anodic 
minor band was also present. It was considered that this anodic band 
represents a modification to the A subunits of factor XIII during 
prolonged storage. 
1. Observed phenotypes 
In addition to the three common phenotypes, 1-1, 1-2 and 
2-2, two other three-banded and one two-banded phenotypes were seen. 
The two three-banded phenotypes were shown to correspond to the l-4 
and 2-4 phenotypes previously described in Fijian Melanesians (Figure 
4. 2) . 
The two-banded phenotype found in a New Zealand blood donor 1s 
described below (Chapter 4.IV . B) . 
2. Distribution of the observed phenotypes 
Examination of plasma samples from the populations studied 
revealed that the two alleles for the A subunit, FXIIIA*l and FXIIIA*2 , 
which are common in populations studied previously are also present in 
each of the populations studied here. The distribution of the observed 
phenotypes is given in Table 4 .1. 
Two of the Indone si an popul ations studi ed, th e Yo gyaka rta and 
Macassarese and one of the Pa pua New Guinean collections from the 
Gulf District, contained individuals with phenotypes resulting from 
the presence of the FXfilA*4 allele . The new pheno type , l-3, was not 
included in the data anal ys i s as the FXIIIA*3 allele codes f or 
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A COMPARISON OF THE l-4 AND 2-4 PHENOTYPES OBSERVED IN 
THIS STUDY WITH THOSE PUBLISHED BY BOARD AND COGGAN 
(1981): 
(a) The l-4 phenotype from Fiji (Board and Coggan, 1981) 
(b) The l-4 phenotype from Indonesia 
(c) The 2-4 phenotype from Indonesia 
(d) The 2-4 phenotype from Fiji (Board and Coggan, 1981) 
(e) The 2-4 phenotype from Papua New Guinea 
+ 
1-1 1-4 
a 
1-4 
b 
2-4 
C 
2-4 
d 
2-4 
e 
TABLE 4.1. 
DISTRIBUTION OF FACTOR XIII A SUBUNIT PHENOTYPES 
POPULATION PHENOTYPE TOTAL x2 d.f. p 
l 2-1 2 1-4 2-4 
INDONESIA 
Yogyakarta (Java) Obs. No. 143 13 - - l · 157 
* Exp. No. 142.36 13.33 0. 31 0.95 0.05 21 .750 3 0. 01 
Lombok (Lombok) Obs. No. 138 20 3 - - 161 
Exp. No. 136.05 23.90 l . 05 - - 4.288 3 0.05t 
Bimanese (Sumbawa) Obs. No. 147 12 2 - - 161 
Exp. No. 145.40 15. 21 0.40 7. 153 3 0.05t 
__J 
- -
~ 
0 
Timorese (Timor) Obs. No. 133 28 - - - 161 
Exp. No. 134. 22 25.57 l . 22 - - l .460 3 0.05t 
Macassarese (Celebes) Obs. No. 134 24 3 l - 162 
Exp. No. 132.48 27. 13 l . 39 0.90 0.09 2.352 3 0.05t 
Buginese (Celebes) Obs. No. 150 l l l - - 162 
Exp. No. 149.26 12.48 0.26 - - 2.274 3 0.05t 
Ternatans (Ternate) Obs. No. 183 29 l - - 213 
Exp. No. 183. 13 28.74 l . l 3 - - 0.017 · 3 0.05t 
Galarese (North Obs. No. 142 38 5 - - 185 
Halmahera) Exp. No. 140. 11 41 . 77 3. 11 l .509 3 0.05t - -
TABLE 4.1. Cont'd 
POPULATION PHENOTYPE TOTAL x2 d.f. p 
1 2-l 2 1-4 2-4 
PAPUA NEW GUINEA 
Eastern Highlanders Obs. No. 111 33 6 - - 150 
Exp. No. 108.38 38.25 3.38 - - 2.826 l o.o5t 
Gulf District Obs. No. 38 11 
- - l 50 
Exp. No. 3 7. 96 l O. 49 0. 71 0.86 0. 12 8.386 3 o.o5t 
Western Highlanders Obs. No. 34 17 5 - - 56 
__. 
Exp. No. 32.26 20.49 3.26 l . 626 l o. 05t .,i::::,. - - __. 
Buka Is. Obs. No. 52 22 2 
- - 76 
Exp. No. 52.22 21 . 55 2.22 - - 0.033 l o. 05t 
Goodenough Is. Obs. No. 104 44 2 - - 150 
Exp. No. 105.84 40.32 3.84 - - l . 250 1 o.o5t 
AUSTRALIA AND 
NEW ZEALAND 
Australian Abar- Obs. No. 59 34 4 - - 97 
1g1nes Exp. No. 59.55 32.91 4.55 - - 0. l 07 ,. o.o5t 
Blood donors Obs. No. l 08 44 l l - - 163 
Exp. No. 103.68 52.64 6.68 - - 4. 390 3 o.o5t 
WESTERN PACIFIC 
New Caledonia Obs. No. 111 37 2 
- - 150 
Exp. No. 111 . 80 35.40 2.80 0. 308 l o.o5t 
TABLE 4. l. Cont'd 
POPULATION PHENOTYPE TOTAL x2 d.f. p 
1 2-1 2 1-4 2-4 
WESTERN PACIFIC 
Guam Obs. No. 101 36 5 - - 142 
Exp. No. 99.73 38.55 3.73 - - 0. 621 3 o.o5t 
Samoan Is. Obs. No. 119 27 1 - - 147 
Exp. No. 119.43 26. 14 l . 43 - - 0. 159 3 o.o5t 
Tokelau Is. Obs. No. 135 27 - - - 162 __,J 
o.o5t 
~ 
Exp. No. 136. 1 3 24.75 l . 13 - - l. 339 3 N 
SOUTH AMERICA 
Pima Indians Obs. No. l 06 47 l - - 154 
Exp. No . l 08. 90 41 . 21 3.90 - - 3.047 3 o.ost 
MIDDLE EAST 
Caspian Sea Obs. No. 44 25 4 - - 73 
Exp. No. 43.73 25.54 3.73 - - 0.033 3 0.05t 
* Significant; 
t Not significant. 
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a functionally abnormal product. 
3. Gene frequencies 
The gene frequencies of the FXIIIA*1 ~ FXIIIA*2 and FXIIIA*4 
alleles for each of the populations studied is given in Table 4.2. 
Only the FXIIIA *1and FXIIIA*2 alleles are at frequencies that are 
considered to be polymorphic. 
B. The type 1-3 phenotype 
l. Electrophoretic studies 
After the observation of a two-banded phenotype in a platelet 
sample from a blood donor in New Zealand (Figure 4.3), other members of 
the probands family were investigated to see if they showed a similar 
phenotype. Study of family J showed his wife and son to be of the 1-1 
type while his daughter, LJ, had a similar two-banded pattern (Figure 
4.4). 
Platelet and plasma samples from the proband, JJ and LJ, 
showed a fast band corresponding to the 1-1 type and a second slower 
band which was electrophoretically slower than the heterodimer of the 
2-1 type but faster than the 2-2 band. No other band was present. The 
two-banded pattern was revealed by the functional stain and by immuno-
fixation. 
During storage of platelets suspended in saline at 4°c for 
14d the second slow band degraded and on subsequent electrophoresis 
only the normal l-1 type band was present from the platelets of JJ and 
LJ. Similarly, plasma samples stored in liquid nitrogen lost the second 
slow band when freeze-thawed several ti mes . Platelets and plasma 
samples from controls stored for a si milar period of ti me and treated 
in a similar manner showed no changes in their banding pattern s after 
electrophoresis. 
It is propo sed that the patt ern seen 1n t he proba nd 1s the 
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TABLE 4.2. 
THE GENE r- qEQUENCIES OF THE ALLELES WITH NORMAL 
PRODUCTS AT THE FXIII A LOCUS 
POPULATION GENE FREQUENCY 
FXIIIA*l FXIIIA *2 FXIIIA *4 
Indonesia 
:. * Yogyakarta 0.952 0. 045 0.003 
Lombok 0.919 0.081 
Bimanese 0.950 0.050 
Timorese 0.913 0.087 
* Macassarese 0.904 0.093 0.003 
Buginese 0.960 0. 040 
Terna tans 0.927 0.073 
Galelarese 0.870 0. 130 
PaQua New Guinea 
Eastern Highlands 0.850 0. 150 
* Gulf District 0.872 0. 125 0.003 
Western Highlands 0.759 0. 24 l 
Buka Is. 0 .829 0. 171 
Goodenough Is. 0.840 0. 160 
·Australia and New Zealand 
Australian Aborigines 0.784 0.217 
Blood donors 0.798 0.203 
Western Pacific 
New Caledonia 0.863 0.137 
Guam 0.838 0.162 
Samoan Is. 0. 901 0.099 
Tokelau Is . 0.917 0.083 
S. America 
Pima Indians 0.841 0. 159 
Middle East 
Caspian Sea 0.774 0.226 
* S.E. = 0.003 
N S.E. 
157 0.012 
161 0.015 
161 0.012 
161 0.016 
162 0.016 
162 0.011 
213 0.013 
185 0.018 
150 0.021 
51 0.032 
56 0.040 
76 0. 031 
150 0.021 
97 0.030 
l63 0.022 
150 0.020 
142 0.022 
147 0. 01 7 
162 0.015 
154 0. 021 
78 0. 035 
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ELECTROPHORESIS OF FACTOR XIII A SUBUNITS FROM JJ, THE 
PROBAND (l-3) AND CONTROLS (l-l, l-2, 2-2): 
(a) Localisation of A subunits by the functional stain 
(b) Localisation of A subunits by immunofi·xation 
a 
+ 
1-1 1-3 1-2 1-3 1-2 1-1 
b 
3-1 2-1 2-2 
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PEDIGREE OF FAMILY J WITH THE FXIIIA*3 ALLELE SHOWING 
THEIR FACTOR XIII A SUBUNIT GENOTYPE: 
/ Proband; () Heterozygotes for the FXIIIA* 3 ALLELE 
THE PLASMA FACTOR XIII ACTIVITY OF THE PROBAND AND HIS 
DAUGHTER (l-3) COMPARED TO THE MEAN+ S.D. OF FIVE 
CONTROLS 
/ .........i 
1-3 1-1 
1-3 1-1 
FAMILY J 
80 
60 
C 
·-
E 
'-..____ 
C 
·-(l) 40 ..,_ 
0 
L.. 
CL 
O'l 
'-..____ 
~ 20 C 
0 
1-1 1-3 
2-1 
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result of an allele for an unstable A subunit protein, designated 3. 
This interpretation suggests that the 3-3 homodimer is unstable and 
is therefore not detected by electrophoresis although it would be 
expected to be electrophoretically slower than the 2-2 homodimer. 
The l-3 heterodimer appears to be stabilised by the Type 1 protein, 
but 1s present at reduced levels. 
It can be seen from Figure 4.3.a that the intensities of the 
bands produced by the functional stain are approximately equal, while 
the protein stained after immunofixation showed the l-l band to be 3-4 
times more intense than the l-3 band (Figure 4.3.b). This finding 
suggests that the Type 3 protein may well have increased enzyme 
activity despite its instability. 
2. Factor XIII levels in plasma 
The transamidase activity of activated plasma factor XIII 
was measured in all members of family J and in five controls. These 
data are presented in Table 4.3 and Figure 4.5 and show that both JJ 
and LJ, who have the abnormal phenotypes had levels of activity which 
were lower than the mean of the controls, but were slightly higher than 
the lowest normal control. 
C. Factor XIII deficient family studies 
Two families with confirmed cases of congenital factor XIII 
deficiency and one with a suspected case were examined by electro-
phoretic and quantitative analysis to determine which allele at the 
FXIII A locus was causing the deficiency. 
Family P: The relationship of the family members studied here 1s 
shown in Figure 4.6. Individual II-l was previously diagnosed as 
factor XIII deficient by clot solubility tests. There 1s one mis-
carriage in the family and individual II-5 died from a Wilm's tumour. 
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PEDIGREE OF FAMILY P WITH THE FACTOR XIII A SUBUNIT 
GENOTYPES 
/ Proband; () Heterozygotes for the FXIIIA*QO allele 
• Miscarriage; 0 deceased from a Wilm's Tumour 
Homozygote for the FXIIIA *QO allele 
THE PLASMA FACTOR XIII ACTIVITY OF MEMBERS OF FAMILY P 
AND TWO CONTROLS 
Controls; • Individual I I-2; A Individual II-4; 
V Individual I-l; 6 Individual I-2; • Individual II-l 
I 
II 
DP 10m 
x10 3 
20 
10 
/ 
0 
0-0 
1 
30 
1-0 
1 
1 -1 
2 3 
1-0 
2 
1-0 
4 
FAMILY P 
60 90 120 
Time (min.) 
5 
150 180 
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TABLE 4.3. 
PLASMA FACTOR XIII ACTIVITY IN NORMAL CONTROLS 
AND FAMILY J 
* PHENOTYPE ACTIVITY 
Normal controls Normal 
Mean of five+ SD 49.4 + 28.86 
Range 19.7 - 95.7 
Proband 
Wife 
Daughter 
Son 
Variant 
Normal 
Variant 
Normal 
22.0 
86.6 
23.4 
39.3 
* nM 14c putrescine crosslinked to a-casein/g 
plasma protein/min at 37°c and pH 7.5. 
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The other members of the family are normal for factor XIII but the 
mother has Von Recklinghausen~ disease . The sample from individual 
II-1 failed to show any transamidase activity, either after electro-
phoresis or 1n the factor XIII assay (Figure 4.7) and no detectable 
factor XIII A subunit protein was found after immunofixation. In 
comparison the other family members presented a phenotypic pattern 
similar to that obtained from a FXIIIA* 1 homozygote, although the band 
was relatively weak in individuals I-1, I-2 and II-4. 
Family E: The relationship of the individuals studied ,s shown in 
Figure 4.8. Individuals II-1 and II-2 were previously diagnosed as 
factor XIII deficient by clot solubility tests and failed to show any 
detectable transamidase activity either after electrophoresis or during 
a factor XIII assay. Both parents present 1-1 phenotypes. 
Family M: Samples from this family were examined as the child had a 
spontaneous unexplained umbilical haemorrhage, which is a character-
istic of factor XIII deficiency (Chapter 3). However, examination by 
electrophoresis and factor XIII assay showed all members of the fa mily 
to be normal for factor XIII activity. 
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PEDIGREE OF FAMILY E WITH FACTOR XIII A SUBUNIT GENO-
TYPES 
/ Pro band; Heterozygote for the FXIIIA*QO allele 
Homozygote for the FXIIIA*QO allele 
I 
/ 
I 
1-0 
1 
o-o 
1 
1-0 
2 
FAMILY E 
0-0 
2 
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IV. DISCUSSION 
A. Distribution of factor XIII A subunit alleles 
The most detailed survey has been carried out 1n Indonesia where 
eight population groups have been studied, but the results from Papua 
New Guinea, Australia and the Western Pacific mean that there is now 
considerable data on the distribution of alleles at the FXIII A locus 
in the area fran the Indonesian archipelago in the West to the Polynesian 
region of the Pacific in the East . This region includes populations 
recognised as being Mongoloid, Melanesian, Micronesian, Polynesian and 
Caucasian. 
l. The FXI IIA*1 and FXIIIA*2 alleles 
All of the populations studied were polymorphic for the 
FXIIIA*1 and FXIIIA*2 alleles with the frequency of the FXIIIA*1 allele 
ranging from 0.759 to 0.960. The values obtained for Australian and 
New Zealand blood donors were in good agreement with those published 
previously for Caucasian populations (Board, 1979 and Kreckel et al . 
l 982) . 
The frequencies of the two alleles were variable between the 
population groups studied 1n Indonesia, but there was no obvious cline 
in frequency in a geographical direction. The frequency of the FXIIIA*1 
was higher than that found in Indians (Board and Coggan, 1981) although 
the Indians studied were from Fiji, but was closer to the frequency 
reported for Japanese (Nishigaki et al. 1981). 
The FXIIIA*1 allele had a lower frequency 1n the Melanesian 
populations of Papua New Guinea than in the Indonesian populations. 
Melanesians from New Caledonia had a similar FXIIIA*1 frequency to the 
Papua New Guinea populations as did Micronesians fro m Guam. Board and 
Coggan (1981) reported a very high frequency of the FXIIIA*1 allele 1n 
Polynesians fro m Coo k Island, 0.98. The two Polynesian populations 
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studied here, Samoan and Tokelau Islanders, showed a lower frequ ency, 
0.901 and 0.917 respectively. Although these values are higher than 
those for the Melanesian populations studied here, they are of a 
similar magnitude to that published previously for Loyalty Island 
Melanesians, 0.925 (Board and Coggan, 1981). 
In addition to the relatively detailed survey of the Western 
Pacific region populations from the Caspian Littoral in Iran and of 
South American Indians were shown to be polymorphic for the FXIIIA*l 
and FXIIIA*2 alleles. 
2. The FXII I A*4 allele 
Board and Coggan (1981) reported the presence of the FXIIIA*4 
allele in the Melanesian populations of Fiji, but failed to find any 
evidence of the presence of the allele in other Pacific populations. 
Although the survey carried out here failed to detect the FXIIIA*4 
allele in four Pacific Island populations, the allele was detected 1n 
Melanesians from Papua New Guinea and the Yogyakarta and Macassarese 
of Indonesia. While these latter two populations are not Melanesian . 
they have been shown to contain some alleles which are considered 
to be Melanesian markers (Sofro, 1982) . Therefore, the data suggests 
that the FXII IA*4 allele may well be a Melanesian marker gene . 
The FXIIIA*4 allele does not appear to be polymorphic 1n any 
of the populations where it has been found. Although the frequency in 
the Gulf District population is 0.01, the sample size is too small for 
this to be considered a reliable esti mate. 
B. The type 1-3 ph enotype 
The two-banded electrophoretic pattern observed in bot h the pro-
band and his daughter suggests that they are heterozygous for an all el e 
for a normal A subunit and an allele for an abnormal A subunit, which 
has been termed type 3 in accordance with the previo usl y defi ned nomen -
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tlature (Board, 1979). Since the A subunit of factor XIII is a dimeric 
molecule, heterozygotes for electrophoretically different allelic 
products normally present a three-banded phenotype. In this case the 
absence of a third electrophoretically slow, enzymatically active, 
component representing the expected 3-3 homodimer, implies that the 
FXIIIA*3 allele product is either inactive or unstable. Immunological 
investigation of these subjects by immunofixation of the electrophor-
etically separated A subunits failed to provide any evidence of an 
inactive 3-3 homodimer, suggesting that the FXIIIA*3 allele product 
1s either unstable as a homodimer, or is both inactive and not recognised 
by the anti A antiserum. However, since there was a rapid breakdown 
of the l-3 heterodimer during storage at 4°c, it seems most likely that 
the Type 3 protein is, 1n fact, unstable (the data presented in Chapter 
5 appears to confirm this hypothesis). 
Despite the apparent instability of the Type 3 protein, the rela-
tively high transamidase staining intensity of the l-3 heterodimer 1n 
comparison with its proportionally low total protein content, as 
evaluated by immunofixation, suggests that the Type 3 protein may, 1n 
fact, have an elevated activity . 
The subjects studied here do not suffer from the clinical features 
of factor XIII deficiency but, because of the apparent instability of 
the 3-3 homodimers, it is likely that no stable product would be found 
in individuals homozygous for this allele, or heterozygous for the FXIIIA*3 
allele and the previously described null allele FXIIIA*QO (Board et al. 
1980). This identification of the FXIIIA*3 allele clearly indicates 
that there are multiple alleles at the FXIIIA structural locus which 
can lead to factor XIII deficiency in man and that can only be differ-
entiated by electrophoretic examination of samples from the parents of 
deficient individuals (see section C). 
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It is not possible to detect heterozygotes for the FXIIIA*QO 
allele by electrophoresis as these individuals show a phenotype identical 
to that of homozygotes for the normal alleles. However, the two-banded 
nature of heterozygotes for the T.XIIIA*3 allele suggests that they should 
be easily identified in population surveys and therefore that an estimate 
of the frequency of this allele could be made . In 2,938 individuals 
studied here and 1940 individuals studied previously, oniy one example 
of a l-3 phenotype has been found, therefore suggesting that the 
FXIIIA*3 allele is relatively rare. Still, it is possible that the 
instability of the 1-3 heterodimer might cause this band to be lost 
under certain storage conditions and after several freeze-thaw episodes . 
In fact, during the population survey carried out here, two samples 
from the Samoan collection showed a two-banded pattern similar to that 
of a l-3 heterozygote albeit with a weak slower band, but when the 
samples were rechecked this band was absent and the samples gave a 1-1 
phenotype. It may, therefore, be that the FXIIIA* 3 allele is only 
detectable in relatively fresh samples . 
C. Factor XIII deficiency 
As mentioned above it appears that there are multiple alleles at 
the FXIII A structural locus which can lead to factor XIII deficiency 
1n man. Therefore, studies by the electrophoretic technique described 
by Board (1979) and used here, of the parents and other family members 
of those cases reported previously, should reveal the relative import-
ance of the FXIIIA *QO~ FXI IIA*3 and other possible alleles with unstable 
or inactive products (Ukita et al . 1976 and Forman et al . 1977) in the 
aetiology of factor XIII deficiency. 
Unfortunately, due to the absence of any reported cases of factor 
XIII deficiency in Australia, it was only possible to study two addition-
al families with cases of factor XIII deficiency here. In both family 
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P and family Ethe results of transamidase activity measurement and 
immunofixation after electrophoresis suggest the factor XIII deficiency 
is a result of the null allele being present in the homozygous state . 
Therefore, in the three families where these studies have been carri ed , 
out, the FXIIIA*QO allele appears to be the causal agent. However, 
there is no proof of identity of the null alleles in these three 
families. 
In previously studied cases of factor XIII deficiency, the absence 
of active A subunits has indicated that heterozygotes could be readily 
identified for genetic counselling because of their considerably reduced 
transamidase activity (Kitchens and Newcombe, 1979 and Board et al . 1980). 
Although the levels of activity in the two heterozygotes for the FXIIIA*3 
allele were lower than the mean for the controls, they were slightly 
higher than the lowest control samples . The occurrence of an unstable A 
subunit with an increased activity in the family reported here, suggests 
that heterozygote detection by enzyme assay may miss some individuals 
who are potential parents of deficient children. Heterozygote detection 
by enzyme assay, combined with electrophoretic studies similar to those 
utilised here, should not miss any of these heterozygotes. Although, 
it is possible that a 2-3 heterozygote will be difficult to distinguish 
from a 2-2 homozygote as the 2-3 heterodimer should migrate close to 
the 2-2 homodimer. However, the relatively low frequency of the FXIIIA*2 
allele in most populations indicates that ' the FXIIIA*3 allele is much 
more likely to be found in combination with the FXIIIA*l allele. 
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V. CONCLUSIONS 
l. The previously reported polymorphism at the structural locus 
for factor XIII A subunits has been extended in its distribution to 
Indonesia, Papua New Guinea and several Island groups in the Western 
Pacific as well as to the Pima Indians of South America and the Caspian 
Littoral. 
2. The FXIIIA*4 allele has been identified in two Indonesian and 
one Papua New Guinean population in addition to the Melanesians of 
Fiji reported previously. The data suggests that this allele may be a 
Melanesian marker. 
3. A new allele with an unstable product, FXIIIA*3, has been 
identified. This allele in the homozygous state or in the heterozygous 
state with the previously described null allele, FXIIIA* QO , is likely 
to result in congenital factor XIII deficiency. This represents the 
first clear evidence of genetic heterogeneity of congenital factor 
XIII deficiency. 
4. The occurrence of an unstable A subunit protein with an 
apparently raised activity casts doubt on the ability of an enzyme 
assay to identify all potential parents of factor XIII deficient 
children. It is, therefore, recommended that the electrophoretic 
technique used here is employed in conjunction with an enzyme assay 
for the identification of heterozygotes for alleles capable of 
resulting in factor XIII deficiency. 
5. The presence of another autosomal allele, FXIIIA *3, capable 
of causing factor XIII deficiency lends further evidence to this 
disorder being an autosomal recessive disease. 
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Chapter 5 
I. INTRODUCTION 
The general reaction and reaction mechanism of transglutaminases 
was established in the early 1970 1 s (Folk, 1969; Chung et al . 1970; 
Chung and Folk, 1972; Folk and Chung, 1973 and Folk and Finlayson, 
1977; also see Chapter 3.IV and Figures 3.2 and 3.3). Specificity 
studies with glutamine-containing polypeptides, glucagon (Loewy et al . 
1966) and the acetylated B chain of oxidised insulin (Chung and Folk, 
1972) indicated that transglutaminases are specific for the carboxa-
mide groups of glutamine. 
Factor XIII catalyses a calcium-dependent acyl-transfer reaction 
1n which the y-carboxamide groups of peptide-bound glutamine are the 
acyl donors. Primary amine groups in a variety of compounds function 
as acyl acceptors, with the subsequent formation of monosubstituted 
y-amides of peptide bound glutamic acid. The acyl receptors of 
physiological substrates are the s-amino groups of peptide bound 
lysine, thus yielding y-glutamyl-s-lysyl crosslinks (Folk and Finlay-
son, 1977). 
A variety of substrates, which include the acetylated B chain 
of oxidised insulin, a -casein, S-casein, y-casein, k-casein and 
fibrin as the acyl acceptors and several synthetic amines, in 
particular 14c methylamine as well as 14c histamine and 14c 
putrescine as the acyl donors, have been used to confirm that the 
factor XIII catalysed reaction conforms to the general transglutam-
inase reaction mechanism (Chung and Folk, 1972; Lorand et al . 1972 
and Folk and Finlayson, 1977). 
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The plasma factor XIII catalysed reaction also conforms to Michaelis-
Menten kinetics with the various substrates (Lorand et al . 1972 and Folk 
and Finlayson, 1977). Therefore, the Michaelis constant (K) has been 
m 
calculated for a number of these substrates (Table 5.1) as well as a 
maximum velocity (V ) of 142 n moles of 14c methylamine incorporated max 
into acetylated B chain of oxidised insulin/min/mg of enzyme (Chung, 
1 97 5) . 
All the kinetic studies of factor XIII have been carried out on 
the purified enzyme from pooled samples. Board (1979) demonstrated 
that the A subunits of factor XIII, which are the enzymatically active 
subunits, are genetically polymorphic. Therefore, the previous studies ~, 
were almost certainly carried out on factor XIII which had a hetero-
geneous genetic origin. Consequently, it was considered important to 
attempt to evaluate any possible differences in the biochemical 
characteristics of the two common types of A subunit, as it is possible 
that selectable differences may exist between them. 
The number of plasma proteins which are potential substrates for 
factor XIII, for example, fibronectin (Mosher, 1975), a 2 -macroglobulin 
(Mosher, 1976a), fibrin (Lorand et al. 1968; Matacic and Loe,wy, 1968 
and Pisano et al . 1968) and a 2 -plasmin inhibitor (Sakata and Aoki, 1980) 
mean that the purification of factor XIII is essential for the deter-
mination of accurate kinetic values. Fortunately, the gene frequencies 
of the two common alleles, FXIIIA*l and FXIIIA*2 in the 
Australian pooulation are such (see Table 3.5) that it was 
feasible to obtain sufficient plasma from homozygotes for each allele 
to allow the purification of each type of A subunit. However, the 
frequency of Type 2 homozygotes is such that the quantity of this 
protein available limited the number of comparative studies which 
could be carried out. 
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TABLE 5.1. 
THE Km VALUES OF PLASMA FACTOR XIII FOR A VARIETY 
OF SUBSTRATES (Lorand et al. 1972 and Folk and Finlayson, 1977) 
Substrate Ki 
m~ 
acetylated B chain 
* of oxidised insulin 2.08 
* a.15 -casein 0.07 
* . s- casein 0.03 
* y- casein 0.02 
* . k- casein 0.09 
fibrin (human) 0.04 * 
14
c methylamine * 0.62 
14c histamine 0.27t 
14c putrescine o. 1st 
* at pH 7.5 and 2s 0 c; 
t at pH 7.5 and 37°c. 
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It was decided to use an assay system based on the incorporation 
f 14c t · · t · t f 1 t t th K ' o pu resc1ne 1n o a var,e yo acy accep ors o compare e ms 
and V 's of the two genetic forms for each of the substrates. Because max 
fibronectin has been shown to be a substrate for factor XIII (Mosher, 
1975) it was planned to compare the reactions of the two types of A 
subunits with the genetically variant forms of plasma fibronectin. 
However, an electrophoretic screening program of plasma fibronectin 
(see Chapter 2) did not show any detectable variation. Therefore, 
the experiments were only carried out on the normal and dimethyl forms 
of plasma fibronectin. 
14 In addition, the assay based on the incorporation of C putre-
scine into dimethylcasein was used to determine pH and heat stability 
curves for the two types of A subunit. 
The observation that an apparently unstable factor XIII A subunit, 
the Type 3 (Castle et al. 1981 and Chapter 4), was present in some 
individuals indicated that some of the biochemical properties of this 
subunit are different to those of the two common types of A subunits. 
The rarity of FXIIIA*3 allele (Chapter 4), has restricted its bio-
chemical characterisation. Homozygotes for FXIIIA*3 have yet to be 
detected and it was not possible to obtain a large enough quantity of 
plasma or platelets from the two known heterozygotes to purify the 
Type 3 A subunits in sufficient yield to allow extensive kinetic 
characterisation. Even if extensive quantities of plasma of this 
type were available, it is unlikely that pure Type 3 homodimers could be 
prepared since none are found in the l-3 samples studied so far 
(Chapter 4). Consequently, the studies reported here were restricted 
to plasma and samples from one heterozygote were compared with plasma 
samples from homozygotes for each of the Type 1 and Type 2 proteins 
for the effects of pH and temperature on the rate of incorJX)ration of 
14c putrescine into dimethylcasein. 
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II. MATERIALS AND METHODS 
A. Protein measurement 
The method of Lowry et al. (1951) was us ed for studies on factor 
XIII, while the technique of Bradford (1976) was utilised for the 
measurement of fibronectin concentrations. Bovine serum albumin was 
used as a standard in each procedure. 
B. SOS electrophoresis 
SOS polyacrylamide electrophoresis in the absence of B-mercapto-
ethanol, according to the system of Laemmli (1970) with the apparatus 
O'Farrell (1975) was used to compare the molecular weights of the Type 
l and Type 2 A subunits of plasma factor XIII. After electrophoresis 
gels were stained in 0.2% (w/v) Coomassie blue R solution (45% (v/v) 
methanol; 10% (v/v) acetic acid; 45% (v/v) water) for l-3 hours. 
Gels were then placed in a minimum of 500 ml of destain solution (25 % 
(v/v) ethanol; 10% (v/v) acetic acid; 65% (v/v) water). 
C. Agarose gel electrophoresis 
The electrophoretic system of Board (1979) was used to determine 
the factor XIII A subunit phenotypes of plasma samples and to check 
the purification fractions for enzyme activity. The specific fluor-
escent stain was the same as that described in Chapter 4. 
D. Plasma fibronectin purification 
Plasma fibronectin was purified by the method described in 
Chapter 2, except that the fibronectin was dialysed against distilled 
water to remove salts. The fibronectin wa s then lyophilised and stored 
at -20°c until use. The fibronectin obtained by this procedure was 
essentially pure and therefore suitable as a substrate in factor XI I I 
assays (see Chapter 2). 
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E. Preparation of N,N-Dimethyl proteins 
The preparation of N,N-dimethylcasein from casein powder (Sigma) 
and N,N-dimethylfibronectin from plasma fibronectin was by the method 
of Lin e t ai. (1969). The lyophilised samples were stored at -20°c 
until use. 
F. Factor XI I I assay 
Thrombin activated plasma factor XIII activity was determined by 
a modification of the procedure described by Dvilansky et ai . (1970). 
The standard enzyme activation mixture which consisted of 25µ1 0.lM 
CaC1 2 (in 0.3M Tris.HCl pH 7.5), 25µ1 0.2M dithiothreitol (OTT) 
(neutralised), 25µ1 enzyme, 50µ1 0.3M Tris-HCl pH 7.5 and 25µ1 throm-
bin (50 units/ml physiological saline) was incubated at 37°c for 30 
minutes, at which time 100µ1 of a solution containing 3 parts lOmg/ml 
dimethylcasein (in 0.3M Tris.HCl pH 7.5) to one part lOmM 14c putre-
scine dihydrochloride (New England Nuclear 0.5 m Ci/mM) was added. The 
reaction was carried out at 37°c and the rate was determined by trans-
ferring 25µ1 aliquots of the reaction mixture onto 2cm Whatman 3MM 
chromatography paper discs which were immediately quenched in 5% TCA 
(w/v) and processed as previously described by Mans and Novelli (1961). 
Aliquots were removed at time zero and after 30 minutes and the 
reaction rates were calculated by the subtraction of the zero time 
value from the value at 30 minutes. Previous pilot studies indicated 
that the reaction rate was linear for at least 150 minutes. 
The dimethylcasein was replaced by a-casein, casein powder, fibro-
nectin and dimethylfibronectin for the determination of the K and V 
m max 
for these substrates. 
Inactivation of plasma factor XIII by iodoacetamide was examined by 
adding various levels of iodoacetamide, 0.1 to 3 µM, to the initial acti-
vation mixture . 
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For those assays where plasma samples were studied, the plasma 
samples were heated at 56°c for 3 minutes and centrifuged at 2000g for 
5 minutes to remove fibrinogen. 
G. pH curves 
Solutions containing 200µ1 of 0.2M OTT (neutralised), 200µ1 of lOmM 
14c putrescine hydrochloride, 600µ1 of lOmg/ml dimethylcasein (or 
lOmg/ml fibronectin) and 400µ1 of buffer (0.3M Tris, 0.3M imidazol, 
0.3M glycine) were prepared at pH's between pH 6 and pH 11 .5. 
An activation mixture of 25µ1 O.lM CaCl 2, 25µ1 thrombin and 25µ1 
enzyme was incubated at 37°c for 30 minutes, after which 175µ1 of 
each buffered pH solution was added. The reaction rate was deter-
mined as described above. 
H. Heat stability curves 
Enzyme samples were either incubated at a range of temperatures 
for 10 minutes before use or incubated at one temperature for 90 
minutes. In the latter procedure 30µ1 aliquots were taken every 15 
minutes and placed on ice until use. The assay was as described above. 
I. Origin of plasma samples 
Plasma was obtained by the procedure described in Chapter 2. 
Each plasma sample was typed by agarose electrophoresis and stained 
for factor XIII activity. Type 1 samples and Type 2 samples were 
both pooled and stored overnight at 4°c before purification. 
J. Plasma factor XIII purification 
Plasma factor XIII was purified by a modification of the proced-
ure described by Lorand and Gotah (1970). The protein fraction pre-
cipitated between 16 and 20% of saturation with ammonium sulphate 
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(4°c) was taken. The precipitates were collected by centrifugation at 
10,800g for 20 minutes and dissolved in a 50mM Tris.HCl buffer, pH 7.0, 
containing lmM EDTA and O.lM NaCl. The solution, containing factor XIII, 
was heated to 56°c, by immersion in an so0 c waterbath, for 3 minutes 
to remove fibrinogen. The solution was centrifuged as above and the 
precipitate discarded after squeezing to remove any trapped soluble 
enzyme. 
Saturated ammonium sulphate was added to the supernatant to a 
final saturation of 30%. After l hour at 4°c the enzyme solution was 
centrifuged as described above and the supernatant was discarded. The 
precipitate was dissolved in a minimal volume of 50mM Tris.HCl 
buffer, pH 7.5, containing lmM EDTA and dialysed overnight against 
1000 volumes of the same buffer. 
After centrifugation, the dialysed enzyme was applied to a DEAE-
cellulose column equilibrated against 50mM Tris. HCl buffer, pH 7.5 
containing lmM EDTA (DE52, 2.0 x 80 cm) and the column was washed 
with 720 ml of equilibration buffer. The column was then developed 
with a linear gradient (total volume, 600 ml),,of0to0.3M NaCl, in the 
equilibration buffer. 
Fractions of 10ml were collected and tested for protein at O. D280 . 
Tubes with protein were tested for factor XIII activity by the electro-
phoretic system described above and protein content by SOS polyacryl-
amide electrophoresis. 
Tubes with pure factor XIII, as judged by SOS polyacrylamide 
electrophoresis were pooled and saturated ammonium sulphate was added 
to a final saturation of 36%. After l hour at 4°c, the solution was 
centrifuged as above and the supernatant discarded. The precipitate 
was dissolved in a mini mal amount of 50mM Tris. HCl buffer, pH 7.5 
containing lmM EDTA and 50mM NaCl and dialysed overni ght against 50 00 
--
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volumes of the same buffer. The enzyme solution was stored 1n l ml 
aliquots at 4°c. 
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I I I. RES UL TS 
A. Plasma factor XIII purification 
The results of the isolation of plasma factor XIII are summarised 
,n Tables 5.2 and 5.3. The two types of A subunit behaved in a simi-
lar manner in the purification procedure with the final enzyme prep-
arations having very similar specific activities . The specific 
activities for the Type 1 and Type 2 subunits were 98.22 and 94 .00 
units/mg respectively (units of activity are defined in Table 5.2) . 
The behaviour of the subunits on the OEAE chromatography column is 
shown in Figure 5.1. 
SOS polyacrylamide electrophoresis showed that the preparations 
of both types of subunits were clear of any major contaminants 
(Figure 5.2). The three bands in each preparation represent the A 
and B subunits of plasma factor XIII. Because factor XIII has been 
shown to migrate on SOS gels to positions which give anomalous 
molecular weights, compared to those obtained by sedimentation equil-
ibrium (Schwartz et al . 1973), SOS gels were used to compare molecular 
weights only. It can be seen from Figure 5.2 that there is no 
obvious difference ,n the molecular weights of the Type 1 and Type 
2 A subunits. 
B. The factor XIII assay 
The ca2+ requirement for the activation of factor XIII are differ-
ent to that for the catalytic reaction of the enzyme (Chung and Folk, 
1972 and Cooke, 1974) and therefore the assay system used was modified 
from that described in Chapter 4 to allow the enzyme to be activated 
before the reaction was started. The use of an activation mi xture 
also eliminated the lag-phase in the reaction rate described in 
Chapter 4 and thus allowed the reaction rate to be calculated from 
TABLE 5.2. 
PURIFICATION OF FACTOR XIII FROM HUMAN PLASMA: TYPE l A SUBUNITS 
Procedure Volume Total Activity 
Total Protein Specific Activity 
ml units* mg units/mgt 
Citrated Plasma 2000 2424.0 101000.00 0.02 
Ammonium sulphate l 00 2152.8 1380. 00 l . 56 
(16-20%) 
Heat treatment and 12 1404.4 24.96 64.23 
ammonium sulphate 
(30%) 
DEAE chromatography 3 957.6 9.75 98.22 
and ammonium sul-
phate (36%) 
* l unit of activity= l nM of 14c putrescine incorporated into dimethylcasein/min 
t Specific activity is per mg of plasma factor XIII zymogen 
Purification Yield 
Factor % 
l l 00. 0 
60 88.8 
~ 
m 
(X) 
2635 57.9 
4087 39.3 
TABLE 5.3. 
PURIFICATION OF FACTOR XIII FROM HUMAN PLASMA: TYPE 2 A SUBUNITS 
Volume Total Activity Total Protein Specific Activity Purification Yield 
Procedure 
* units/mgt ml units mg Factor % 
Citrated plasma 1000 1856.0 58000.00 0.03 l l 00 · 0 
Ammonium sulphate 50 1103. 6 680.00 1 . 62 51 59.4 
(16-20%) 
Heat Treatment and 18 777.6 31 .68 24.55 767 41 . 6 
.......1 
m 
ammonium sulphate I...D 
(30%) 
DEAE chromatography 2 413.6 4.40 94.00 2938 22.3 
and ammonium sul-
pha te ( 31S% ) 
* 1 unit of activity= lng of 14c putrescine incorporated into dimethylcasein/min 
t Specific activity is per mg of plasma factor XIII zymogen 
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Figure 5.1: THE BEHAVIOUR OF THE TYPE l AND TYPE 2 A SUBUNITS OF 
PLASMA FACTOR XIII ON A DEAE CELLULOSE CHROMATOGRAPHY COLUMN 
a) Type l A subunits 
b) Type 2 A subunits 
G = salt gradient applied; fraction volume was 10 ml. 
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SOS POLYACRYLAMIDE GEL ELECTROPHORESIS OF PURIFit• 
FACTOR XIII FROM PLASMA 
l = Type l A subunits; 2 = Type 2 A subunits 
+ 
1 2 
111 TYPE A SUBUNITS 
111 TYPE B SUBUNITS 
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readings taken at time zero and after 30 minutes. 
All the results described below are the average v~lues from 
duplicate samples which were used in all experiments. 
C. Purified factor XIII 
l. Substrate studies 
The kinetic constants obtained for the Type l and Type 2 A 
subunits of plasma factor XIII for a-casein, casein powder, dimethyl-
casein, fibronectin, dimethylfibronectin, 14c putresci·ne and ca 2+ are 
given in Table 5.4. The kinetic constants were obtained from the 
plot of the equation described by Hanes (1932): 
s 
V 
K l 
= _!!l_+ - ·s V V 
as plotted by Dixon and Webb (1966). For V the values from the plots 
max 
were corrected for Zymogen concentration. The plots are shown in Figures 5.3-
5.9. 
2. Inactivation by iodoacetamide 
Figure 5.10 illustrates that the effect of iodoacetamide 
inactivation was the same for both the Type l and Type 2 A subunits. 
3. pH curve 
The pH curves for the two types of A subunits with dimethyl-
casein as the acyl acceptor are shown 1n Figure 5.11. All the points 
are calculated as a percentage of the enzyme activity at pH 8.32. 
There was a small, but repeatable difference between the pH optima 
of the enzyme preparations in three separate exper iment s. The pH 
opti ma for the Type l and Type 2 A subunits were approximately pH 8.74 
and pH 8.32 respectively. 
If fibronectin was used as the acyl acceptor the pH opti ma were 
approximately pH 8.34 for both types of A subunits (Figure 5.12). 
4. Heat stability 
The heat stability curves from 20°-7o0 c for the two enzyme 
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TABLE 5.4. 
KINETIC CONSTANTS FOR THE TYPE 1 AND TYPE 2 A SUBUNITS OF 
PLASMA FACTOR XIII 
* t K V Substrate m max 
Type 1 Type 2 Type 1 ·Type 2 
a-casein 0.72 0.70 85. 23 84.72 
casein powder 0. 58 0.54 86.34 85.29 
dimethyl casein 0.95 1 . 00 90.03 90.82 
fibronectin 0.54 0.55 49.48 42.84 
dimethylfibronectin 0.41 0.41 4.S.68 49.38 
14 C putrescinett 0 .45 0 .45 88.80 85 .10 
Ca 2+ tt 0. 10 0. 1 0 
* Km d . / 1 t f 14c t . d C 2+ measure 1n mg m excep or pu resc,ne an a 
which are mM 
t V measured 1n nM 14c putrescine incorporated/min/mg 
max 
zymogen 
t t dimethylcasein was the acyl acceptor 
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PLOTS OF s AGAINST s/v FOR THE INCORPORATION OF 
14c PUTRESCINE INTO VARYING CONCENTRATIONS OF: 
5.3: a -casein 
5.4: casein powder 
5.5: di me thylcasein 
5.6: fibronectin 
V = Type l A subunits 
0 = Type 2 A subunits 
Figure 5. 3 s/v x 10 
9 
1 0·5 0 0·5 1 1·5 
mg/ml • a-casein 
Figure 5.5 20 
s/v x105 
10 
1 0·5 1 1·5 
mg/ml dimethylcasein 
Figure 5.4 s/v x 105 
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A PLOT OF s AGAINST s/v FOR THE INCORPORATION OF 14c 
PUTRESCINE INTO VARYING CONCENTRATIONS OF DIMETHYL-
FIBRONECTIN 
A PLOT OF s AGAINST s/v FOR THE INCORPORATION OF 
VARYING CONCENTRATIONS OF 14c PUTRESCINE INTO DIMETHYL-
CASEIN 
A PLOT OF s AGAINST s/v FOR THE INCORPORATION OF 14c 
PUTRESCINE INTO DIMETHYLCASEIN AT VARYING Ca 2+ 
CONCENTRATIONS 
FACTOR XIIIa INACTIVATION BY IODOACETAMIDE 
FOR FIGURES 5.7-5.10 v= Type 1 A subunits 
o= Type 2 A sububits 
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Figure 5.9 
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THE pH CURVES FOR PURIFIED SAMPLES OF THE TWO COMMON 
TYPES OF A SUBUNIT WITH DIMETHYLCASEIN AS THE ACYL 
ACCEPTOR 
v = Type l A subunits; o = Type 2 A subunits 
THE pH CURVES FOR PURIFIED SAMPLES OF THE TWO COMMON 
TYPES OF A SUBUNIT WITH FIBRONECTIN AS THE ACYL 
ACCEPTOR 
v= Type l A subunits; o = Type 2 A subunits 
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preparations are shown 1n Figure 5.13. All the points are calculated 
as a percentage of the activity at 35°c. The preparation of the Type 2 
enzyme consistently (in three experiments) showed greater heat inacti-
vation between 55° and 65°c. This is illustrated for 55°c in Figure 
5. 14. 
D. Plasma factor XIII 
1. pHcurve 
The pH curves of plasma samples from individuals homozygous for 
Type 1 and Type 2 A subunits as well as a heterozygote for Type 1-3 
A subunits are shown in Figure 5.15. Dimethylcasein was the acyl 
acceptor in these studies. The pH optima of the homozygotes for 
Type land Type 2 A subunits are essentially the same at approximately 
pH 8.38. The Type 1-3 plasma, however, showed two pH peaks at pH 8.38 
and pH 9.10 in three separate experiments. 
2. Heat stability 
The heat stability curves from 40°-65°c for the above three 
samples are illustrated in Figure 5.16. While the curves for the two 
homozygotes are essentially the same, the plasma sample from the Type 
1-3 individual, showed heat inactivation as early as 50°c compared 
with 60°c for the other two samples in three experiments. The loss of 
only part of the enzyme activity in Type 1-3 plasma at a more rapid 
rate than the other two samples is illustrated by the heat stability 
curves at 55°c of the three samples (Figure 5.17). 
. . .• ... ~ .. • 
, , ~t:!~~; 1St~:~ · ~-~;, !..:~ \;:~ ~:" · • 
.:~{~. ' ~\l . '. t ,-t• •l:.1t·•·1 
1,~.-
1,-...; 1.• 
·-· .-.i:• f• ~ i .fi 
;t•~t 
:!tr: 1~~·, 
-•,.• 
S~i 
:P. !'1·1·. , .  
t;' i 
., :,., 
.. , . 
. .,. 
~ .. : 
., .,, 
1"1 ;• il ,,•i 
t'.; ~.; 
a .... 
..-',t·r1 
11:• ·1• ti :,,. 
~,:, .~ 
~ ..,, 
:i',!i 
:ii;a 
t i;; 
~ ol 
w.:1, 
'f• I ~ I 
..... ,, 
~;.1, 
., ,t 
~l il 
? li.: 
-
Figure 5.13: 
Figure 5. 14: 
- 178 -
THE EFFECT OF TEMPERATURE ON THE ENZYME ACTIVITY OF 
PURIFIED SAMPLES OF THE TYPE 1 AND TYPE 2 A SUBUNITS 
OF FACTOR XIII 
The A subunits were incubated for 10 minutes at the 
specific temperatures before the assays were started. 
v= Type 1 A subunits; o = Type 2 A subunits 
THE INACTIVATI ON OF PURIFIED SAMPLES OF FACTOR XIII 
TYPE 1 and TYP E 2 A SUBUNITS AT 55°c 
v = Type 1 A subunits; o = Type 2 A subunits 
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THE pH CURVES OF UNPURIFIED PLASMA SAMPLES OF TYPE l, 
TYPE 2 AND TYPE l-3 A SUBUNITS OF FACTOR XIII 
v = Type l A subunits; 0 = Type 2 A subunits; 
• =Type l-3 A subunits. 
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THE EFFECT OF TEMPERATURE ON UNPURIFIED PLASMA .SAMPLES 
OF TYPE l, TYPE 2 AND TYPE l-3 A SUBUNITS OF FACTOR 
XIII 
v= Type 1 A subunits; o = Type 2 A subunits; 
• = Type l-3 A subunits 
THE INACTIVATION OF UNPURIFIED PLASMA SAMPLES OF TYPE l 
TYPE 2 and TYPE l-3 A SUBUNITS OF FACTOR XIII AT ss0 c. 
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IV. DISCUSSION 
A. Purification of plasma factor XIII 
The behaviour of the Type l and Type 2 A subunits of plasma factor 
XIII was similar in the purification procedure, . therefore suggesting 
that there are no major structural differences between them. The 
better yield of the Type l subunits, 39.3%, compared to 22.3%, was 
possibly due to the fact that 60% of the Type 2 plasma was stored for 
l month at -20°c prior to purification, whereas all of the Type l 
plasma was from newly outdated whole blood packs. 
The purification procedure used here produced a relatively high 
yield of an enzyme preparation without any major contaminants, as 
determined by SOS polyacrylamide electrophoresis: The two closely 
spaced bands at the position of the A subunits on the polyacrylamide gel 
(Figure 5.2) are thought to represent the normal A subunits and activa-
ted A subunits with a 4000 M.W. peptide cleaved off. The activation of 
some of the A subunits occurred in the purification of both types of 
factor XIII. 
B. Relative molecular weight studies 
The molecular weight of the A and B subunits has been shown to be 
approximately 75,000 and 88,000 respectively (Chung, 1972; Schwartz 
e t al . 1973 and Chung et al . 1974). Both subunits are known to give 
anomalous molecular weights after SOS gel electrophoresis (Schwartz 
et a l. 1973). Therefore SOS polyacrylamide gels were only used to 
compare the relative molecular weights of the two types of A subunit. 
The samples were not treated with 8-mercaptoethanol prior to electro-
phoresis as better separation of A and B subunits is obtained from 
non-reduced samples (Schwartz et al . 1971a). This finding was con-
finned by studies not shown here. 
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It can be seen from Figure 5.2 that there was no detectable mobility 
difference between the two enzyme preparations. This result indicates 
that the molecular weights of the Type l and Type 2 A subunits are 
essentially the same. The occurrence of similar molecular weights for 
the two types of A subunit suggests that the difference in the alleles 
for each subunit has arisen by point mutation, leading to a single amino 
acid substitution in the subunits themselves. A frame shift mutation 
or an unequal crossing over event resulting in a deletion or insertion 
would be expected to cause changes in the subunits which would result 
in detectable molecular weight differences. 
C. A comparison of the Type l and Type 2 A subunits 
l. Substrate studies 
If the initial rate of an enzyme reaction is measured at a 
series of substrate concentrations, it is possible to obtain values 
for Vmax the maximum rate attained by the reaction at saturating 
substrate concentrations and K, the Michaelis constant, which is the 
m 
concentration when the rate is half the maximum attainable rate. 
The Km and Vmax values for the purified Type l and Type 2 A sub-
units, for the substrates tested, a~casein, casein powder, dimethyl-
casein, fibronectin, dimethylfibronectin and ca2+, were similar for 
each substrate. These results indicate that the mutational eventthat 
gave rise to the two forms of A subunits does not effect their reaction 
kinetics at pH 7.5 and 37°c. Therefore, in these conditions the 
probable amino acid substituion does not effect the active site, the 
substrate binding sites or the conformation of factor XIIIa. Board 
et al . (1980) have shown that the reaction rates for the incorporatio n 
of 14c putrescine into a -casein are the same for unpurified plasma 
samples of both types of enzyme. The possibility that the mutation 
occurred in the part of the gene coding for the 4000 M.W. peptide 
lost in the activation process was ruled out -by Board (1979). 
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The N1 N-dimethyl forms of both casein and fibronectin were used in 
these studies as the s -amino groups of lysine residues of these modi-
fied proteins are blocked. Therefore, they should not be cross-linked 
to themselves by the action of factor XIII, which could occur when the 
unmodified proteins are used as substrates . 
2+ The Km value for Ca of O.lOmM is in reasonable agreement with 
. 14 
the value of Cooke (1974) of O.l7mM, while the Km value for C putre-
scine of 0.45mM is three times that of the value of 0.l5mM obtained by 
Lorand et al. (1972). However, the latter value was obtained from 
plasma samples which contain several other possib]e substrates for 
factor XIII. 
2. Inactivation by iodoacetamide 
Chung et al. (1974) examined the effects of low levels of 
14
c iodoacetamide on plasma and platelet factor XIII. In both cases 
it was shown that the loss of catalytic activity of factor XIII, in 
the presence of ca 2+, was accompanied by the incorporation of 14c 
iodoacetamide at the sulphydryl group of a cysteine residue. The 
addition of iodoacetamide to the enzyme activation mixture produced 
similar results for both forms of the plasma enzyme (Figure 5.10). 
This result indicates that iodoacetamide is able to bind to the active 
site of both forms of the enzyme in a similar manner at pH 7.5 and 37°c, 
which suggests that the conformation of the A subunits around the 
active site 1s similar in both types of A subunit. 
3. pH 
An enzyme 1s only active as a catalyst within a relatively 
narrow range of pH and usually the enzyme is most active at a specific 
pH, called the optimum pH. Two explanations are possible for this 
phenomenon (Wynn, 1973). The first considers that at pH values 
removed from the optimum the enzyme starts to lose the tertiary 
structure necessary for the conformation of the active site. The 
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second, and more probable explanation in most cases, 1s that the pH 
affects the ionisation of acidic and basic groups at the active centre 
of the enzyme. 
The purified preparations of the two types of A subunit showed a 
slight, but consistent, difference in their pH optima when dimethyl-
casein was used as a substrate . The pH optima were, on three occas-
ions, approximately pH 8.74 and pH 8. 32 for the Type 1 ·and Type 2 A 
subunits respectively. When fibronectin was substituted for dimethyl-
casein, the pH optimum for the Type 1 A subunits dropped to the same 
value as that for the Type 2 A subunits, approxi mately pH 8.34. When 
unpurified plasma factor XIII was used with dimethylcasein as a 
substrate the pH optima were similar for the two .types of A subunit 
at approximately pH 8.38. 
The reason that the value for the purified Type 1 A subunits, 
with dimethylcasein as a substrate, differs from all the other values 
is difficult to explain exactly. It is possible that the charge 
difference of the Type 1 enzyme, compared to the Type 2 enzyme 
apparent during electrophoresis at a pH around 8.6 (Chapter 4) results 
in either the active site or the substrate binding site of the Type 1 
form having a greater affinity for dimethylcasein at pH 8.74. The 
fact that this difference was not evident when unpurified plasma 
samples were used suggests that plasma factors interact with factor 
XIII in such a manner as to negate the difference between the two 
forms of A subunits. 
Both the Type 1 and Type 2 enzyme preparations only showed 
significant activity in the range, pH 6.5-10.0. In contrast the 
plasma samples show significant enzyme activity over a more extended 
range, pH 6.0-11 .0. Whether this is due to plasma components inter -
acting with factor XIII either to maintain the tertiary structure of 
---
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the enzyme or to inhibit the ionisation of the basic and acidic groups 
of the enzyme, at the extreme pH values requires further study to 
determine. 
4. Heat stability 
At a specific temperature the energy of the system is suffic-
ient to cause the breakdown of hydrogen bonding and other forces which 
maintain the tertiary structure of an enzyme. At this temperature the 
enzyme starts to lose its activity and eventually becomes completely 
inactive. 
The more rapid heat inactivation of the Type 2 enzyme between 
55°-6s 0 c observed in these studies indicates that the Type 2 A sub-
units are more unstable and lose their tertiary structure at a lower 
temperature than the Type 1 A subunits. However, the fact that 
plasma samples of the two forms do not show any differences in their 
heat profiles suggests that the · environment provided by plasma and 
the interaction of the factor XIII molecule with other plasma compon-
ents protects the tertiary structure of the Type 2 A subunits from 
heat denaturation at lower temperatures. It has been suggested that 
factor XIII circulates in plasma bound to both fibrinogen (Greenberg 
and Shuman, 1981 and 1982) and fibronectin (McDonagh, 1981). However, 
in the present studies fibrinogen was removed from the plasma samples 
before the assays were car1ri ed out. 
D. Plasma factor XIII studies: The Type 3 A subunit 
1 . pH 
The pH curve of the plasma sample from the Type 1-3 individ-
ual shows two peaks of activity at pH 8.38 and pH 9.10. The biphasic 
curve shown by this sample is what would be expected if the Type l and 
Type 3 A subunits have distinct pH optima. As the opti mum pH for the 
Type 1 A subunits was pH 8.38 it is reasonable to conclude that the 
,, 
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lower value in the heterozygous sample represents the peak activity of 
the Type l subunits. Therefore, the pH optimum of the Type 3 subunits 
for dimethylcasein at 37°c is approximately pH 9.10. 
2. Heat stability 
The electrophoretic studies of Type 1-3 A subunits from plate-
lets suggested that the Type 3 A subunits were unstable when compared to 
-
the common Type 1 and Type 2 subunits (Chapter 4). Therefore, plasma 
samples from individuals homozygous for the latter two forms of factor 
XIII were compared with a Type 1-3 plasma sample for the effects of 
heat denaturation. 
Both the Type 1 and Type 2 samples showed no loss of enzyme activi-
ty when incubated at temperatures up to 55°c for JO minutes prior to 
enzyme assay. By comparison, the Type 1-3 sample lost approximately 20% 
and 30% of its enzyme activity at 50° and 55°c respectively (Figure 
5.16). However, at 65°c all three samples showed similar losses 1n 
activity, although the Type 1-3 sample still showed the largest 
reduction 1n activity. These results suggest that the Type 3 A 
subunits are denatured at 50°c and above,and that the majority of the 
enzyme activity lost at 65°c in the Type 1-3 sample is due to the 
inactivation of Type l A subunits. 
The results of prolonged incubation of all three samples at 55°c 
(Figure 5.17) support this idea. In the first 30 minutes approximately 
40% of the enzyme activity of the Type 1-3 sample is lost compared to 
less than 5% 1n the other two samples. Therefore, the Type 3 A subunits, 
which appear to account for between approximately 25%-50% of the enzyme 
activity of Type 1-3 plasma (Chapter 4), are largely inactivated before 
the Type l and Type 2 A subunits show any loss of activity at 55°c. 
The results of the heat stability studies, therefore, appear to 
confirm the hypothesis proposed in Chapter 4 that the FXIIIA*3 
- 187 -
allele codes for subunits with a tertiary structure which is unstable 
1n the plasma environment. It is, therefore, possible that the presence 
of this allele in the homozygous state or) in combination with the 
FXIIIA*QO allele, may result in congenital factor XIII deficiency. 
E. Fibronectin as a substrate for factor XIII 
Mosher (1975) showed that fibronectin was a physiological substrate 
for factor XIII. The results shown here confirm this finding by demon-
14 . 
strating the factor XIII catalysed incorporation of C putrescine into 
the plasma fibronectin molecule. The fact that the dimethylation of 
plasma fibronectin had no effect on the V x of the reaction suggests 
ma 
that, in the assay conditions used here, fibronectin is not cross-
linked to itself by factor XIII, as the dimethyla~ion process blocks 
the s-amino groups of lysine residues on the protein thereby prevent-
ing the formation of fibronectin multimers. 
'', 
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V. CONCLUSIONS 
1. The results given and discussed above indicate that there are no 
differences in the substrate specificities or the iodoacetamide 
inactivation at pH 7.5 and 37°c between the commonly found Type 1 and 
Type 2 A subunits of factor XIII. However, the pH optimum of the 
purified Type 1 enzyme for dimethylcasein is slightly higher than 
that of the Type 2 enzyme. Also, the purified Type 2 A subunits 
appear to be inactivated at a lower temperature than the Type 1 A 
subunits. As neither of these differences were apparent in plasma 
samples, it is uncertain if there are any physiologically signifi-
cant differences between the two common types of .A subunits. 
2. The Type 3 A subunits are unstable compared to the two common 
forms of the subunit and have a higher pH optima for dimethylcasein. 
As both these differences are present in plasma samples they are 
probably physiologically significant and, therefore, the Type 3 A 
subunits may be subject to different selection pressures than the 
Type 1 and Type 2 A subunits. 
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